University of Nebraska Medical Center

DigitalCommons@UNMC
Theses & Dissertations

Graduate Studies

Summer 8-14-2015

Development of Polymer Peptide Conjugates for Enhanced
Pancreatic Cancer Imaging
Wen Shi
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/etd
Part of the Medicinal Chemistry and Pharmaceutics Commons

Recommended Citation
Shi, Wen, "Development of Polymer Peptide Conjugates for Enhanced Pancreatic Cancer Imaging" (2015).
Theses & Dissertations. 7.
https://digitalcommons.unmc.edu/etd/7

This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

I

DEVELOPMENT OF POLYMER PEPTIDE CONJUGATES FOR
ENHANCED PANCREATIC CANCER IMAGING

BY
Wen Shi

A DISSERTATION

Presented to the Faculty of
the University of Nebraska Graduate College
in Partial Fulfillment of the Requirements
for the Degree of Doctor of Philosophy

Pharmaceutical Sciences Graduate Program

Under the Supervision of Professor Jered Garrison

University of Nebraska Medical Center
Omaha, Nebraska
July 2015

Supervisory Committee:
Surinder Batra, Ph.D.
Yazen Alnouti, Ph.D.

Dong Wang, Ph.D.

I
Table of Contents

Acknowledgements ........................................................................................................III
Abstracts ........................................................................................................................ V
List of Figures ............................................................................................................... VII
List of Tables .................................................................................................................. X
List of Abbreviations ...................................................................................................... XI
List of Contributors ...................................................................................................... XIV

Chapter 1. Introduction
1.1 Pancreatic cancer ..................................................................................................... 1
1.2 Current diagnostic methods for pancreatic cancer .................................................... 3
1.3 Nanomaterials for pancreatic cancer imaging ........................................................... 7
1.4 Radiolabeled HPMA copolymers for cancer imaging and radiotherapy ....................11
1.5 Summary and current proposal................................................................................38

Chapter 2. 177Lu-labeled HPMA copolymers utilizing cathepsin B and S cleavable
linkers: synthesis, characterization and preliminary in vivo investigation in a
pancreatic cancer model
2.1 Introduction..............................................................................................................39
2.2 Materials and methods ............................................................................................42
2.3 Results ....................................................................................................................50
2.4 Discussion ...............................................................................................................68
2.5 Conclusion...............................................................................................................73

II
Chapter 3. The influence of linker length on the properties of cathepsin S
cleavable 177Lu-labeled HPMA copolymers for pancreatic cancer imaging
3.1 Introduction..............................................................................................................75
3.2 Materials and methods ............................................................................................77
3.3 Results and discussion ............................................................................................85
3.4 Conclusion.............................................................................................................109

Chapter 4. Comparison of 177Lu-labeled plectin-1 targeted peptide (PTP) and PTPHPMA conjugate for pancreatic tumor targeting
4.1 Introduction............................................................................................................110
4.2 Materials and methods ..........................................................................................112
4.3 Results ..................................................................................................................124
4.4 Discussion .............................................................................................................148
4.5 Conclusion.............................................................................................................152

Chapter 5. Summary..................................................................................................153

III
Acknowledgements
First, I would like to thank my mentor, Dr. Jered Garrison, for his enthusiastic and
tireless guidance throughout my Ph.D. studies. He has always been willing to share his
knowledge, to answer my questions, to discuss details of my work and to emphasize on
high standard and quality in my research. I also want to thank him for teaching me to be
not just a good researcher but also a good listener and communicator. Without his
support and patience, I would not have been able to overcome my limitations and so
many difficulties. His creativity and his passion for research are always encouraging me
to devote myself to the development of pharmaceutical sciences.

I would like to thank my supervisory committee members - Dr. Surinder Batra, Dr.
Dong Wang and Dr. Yazen Alnouti for their valuable suggestions and helps. It’s been a
great honor and wonderful experience to work with and guided by such a group of
talented professors. Their profound insight and critical review of my work and progress
helped me grow as an independent scientist with critical thinking.

I would like to acknowledge all the past and present members in Dr. Garrison's lab.
You all have been very supportive and helpful. My special thanks to our post-doctors Dr.
Sunny Ogbomo and Dr. Nilesh Wagh for their consistent help during my graduate
studies. They have always been patient to explain things to me and teach me a lot about
chemical synthesis. I would like to thank Sonne (Zhengyuan Zhou), who came to the lab
at the same time with me and worked with me for five years. His expertise in equipments
and IT has been a great help to all. Thank Sue Brusnahan for her five years’ dedicated
support to my cell culture and animal work. Without her, many of these couldn’t be
achieved. Thank her for checking every abstract and manuscript I wrote. She’s always a
good teacher and a good friend.

IV

I would like to thank all the faculty members from the Department of Pharmaceutical
Sciences for teaching me a variety of useful courses, thank all the past and present staff
members from College of Pharmacy, especially Ms. Katina Winters, Ms. Christine
Allmon, Ms. Micelle Parks, Ms. Ashley Calhoon and Ms. Erin Plouzek for their generous
support and indispensable help in administrative matters.

I would like to thank all the graduate students from the Department of
Pharmaceutical Sciences. They are always kind and ready to help me. Special thanks to
a few friends: thank my previous roommate Weike Ji. He’s a good researcher and great
thinker. We always discussed scientific questions till midnight. Thank my best friend and
partner Li Zheng, who always takes care of me and encouraged me when I was down.

Finally, I would like to thank the most important people - my parents. I am very sorry
for being always from them for almost ten years now. Without their love, understanding
and encouragement, I would not achieve all these. Thank you!

V

DEVELOPMENT OF POLYMER PEPTIDE CONJUGATES FOR ENHANCED
PANCREATIC CANCER IMAGING

Wen Shi, Ph.D.
University of Nebraska, 2015
Supervisor: Jered Garrison, Ph.D.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related
deaths in the US with very poor prognosis. All clinically available biomarkers and
diagnostic tools either fail to detect early stage PDAC or suffer from low specificity and
sensitivity. There is an urgent need for diagnostic agents with greater efficacy for PDAC
detection and staging. Nanomaterials such as N-(2-Hydroxypropyl) methacrylamide
(HPMA) copolymers can effectively target tumors, and offer novel opportunities for the
development of effective diagnostic agents for cancer. However, a major problem of
many nanomaterials-based diagnostics is their opsonization and sequestration by the
mononuclear phagocyte system (MPS), leading to substantial accumulation in MPS
tissues such as the liver and spleen. This MPS accumulation in non-target tissues can
hinder identification of resident or nearby metastatic malignant lesions thereby
decreasing the diagnostic efficacy.

In this thesis, we focused on developing new approaches in which radiolabeled
HPMA copolymers can be synthetically modified to significantly reduce the MPS
accumulation and/or to increase the tumor accumulation, thereby enhancing the
diagnostic and/or radiotherapeutic efficacy of the agents. First, we evaluated the
effectiveness of incorporating metabolic active linkers into HPMA copolymers to
decrease the radioactivity retention in the liver and spleen in pancreatic tumor xenograft
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mice. We demonstrated that 177Lu-labeled HPMA copolymers conjugated with cathepsin
B/S cleavable peptide linkers exhibited significant long-term reduction in hepatic and
splenic radioactivity accumulation as compared to the non-cleavable control. Next we
conjugated a 109 kDa HPMA copolymer with three different cathepsin S cleavable
linkers and evaluated the structure-activity relationship with regard to the lengths of the
linking groups on the in vitro and in vivo efficacy of

177

Lu-labeled cathepsin S cleavable

HPMA copolymers. Biodistribution results showed that the 177Lu-labeled HPMA
copolymer with the shortest length linker had a significant enhancement in the tumor-tonon-target ratios, which was also confirmed by SPECT/CT imaging. Finally, the potential
of active tumor targeting for PDAC was evaluated using a plectin-1 targeted peptide
(PTP) conjugated HPMA copolymer on pancreatic cancer cells in vitro. Unfortunately, we
found that incorporation of the PTP into the HPMA copolymer diminished the binding of
the peptide, possibly due to steric hindrance.

Overall, our 177Lu-labeled cathepsin cleavable HPMA copolymer showed decreased
MPS tissue accumulation and significant improvement in tumor-to-non-target organ ratio,
and was successfully applied to SPECT/CT imaging of pancreatic tumors in a xenograft
mouse model.
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Chapter 1
Introduction

1.1 PANCREATIC CANCER
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancerrelated death in the US with a median survival of <6 months and a dismal 5-years
survival rate of 3%–5% [1]. This severe prognosis is mainly due to the cancer’s
aggressive clinical behavior with early invasion and metastasis as well as its resistance
to conventional and targeted chemotherapeutics, leading to an initial diagnosis at an
advanced and incurable stage in more than 80% patients [2].

PDAC commonly arises in the head region of the pancreas and infiltrates into nearby
tissues including lymphatics, spleen, and peritoneal cavity, and metastasizes to the liver
and lungs [3]. The disease is characterized by the presence of a dense stroma
consisting of abundant extracellular matrix and mainly fibroblasts and inflammatory cells,
termed desmoplasia [3]. Clinical and histopathologic studies have identified three PDAC
precursor lesions (Figure 1.1): pancreatic intraepithelial neoplasia (PanIN), mucinous
cystic neoplasm (MCN) and intraductal papillary mucinous neoplasm (IPMN) [4, 5]. The
most common and best studied type is the PanIN, which can be graded from stages I to
III, with the beginning stage characterized by the presence of columnar epithelial cells
with increasing architectural disorganization and cytological changes through stages II
and III [4, 6, 7]. High grade PanINs will ultimately progress into PDAC [3].
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Figure 1.1: Pancreatic precursor lesions and genetic mutations involved in pancreatic
adenocarcinoma progression. Adapted from Ref[3]. Pictured are three known human
PDAC precursor lesions: PanIN, MCN, and IPMN. The PanIN grading scheme is shown
on the left; increasing grade (1–3) reflects increasing morphology change, eventually
leading to invasive adenocarcinoma. The right side shows the potential progression of
MCNs and IPMNs to PDAC. The genetic alterations existing in adenocarcinomas also
occur in PanIN, but to a lesser extent MCNs and IPMNs.
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PDAC are highly resistant to conventional chemotherapy due to the impairment of
drug delivery pathways caused by the hypovasculature within the tumor sites [8].
Besides, the surrounded stroma has been shown to induce resistance to chemotherapy
and radiation therapy [9]. Gemcitabine is the standard chemotherapy for all stages of
pancreatic adenocarcinoma in the last decade with the median overall survival of 6.7
months and a response rate as low as 7% [10]. Although there has been progress made
in improving the various chemotherapeutic regimens and in the development of targeted
therapies against pancreatic cancer, the overall survival has not been significantly
improved.

1.2 CURRENT DIAGNOSTIC METHODS FOR PANCREATIC CANCER
Given the non-symptomatic nature of this disease, surgery is only a viable option for
15- 20% of PDAC patients with localized diseases [11]. Like many cancers, the earlier
pancreatic cancer is detected, the more likely surgery will be successful and lead to
longer patient survival. It was found that the 5-year survival of resectable PDAC is about
20%, increasing to 30% to 60% for node-negative tumors of less than 2 cm, and higher
than 60% for small lesions less than 10 mm. More encouraging results come from
patients who are diagnosed with high-grade dysplastic, but still noninvasive precursor
lesions [12]. Large tumor size is directly related to poor prognosis. Early diagnosis of
small or even pre-invasive cancers before the onset of metastasis offers the best hope
for survival [13].

Unfortunately, all clinical available biomarkers and diagnostic tools fail to detect early
stage PDAC and suffer from low specificity and sensitivity [14]. Blood biomarker
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carbohydrate CA 19-9 is an oligosaccharide sialylated Lewis A antigen attached to
mucin core proteins, and is the only available test in routine clinical use for PDAC [15].
But it is only used for PDAC patients’ therapeutic management not diagnostic purposes,
because only 50% of patients with small lesions (< 2 cm) presented with an increased
CA19-9 value [16]. Also, this marker can be elevated in patients with other types of
cancer [17] as well as in nonmalignant conditions including liver cirrhosis, cholangitis
and chronic pancreatitis [18, 19]. Recent studies have identified some promising
biomarkers from blood, saliva, stool and pancreatic juice [12]. But these biomarkers are
still in the process of being validated in clinical trials.

Diagnostic imaging tools are highly valuable because they not only provide early
detection but also enable appropriate treatment stratification (and staging) and in vivo
therapeutic response monitoring. Imaging techniques currently applied for diagnosis and
preoperative staging of pancreatic cancer include abdominal ultrasound (US), contrastenhanced computed tomography(CT), magnetic resonance imaging (MRI), positron
emission tomography (PET) and the minimal invasive endoscopic ultrasound (EUS) [20].
Below, we discuss the strengths and weakness of each imaging modality.

EUS allows the identification of diminutive structures with sizes ranging from 1-5 mm,
including lymph nodes, bile ducts, pancreatic ducts, blood vessels, solid masses and
cystic masses, so it is able to locate lymph node metastases and vascular tumor
infiltration with high sensitivity [21]. However, EUS is an operator highly dependent
technique and suffers from poor specificity for pancreatic cancer imaging [22]. The
presence of pancreatitis like features such as cysts and solid nodules can lead to great
doubt with regard to the importance of any discovered small pancreatic lesions [12].
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Abdominal US is often used first to find out the reason for abdominal pain or jaundice.
The sensitivity of conventional US for diagnosing PDAC is only 50–70% [23]. There are
no characteristic signs for different kinds of pancreatic lesions including PDAC, chronic
pancreatitis and endocrine cell tumors [20]. US might be an initial screening examination
as it is a cost-effective method, but CT or MRI are still needed for further, more accurate
diagnosis of malignant lesions [20].

CT is the most widely used imaging tool for the detection and staging of PDAC. Due
to the abundance of fibrous stroma and hypovascularity in PDAC, non-contrast CT
scans have very poor sensitivity and specificity [24]. Using contrast-enhanced CT, PDAC
is poorly enhanced compared to the surrounding parenchyma in the early phase of
dynamic CT but gradually enhanced with delayed images [20]. It’s usually seen as a
hypoattenuating area but may occasionally be seen as isoattenuating, thus resulting in
misdiagnosis [24]. Although the sensitivity and specificity in diagnosis of PDAC by CT
has been greatly improved recently (such as the introduction of multi-detector-row CT,
MDCT), this modality still has difficulty in diagnosing PDAC at an early stage [25]. The
difficulties are thought to be due to the small tumor size (<2 cm), loss of biliary dilatation,
vascular involvement and mass effect, and little attenuation difference compared with
normal pancreatic parenchyma [26].

MRI is commonly used to detect PDAC when a mass lesion is not detectable on CT
scan as it provides better soft tissue contrast compared to non-contrast enhanced CT.
However, there is no significant diagnostic advantage of MRI over contrast enhanced CT
(sensitivity of 86% on CT vs. 84% on MRI) [27]. Combination of two modalities did not
improve diagnostic efficacy relative to either one alone. Another problem with the use of
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MRI for PDAC detection/staging is that chronic pancreatitis remained difficult to be
differentiated from PDAC since both show enhanced contrast images on MRI and both
may be associated with pancreatic ductal obstruction [28, 29]. The choice of MRI or CT
may depend on the availability in hospitals and clinician’s comfort with either modality.

PET imaging, using radiolabeled glucose analog 18F-fluorodeoxyglucose (18F-FDG),
is a promising tool for noninvasive differentiation between benign and malignant lesions
[30]. But the utility of PET in PDAC diagnosis and staging remains uncertain. Integrated
PET/CT is considered superior to conventional imaging (MDCT, CT, EUS) used for
tumor staging and identification of additional distant metastases (sensitivity and
specificity rates were 81% versus 56% and 100% versus 95%, respectively, as reported
in one study [31]). However, it has been argued that when compared to contrast
enhanced MDCT, currently available data does not support that PET or PET/ CT provide
any additional information for PDAC [24]. Additionally, chronic and acute pancreatitis
and autoimmune pancreatitis can occasionally exhibit substantial FDG uptake and result
in false positive results. Lastly, the sensitivity of 18F-FDG PET in hyperglycemic patients
could be lower than that in euglycemic patients because the elevated serum glucose
levels suppress 18F-FDG uptake in tumors by 50% due to the competitive inhibition [32].

The application of the single-photon emission computed tomography (SPECT)
modality in PDAC is hampered by the lack of an effective radiotracer. Many radiotracers
were reported in the literature, but these studies were limited to pre-clinical evaluation
[14, 33, 34]. The αvβ3-integrin is often over-expressed in pancreatic tumor cells, whereas
it is rarely expressed in normal pancreatic cells [35]. In one study, Indium-111 (111In)labeled DOTA-c(RGDfK) was evaluated in a hamster pancreatic carcinogenesis model
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[33]. The c(RGDfK) is a cyclic, stable arginine-glycine-aspartic acid peptide analogue
that binds with αvβ3-integrin with high affinity [36]. Using the radiolabeled peptide 111InDOTA-c(RGDfK), malignant lesions as small as 3mm in diameter could be clearly
visualized in using SPECT/CT and the uptake of the radiolabeled peptide was found to
be well correlated with αvβ3-integrin expression. In another study, Technetium-99m
(99mTc) labeled integrin αvβ6-targeted peptide was found to effectively detect primary and
metastatic lesions of αvβ6-positive pancreatic tumors [34]. Lastly, plectin-1 is a protein
that is ubiquitously expressed in cells, but is normally constrained to the intracellular
compartment. However, in the case of PDAC, plectin-1 becomes aberrantly expressed
on the extracellular surface [14]. The peptide sequence KTLLPTP, discovered by phage
display, was found to have submicromolar affinity for plectin-1 [37]. An 111In-labeledtetrametric form of plectin-1 targeting peptide exhibited high tumor uptake and visualized
the primary and metastatic pancreatic tumors by SPECT/CT [14].

1.3 NANOMATERIALS FOR PANCREATIC CANCER IMAGING
The advancement in nanomedicine has sparked the development of emerging tools
in cancer diagnostics and treatment [38]. Nanoparticles (1-100 nm in size), with carefully
controlled chemistry, size, surface charge and other properties can delivery diagnostic
and/or therapeutic agents to targeted locations in the body [39]. These nanoparticle
systems include paradigms such as gold/magnetic nanoparticles, quantum dots,
liposomes, polymer micelles, dendrimers, and polymer conjugates. In the case of cancer
diagnosis and therapy, these nanoparticles can passively accumulate in tumors due to
enhanced permeability and retention (EPR) effect [40]. The presence of larger than
normal fenestrations in the tumor vasculature endothelial walls with the impairment of
tumor lymphatic drainage system results in the retained accumulation of nanoparticles
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[41]. Recent developments have led to the transformation from passive to active tumor
targeting, which is normally achieved by covalently conjugating nanoparticles with cellspecific targeting ligands such as antibodies, small molecules or peptides [42]. Active
targeting allows efficient intracellular accumulation of the anticancer therapeutic agents
in specific tissues/cells which largely increase the efficacy [43]. PDAC expresses many
different specific protein/receptors, making them potential biomarkers for targeted
imaging and therapy [44].

A variety of nanoparticles have been investigated for pancreatic cancer imaging over
the years [43]. Magnetic nanoparticles are biocompatible and have been used as
contrast agents for MRI imaging for pancreatic cancer. For example, Hedgire et al.
proved that using superparamagnetic iron oxide nanoparticles (SPION) as a contrast
agent for MRI offered better delineation of pancreatic cancer in patients receiving
preoperative imaging, which might contribute a roadmap for the surgeons [45]. Yang’s
group modified SPION with the urokinase amino-terminal fragment, which is a targeting
ligand for the urokinase plasminogen activator receptor (uPAR) with high affinity [46].
uPAR is found to be highly expressed in pancreatic cancer cells and tumor stromal cells
[47]. The modified nanoparticles produced significant MR signal changes in pancreatic
tumor xenograft mice and allowed the distinction between malignant lesions and
pancreatitis. Many pancreatic tumors highly express epidermal growth factor receptor
(EGFR) [48]. Single chain anti-EGFR antibody (ScFvEGFR) has been conjugated to iron
oxide (IO) magnetic nanoparticles, the resulting ScFvEGFR-IO nanoparticles selectively
accumulated within the pancreatic tumors in an orthotopic pancreatic cancer xenograft
model, as evidenced by an enhanced contrast in MRI signal in the area of the tumor [49].
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A 4.8 fold MRI signal change was observed when comparing the ScFvEGFR-IO
nanoparticles with the non-targeted IO nanoparticles.

Quantum dots (QD) are a class of semiconducting nanocrystals composed of
inorganic cores and surrounding metal shells, with excellent optical properties [50]. They
have been well studied for imaging pancreatic cancer [43]. Prasad’s group attached
many different targeting ligands including folic acid, cyclic arginine-glycine-aspartic acid
(cRGD) and anti-mesothelin antibody, to CdTe quantum dots and successfully applied
them for in vivo pancreatic cancer imaging [51-53]. Those QDs showed minimal toxicity
in vivo and could target tumors with high signal-to-noise ratio, which allowed near
infrared optical imaging of pancreatic tumors. ScFvEGFR conjugated quantum dots
bound and internalized to EGFR positive pancreatic tumor cells and targeted efficiently
to tumor in pancreatic tumor bearing mice while the non-targeted QD was almost
undetectable in tumor [49]. These results suggest that QDs might be promising
diagnostic agents for PDAC detection.

Liposomes have been successfully used as carriers for chemotherapeutics in clinic
[54]. The development of liposome formulations has led to clinical trials investigating
liposomal drug delivery systems for pancreatic cancer. Some of them have shown
improved efficacy as compared to gemcitabine alone [55]. Liposomes have also been
evaluated as pancreatic cancer diagnostic agents but only in animal models. Kato’s
group developed L-fucose-bound liposomes containing Cy 5.5 for effective near infrared
optical imaging of CA19-9 expressing pancreatic tumors [56]. A multifunctional liposome
platform conjugated with anti-mesothelin antibodies was loaded with SPION for MR
imaging of pancreatic cancer. The in vivo imaging results showed that tumor signal
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intensity dropped by 4 hour post injection (p.i.) and the decrease was much higher than
free SPION without antibodies [57].

Many different polymers and polymer conjugates have been evaluated for pancreatic
cancer imaging. Eser et al. developed a cathepsin-activatable, near-infrared probe
based on PEG modified poly-l-lysine for pancreatic cancer imaging in a genetically
mutated Kras mouse model [58]. The 35.5 kDa poly-l-lysine backbone was attached with
92 molecules of 5 kDa PEG and 11 molecules of Cy5.5. The fluorescence of the polymer
conjugates was initially relatively low due to self-quenching, but could be substantially
increased when cleaved by proteases. They identified increased expression of cathepsin
proteases during pancreatic tumor progression. The elevated amount of cathepsins from
PanIN lesions and early stage PDAC digested the accumulated conjugate in the tumor,
thereby generating near-infrared fluorescence for pancreatic tumor imaging. They
concluded that utilization of this technique enabled the detection and evaluation of early
precursors of PDAC in vivo, holding great promise to improve early detection of PDAC.
The Lammers’ group prepared near infrared fluorophore labeled N-(2-Hydroxypropyl)
methacrylamide (HPMA) copolymers and compared the active targeting RGD peptide
conjugated HPMA copolymer with passive targeting HPMA copolymer modified with
scrambled peptide DRG or without peptides in a pancreatic tumor xenograft model [59].
Interestingly they found that vascular targeting only worked in early time point at 1~2 h
p.i., but passive targeting was more efficient at the long-term points (24~72 h). Work
from Ghandehari’s group demonstrated that pancreatic tumor targeting efficacy could be
increased by utilizing hyaluronidase to break down the hyaluronic acid present in the
PDAC stroma prior to the administration of 111In-labeled, targeted HPMA copolymer [60].
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1.4 RADIOLABELED HPMA COPOLYMERS FOR CANCER IMAGING AND
RADIOTHERAPY
N-(2-Hydroxypropyl)methacrylamide or HPMA copolymers possess many distinct
advantages including good biocompatibility and water solubility as well as prolonged in
vivo circulation time. By means of EPR effect, these copolymers extravasate to tumor
sites effectively and selectively [61]. The research on the use of HPMA copolymers as
drug carriers started in the early 70s in Dr. Kopeček’s laboratory [62]. To date, six HPMA
conjugates have entered different stages of clinical trials, including two of them applied
as theranostic agents (Table 1.1) [63]. Clinical trials have proven that HPMA conjugates
were non-immunogenic and can be safely administered parenterally and exhibited
anticancer activity. Given the high sensitivity of imaging modalities like SPECT and PET,
radiolabeled HPMA copolymers have been successfully used to quantify the in vivo
biodistribution of the copolymers and to visualize the tumor size and location for
diagnostic imaging [61]. These agents can also serve as a platform to selectively deliver
therapeutic doses of ionizing radiation to the tumor [64]. The application of radiolabeled
HPMA copolymers for tumor imaging and radiotherapy is summarized here.
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Table 1.1: HPMA-drug conjugates that have entered clinical trials. Modified from Ref[63].
Code

Compounds

Molecular Weight

Status

FCE 28068

HPMA-GFLG-doxorubicin

30,000

Phase I/II

FCE 28069

HPMA-galactosamine-GFLG-doxorubicin

25,000

Phase I/II

PNU 166945

HPMA-paclitaxel

PCNU 166148

N.A.

Phase I- stopped

HPMA-camptothecin

18,000

Phase I - stopped

AP5280

HPMA-carboplatinate analogue

25,000

Phase I/II

AP5346

HPMA-DACH platinate analogue

25,000

Phase I/II
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1.4.1 Design and Structure of Radiolabeled HPMA Copolymer
The radiolabeled HPMA copolymer typically comprises at least three parts: a
synthetic HPMA copolymer for prolonged circulation and tumor targeting; a polymer
conjugated radionuclide chelator system to stably chelate the radioisotope, and the
corresponding radionuclide for imaging or radiotherapy purpose. Different types of
radionuclides utilized in HPMA copolymers, so far, with their respective characteristics
and chelation systems utilized are summarized here in Table 1.2.
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Table 1.2: Different radionuclides and their corresponding chelators applied in HPMA
copolymers evaluated to date.
Radionuclide

Emission
Type

Halflife

Emax

Chelator

Status

Ref

(kev)

123

γ

13.3 h

159

tyrosine analogue

Phase 1

67,68,69,84,97

125

γ

60.1 d

35.5

tyrosine analogue

Pre-clinical

74,78

β -, γ

8.04 d

β-: 600

tyrosine analogue

Phase 1

69,73,75,76,94,96

I
I

131

I

99m

γ: 364
γ

6.02 h

140

DPK

Pre-clinical

70,77,90

In

γ

2.8 d

245

DTPA, DOTA

Pre-clinical

60,65,78,91

Lu

β -, γ

6.7 d

β-: 497

DOTA

Pre-clinical

66

β-

2.7 d

2280

DTPA

Pre-clinical

64,98

F

β+

1.83 h

640

[18F]FETos

Pre-clinical

71,80,81,86

72

As

β+

26.0 h

3340

hydrosulfuryl

N.A.

72

74

As

β+

17.8 d

1675

hydrosulfuryl

N.A.

72

Tc

111

177

γ: 208
90

Y
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There are two main approaches that can introduce the radionuclide chelators into
HPMA copolymer: the co-polymerization method and the post-polymerization method.
The co-polymerization method involves either free radical or controlled polymerization
(e.g. the atom transfer radical polymerization (ATRP) and reversible additionfragmentation chain transfer polymerization (RAFT)) of HPMA monomer, monomers
containing the chelation system and other desired monomers. The polymerization is
carried out in homogeneous solution phase and in the presence of radical initiators. The
reaction is mostly initiated through heating (40 ºC to 80 ºC). Chain transfer agents can
be added to better control the polydispersity and molecular weight. For example, to
prepare the human epidermal growth factor receptor 2 (HER2) targeted 111In-labeled
HPMA copolymer, four monomers: HPMA monomer, a chelator containing monomer: Nmethacryloylaminopropul-2-amino-3-(isothiurea-phenyl)propylcyclohexane-1,2-diamineN,N-N’,N’,N’’,N’’-pentaacetic acid (APMA-CHX-A’’-DTPA), the drug containing monomer
N-methacryloylglycylphenyl-ananylleucylglycyl-gemcitabine and a HER2 targeted
peptide conjugated monomer: N-methacryloylglycylglycyllysylcystylcystyltyrylserylleucine (MA-GG-KCCYSL) were dissolved together and RAFT
polymerized for 24 hours using 2-cyano-2-propyl dodecyl trithiocarbonate as the chain
transfer agent and 2,2’-azobis[2-(2-imidazolin-2-yl)propane] as the initiator (Figure 1.2)
[65]. The copolymer was then radiolabeled with 111InCl3 after heating at 50 ºC for 45 min
in sodium acetate buffer. The radiolabeled copolymer was finally purified using size
exclusion chromatography.
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Figure 1.2: Preparation of 111In-labeled HPMA copolymers by co-polymerization method.
Adapted from Ref[65].
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The co-polymerization method is quite straightforward. Many different functional
monomers, modified with either a targeting moiety or therapeutic drugs, can be
introduced at the same time with the chelation system. The content of each component
in the copolymer can be controlled by adjusting the feeding ratios of each monomer. The
resulting copolymer can be easily purified and characterized using size exclusion
chromatography. One problem is that the preparation of many modified monomers may
require expensive and time-consuming synthesis development.

The other method for the synthesis of a radiolabeled HPMA copolymer is the postpolymerization method. In this case, a copolymer precursor, containing a certain reactive
functional group, is prepared after the polymerization step and subsequently conjugated
to the chelation system. For example, HPMA and N-(3-aminopropyl)methacrylamide
(APMA) were RAFT polymerized using 4,4’-azobis(4-cyanovaleric acid) as the initiator
and 4-cyanopentanoic acid dithiobenzoate as the chain transfer agent (Figure 1.3) [66].
Activated 2-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)
acetic acid (DOTA(tBu)3) was conjugated to the primary amine functional groups from
APMA. The amount of conjugated DOTA(tBu)3 was determined by ninhydrin assay. The
HPMA-DOTA conjugate was treated with TFA, to remove the t-butyl protecting groups
before it was radiolabeled with Lutetium-177 (177Lu) through heating at 90 ºC in water.
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Figure 1.3: Preparation of 177Lu-labeled HPMA copolymers by post-polymerization
method. Adapted from Ref[66].
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Post-polymerization is a relatively straightforward way to introduce the radionuclide
chelator. However, the conjugation reaction efficiency can be adversely affected by the
steric hindrance from randomly coiled polymer chains and the side chains of the other
block components [61]. The degree of conjugation can be hard to control at times and
additional characterizations are required to determine the conjugation efficiency. The
characterization techniques may include colorimetric analysis, MS or NMR. The choice
of co-polymerization or post-polymerization method depends on many factors, such as
time, the availability of different functional monomers and the experimental purpose, and
should be carefully selected in each case.

A variety of radionuclide chelators have been incorporated into HPMA copolymers.
For the radioactive iodine labeled HPMA copolymer, tyrosine analogues are most
commonly introduced in the modified monomer form (N-methacryloyltyrosinamide (MATyr)) during the co-polymerization step [67-69]. The labeling is done under mild
conditions by treatment of the copolymer with radioactive sodium iodine in the presence
of an oxidizing reagent, to generate the electrophilic radio-iodine. The electrophilic
species then react with the aromatic moiety of the compound to be labeled and form the
radio-iodine-labeled copolymer.

For the preparation of 99mTc-labeled polymer, a monomer called N-methacryloylglycyl
glycyl-(N-ω-bis(2-pyridylmethyl)-l-lysine) (MA-GG-DPK) was synthesized and introduced
in the co-polymerization step [70]. N-ω-bis(2-pyridylmethyl)-l-lysine (DPK) can provide a
compact tridentate coordination with 99mTc-tricarbonyl core and form very stable
complexes. For most radio-metals, DTPA or DOTA analogues have been utilized [60,65,
66]. These macrocyclic chelators have good radiolabeling yield and can form stable
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complexes with radio-metals. DTPA or DOTA moieties can be introduced in the copolymerization step or by post-polymerization conjugation. However, one concern is that
those macrocyclics themselves are rather bulky and mostly charged and as a result may
influence the copolymer structure and consequently in vivo biological behavior [71].

For the most part, efforts in the pursuit of diagnostic HPMA copolymers have mainly
focused on SPECT compatible radioisotopes. However, the last few years has seen an
increase in the number of reports describing PET radionuclide incorporated into HPMA
copolymers. Herth et al. prepared 18F- labeled HPMA copolymers for short-term blood
pool imaging [71]. They reacted 2-[18F]fluoroethyl-1-toylate ([18F]FETos) with the phenol
group of a tyramine moiety from an HPMA copolymer after deprotonation of phenolic
tyramine with a smaller amount of NaOH (Figure 1.4A). They reported radiochemical
fluoroalkylation yields of ∼80% for block copolymers and >50% for random polymers
after a 10 min reaction at 120 °C. The synthesized 18F-labeled HPMA copolymer could
be purified and collected within 90 min. The same group also tried to label HPMA
copolymers with the longer-living positron emitter Arsenic-72/74 (72/74As) (Figure 1.4B)
[72]. HPMA copolymers were prepared by RAFT polymerization, using the dithiobenzoic
ester as the chain transfer agent. The end group in each copolymer, coming from the
chain transfer agent was converted to -SH group after reduction with tris(2-carboxyethyl)
phosphine treatment. 72/74As-labeling of HPMA was carried out in water at 70 ºC with
increased labeling yields after longer incubation.
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A

B

Figure 1.4: Preparations of 18F-radiolabeled HPMA copolymers for PET imaging.
Adapted from Ref [72]
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1.4.2 Preclinical Evaluation of Radiolabeled HPMA Copolymers in Animal Models
Various radiolabeled HPMA copolymers have been evaluated in different animal
models and have shown great potential as tumor imaging agents. With respect to tumor
targeting mechanism, those copolymers can be briefly categorized into two types: the
passive tumor-targeting HPMA copolymers and the active tumor-targeting HPMA
copolymers. The following part will mainly discuss about the design and in vivo
performances of different kinds of radiolabeled HPMA copolymers in animal models:

Passive tumor-targeting HPMA copolymers
Early studies have assessed the in vivo pharmacokinetics and imaging characteristic
of HPMA copolymer labeled with different radioiodines (123I, 125I and 131I) [67-69, 73]. The
biodistribution of the radioactive conjugates in tumor xenograft mice were monitored
using the gamma scintigraphy and also by ex vivo biodistribution measurements.[67]
There was a clear relationship between the copolymer molecular weight and body
clearance and tumor uptake of HPMA copolymers [73]. It was found that the urinary
excretion of radioactivity was dependent on the molecular weight of the copolymer.
HPMA copolymers with molecular weight below the renal threshold (~45 kDa) cleared
mostly through the renal system, which lead to the kidney containing the highest
radioactive content [68]. Contrastingly, high molecular weight (Mw) HPMA copolymers
were predominately cleared by the mononuclear phagocyte system (MPS) and the
hepatobiliary system, leading to retention in the liver and spleen. The tumor uptake
displayed continuous increase with time even after 72 h and was much higher as
compared to the low molecular weight HPMA copolymer.
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The biodistribution of HPMA copolymers can be easily affected by the other
components in the copolymer. Biotin-labeled HPMA copolymers were initially prepared
to investigate the cellular localization of HPMA copolymers in normal and tumor tissues.
However, it was found that biotinylation could significantly alter the biodistribution, which
was assessed by 125I-labeled HPMA copolymers [74].The biotinylated HPMA copolymer
cleared faster from the circulation than the unmodified HPMA copolymer of comparable
molecular weight and had lower accumulation in the liver, spleen and tumor. The kidney
uptake was 33 times higher for the biotinylated HPMA copolymer possibly due to the
presence of biotin transporters in the brush border membrane.

Lammers et al. used the scintigraphic imaging method to investigate the influence of
the incorporation of various functional groups into 131I-labeled HPMA copolymers on the
whole-body distribution and tumor accumulation of the copolymers [75]. They prepared
ten functionalized HPMA copolymers and evaluated the in vivo behaviors in AT1 tumor
bearing rats. The authours found that the incorporation of carboxyl and hydrazide groups,
as well as introduction of spacer, drug and peptide moieties reduced the long-circulating
properties of the copolymers thereby lowering the accumulation in tumors and in all
tissues except for kidney. But tumor-to-organ ratios were comparable to unmodified
controls for the majority of the chemically modified copolymers. It was concluded that
functionalization did not affect the tumor targeting ability of the copolymers (Figure 1.5).
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Figure 1.5: Evaluation of the tumor to organ ratio of HPMA copolymers with different
functional groups at 168 h p.i. indicated that except for the pentapeptide PHSCN, other
functional groups did not reduce the relative tumor targeting ability. Adapted from
Ref[75].
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The administration route could also affect the tumor accumulation of radiolabeled
HPMA copolymers. Lammers et al. compared the effect of intratumoral (i.t.) injection
versus intravenous (i.v.) injection on the biodistribution of HPMA copolymers in prostate
tumor bearing rats [76]. HPMA-MA-Tyr copolymers with different molecular weight were
labeled with 131I in high efficiency. It was found the i.t. injected HPMA copolymers had
significantly less blood radioactivity as compared to those from i.v. injection. The tumor
to organ ratios from i.t. injection were 5 times higher for the 31 kDa copolymer and up to
20 times higher for the 65 kDa copolymer compared to those from i.v. injection. Based
on the findings, they suggested i.t. injection of polymer-based chemotherapy as an
alternative to routine administration routes.

Radioiodine has a number of disadvantages, which may limit its translational
application for the HPMA copolymer based radiopharmaceuticals. 125I emits low-energy
gamma rays with low tissue penetration that could limit its application in human. 131I has
high gamma emission energy (364 keV) and ionizing radiation associated with its beta
emission, so it’s not generally used for diagnostic imaging. 123I is more suitable than the
aforementioned radionuclides for clinical imaging, but it is relatively expensive to
produce [77]. Given the wide use of Technetium-99m in clinic for nuclear imaging and its
ideal imaging energy, 99mTc-labeled HPMA copolymers were developed and evaluated in
vivo. Ghandehari’s group prepared 99mTc-labeled HPMA copolymers of various charges
and molecular weights at 7, 21 and 70 kDa and determined their biodistribution in nontumor bearing mice [77]. Neutral HPMA copolymers contained 95% HPMA and 5% MAGG-DPK while negatively charged HPMA copolymers contained 70% HPMA, 5% MAGG-DPK, 23% N-methacryloylglycylglyine (MA-GG-COOH) and 2% MA-Tyr. The 7 kDa
negatively charged copolymer showed 8.1 ± 0.74% ID/g in the kidney at 24 h, while
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higher renal activity was found for the 21 kDa and 70 kDa copolymer, which showed
33.1 ± 1.6% and 23.3 ± 4.8% ID/g, respectively. At 24 h, the 70 kDa electronegative
copolymer had little accumulation in the blood (1.5 ± 0.3% ID/g), spleen (1.4 ± 0.7%
ID/g), and liver (2.2 ± 0.6% ID/g) while the other two showed < 1%ID/g in all tissues. For
neutral copolymers, higher molecular weight showed longer circulation time and higher
tissue retention, which is consistent with radioiodine labeled HPMA copolymers. At 24 h,
the neutral 7 kDa copolymer had some hepatic (5.3 ± 1.7% ID/g) and splenic retention
(5.9± 1.9% ID/g). The 21 kDa copolymer showed high renal (18.3 ± 6.9%ID/g) and
splenic retention (10.3 ± 1.3% ID/g). The 70 kDa copolymer showed the highest blood
activity (19.2 ± 4.2% ID/g) and retention in lung (12.8 ± 3.1% ID/g), spleen (14.9 ± 4.5%
ID/g), and liver (25.3 ± 2.8% ID/g). Overall, all three negatively charged copolymer were
more efficiently cleared from the body than the neutral copolymers and did not, with
exception to the kidneys, exhibit substantial, long-term retention in any major tissues.

More recently, HPMA copolymer labeled with different radiometals through
coordination with DOTA or DTPA were evaluated in mice. Garrison’s group synthesized
a 343 kDa HPMA-APMA copolymer and conjugated it with DOTA(tBu)3. The copolymer
was successfully labeled with 177Lu after deprotection with TFA. The radiolabeled HPMA
copolymer was mainly eliminated by the MPS and its high molecular weight resulted in
high blood and tumor radioactivity after 72 h p.i. [66].

Dr. Kopecek’s group recently developed a series of backbone degradable HPMA
copolymers. A 109 kDa HPMA copolymer was first RAFT synthesized, and then was
extended to a 335 kDa backbone degradable HPMA conjugate through a cathepsin B
cleavable linker using “click chemistry” [78]. The copolymer was radiolabeled with 125I to

27
permit pharmacokinetic and imaging studies in mice. SPECT/CT imaging in mice
bearing orthotopic ovarian tumor demonstrated biodegradability and elimination of the
backbone degradable HPMA from the body. In the next study, they applied duallabeling
to a 110 kDa backbone degradable HPMA copolymer to separately investigate the
behavior of the carrier and payload [79]. The HPMA copolymer backbone was labeled
with 125I and the 111In-DTPA complex was attached at the GFLG side-chain termini and
served as the drug model. SPECT/CT imaging results demonstrated that payload ( 111In)
had similar blood half-life and tissue uptake as polymeric carrier (125I), which indicated
that the GFLG bond was stable in blood circulation. This “second generation” highmolecular weight backbone-degradable HPMA copolymer showed five- (111In) to eight(125I) times higher tumor accumulation as compared to the “first-generation” backbone
non-degradable low molecular weight (< 50 kDa) conjugates.

The in vivo behavior of
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F-labeled HPMA copolymer has also been investigated in

mice, but mainly in the early time points. Different molecular weights of either HPMA
homopolymer or HPMA-ran-LMA (LMA = lauryl methacrylate) copolymer was
synthesized and labeled with [18F]FETos [80]. HPMA-ran-LMA copolymers could form
aggregates in ~ 40nm size above their critical micelle concentration. The copolymer was
less efficiently labeled as compared to the homopolymer, presumably due to the lower
accessibility of phenolic groups in the interior of the polymer coils. MicroPET imaging
was utilized over 2 h period of time after i.v. injection of the labeled polymers. The ex
vivo biodistribution study was carried out at 2 h after i.v. injection and it was found that
independently from the molecular weight, the HPMA-ran-LMA copolymer showed longer
blood circulation, and the uptake of the larger Mw copolymer by the liver and spleen was
much lower than that of the comparable homopolymer, which was also confirmed by the
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PET imaging results. It was assumed that that the incorporation of the hydrophobic lauryl
methacrylate block had significant impact on the biodistribution and helped avoid the
uptake of the polymers by the MPS.

The same group also studied the effect of PEGylation on the in vivo behavior of 18F
labeled HPMA-b-LMA copolymer [81]. Different amounts of PEG 2000 were grafted to
the polymer backbone from 0% to 11% while the ratio of polymerization with HPMA and
LMA monomer was kept constant. The copolymer was labeled with 18F with a relatively
low yield of less than 20%. Non-invasive PET imaging over 2h and quantification by ex
vivo biodistribution measurements at 2 h and 4h p.i. were performed on mammary
carcinoma bearing rats. The study showed that the lower PEG content copolymer had
major kidney and MPS uptake with comparatively low blood retention as well as tumor
accumulation while higher PEG content caused prolonged blood circulation times and
led to a tumor accumulation constantly increasing with the increased amount of PEG.

Active tumor-targeting HPMA copolymers
Distinct from passive tumor targeting HPMA copolymers, active tumor targeting
HPMA copolymers have been conjugated with different targeting ligands, including small
molecules, peptides and antibodies with the aim of improving tumor-targeting efficacy.
Many of these targeted HPMA copolymers have been radiolabeled and evaluated by
nuclear imaging studies.

The galactose receptor is highly expressed on liver hepatocytes [82]. Galactosamine,
which was the first small molecule ligand conjugated to an HPMA copolymer, has good
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affinity to the galactose receptor. As a consequence, HPMA-galactosamine conjugates
have been investigated for liver-targeted drug delivery [83]. The galactose receptortargeted HPMA copolymer was labeled with a variety of radioiodines (123I, 125I, 131I) for
biodistribution and gamma scintigraphy studies [69, 84]. Substantial hepatic
accumulation of the galactosamine conjugated HPMA copolymer was seen as early as
20 min p.i., which confirms the liver-targeting capability of galactosamine conjugated
HPMA copolymers.

Folate receptor is over-expressed on many different types of cancer cells including
breast cancer, while its expression in healthy tissues and organs is limited [85]. The
potential of folate receptor-targeted HPMA copolymers was evaluated in mammary
tumor bearing rats [86]. HPMA copolymer of 10.5 and 52.5 kDa were functionalized with
folate through copper catalyzed “click chemistry” and labeled with 18F as described in
section 1.4.1. In vivo biodistribution and micro-PET imaging studies revealed a 1.5 to 2
fold increase in tumor accumulation at the 2 and 4 h time-points for the folate-conjugated
HPMA copolymer relative to the non-targeted HPMA copolymer control. The increased
accumulation could be blocked by co-administration of native folic acid with 18F-labeled
folate-HPMA copolymer. This work demonstrated the effectiveness of folate-conjugated
HPMA copolymers for folate receptor positive tumor-targeting.

Angiogenesis in tumor sites is critical for tumor growth and metastasis [87]. Targeting
angiogenesis is an important area in tumor diagnosis and targeted therapy [88]. Tumor
blood vessels highly express αvβ3 integrin receptors, which can be targeted by the RGD
peptides. Numerous reports on the RGD peptides and analogues have demonstrated
the in vivo efficacy of this integrin-targeted peptide [89]. A decade ago, RGD peptides
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were firstly conjugated to HPMA copolymers in order to evaluate the potential of these
integrin-targeted agents. 99mTc-labeled HPMA copolymer bearing a double cyclized RGD
analogue (RGD4C) or a non-targeted control (RGE4C) was synthesized and evaluated
in a DU-145 prostate tumor xenograft mouse model [70]. Based on this report, the
HPMA-RGD4C conjugate had almost 4 times higher tumor accumulation (4.60 ± 1.80%
ID/g) than the non-integrin-targeted HPMA copolymer (1.24 ± 0.15% ID/g) from the 24 h
scintigraphic image results (Figure 1.6). The targeted copolymer had sustained tumor
retention over a 72 h period with substantial clearance from non-target tissues. In
addition, the authors also compared the biodistribution of 99mTc labeled HPMA-RGD4C
conjugate with 99mTc labeled RGD4C peptide [90]. They found that the liver and spleen
uptake at 24 h was higher for the radiolabeled peptide compared to polymer peptide
conjugate, which might be due to reduced extravasation of the targeted polymeric
conjugates in normal tissues.
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Figure 1.6: A, scintigraphic image of 99mTc-labeled HPMA-RGD4C conjugate in a DU145 xenograft mouse model at 24 h p.i. B, scintigraphic image of 99mTc-labeled HPMARGE4C conjugate in a DU-145 xenograft mouse model at 24 h p.i. C, biodistribution of
three different 99mTc-labeled copolymers (white: HPMA-RGD4C, black: HPMA-RGE4C
and grey: HPMA homopolymer) in a DU-145 xenograft mouse model at 24 h p.i.
Adapted from Ref[70].
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RGD4C peptide is susceptible to degradation in vivo. To solve the stability issue
associated with RGD4C, Ghandehari’s group attached a stable cyclic RGD analogue,
RGDfK, to the HPMA copolymer, and compared it with the RGD4C-HPMA conjugate
[91]. After labeling both with 111In, the in vivo efficacy of the αvβ3–targeted HPMA
copolymers were evaluated in a LLC1 xenograft lung carcinoma mouse model. Both
showed significant tumor accumulation after 24 h p.i. with peak accumulations at 4.9 ±
0.9% and 5.0 ± 1.2% ID/g, respectively. There was no statistical difference in tumor and
non-target tissues retention between the two peptide copolymer conjugates.

Ghandehari’s group developed peptide conjugated HPMA copolymers for active
targeting of HER2 positive pancreatic tumors [60]. The HPMA copolymer was
conjugated with the HER2 targeted peptide (KCCYSL) by aminolysis and was
radiolabeled with 111In using the DTPA chelator. Pancreatic tumors are characterized by
the existence of dense stroma consisting of abundant hyaluronic acid, which prevents
the diffusion of macromolecules. Their work demonstrated that the targeting efficacy of
the HER2 targeted HPMA copolymer could be increased 2-3 fold after utilizing
hyaluronidase prior to the injection of the radiolabeled copolymer. Hyaluronidase broke
down the hyaluronic acid in the stroma thereby increasing the extravasation of HER2
targeted HPMA copolymers into pancreatic tumors.

Prostate tumors can over-express galectin-3 [92]. The G3-C12 peptide, with the
sequence of ANTPCGPYTHDCPVKR, was discovered by phage display and has specific
binding affinity galectin-3 [93]. Huang’s group developed the prostate carcinoma targeting

HPMA copolymer conjugated with 3 mole% the G3-C12 peptide and labeled it with 131I
[94]. Scintigraphic imaging was used to visualize the biodistribution of the peptide
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modified copolymers and control copolymer (without peptide) in a PC-3 prostate tumor
xenograft mouse model. It is important to note that both the targeted and the control
HPMA have analogous molecular weights. At 2 h and 24 h p.i., the 131I-labeled G3-C12
HPMA copolymer conjugate had significantly higher tumor accumulation (1.60 ± 0.08%
ID/g and 1.04 ± 0.19% ID/g) as compared to the non-target HPMA copolymer (1.19 ± 0.04%
ID/g and 0.36 ± 0.04% ID/g), implying the active tumor targeting effects of the G3-C12

peptide in the HPMA copolymer paradigm.

1.4.3 In Vivo application in human patients
Based on many promising preclinical findings, in 1994, HPMA-GlyPheLeuGly-Dox
(PK1) became the first applied passively tumor-targeted polymeric prodrug to enter
clinical trials [95] and was given by i.v. administration to 36 patients with different types
of tumors [96]. As part of the clinical investigation of PK1, planar scintigraphy imaging
studies using 131I- and 123I-labeled PK1 was utilized to quantify the in vivo biodistribution
and to visualize its tumor uptake. The tumor uptake of 131I-labeled PK1 allowed for clear
visualization of the primary cancer in a number of patients. The scintigraphy study
clearly showed the clearance of the 28 kDa radiolabeled HPMA copolymer from the
body through renal filtration. 123I-labeled PK1 was found to localize into the metastatic
lesions of some patients. For example, a large metastasis was observed in the left
shoulder region of a breast cancer patient (Figure 1.7A) [97]. Further clinical
investigations were carried out on PK2, an analogue to PK1, but functionalized with
galactosamine to improve the liver targeting ability. 123I-labeled PK1 and PK2 were
administered to some hepatocarcinoma patients and their in vivo behavior was
compared [97]. Significant liver accumulation of PK2 was present even after 48 h p.i.,
while little accumulation was observed for PK1 at the same time point. However, the
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integrated SPECT/CT images showed that the active targeting conjugate mainly
accumulated in healthy liver tissues (17 ± 4% ID) instead of in hepatocarcinoma (3 ± 6%
ID). This was explained by the relatively small size of liver tumors as compared to

healthy livers and by the fact that hepatocarcinoma was not as well-perfused as healthy
liver tissues.
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A

B

Figure 1.7: A, Gamma scintigraphic imaging of 123I-labeled PK1 in a breast cancer
patient with a metastatic lesion in the left shoulder region as indicated by the arrow; B,
gamma scintigraphic imaging of 123I-labeled PK2 in four hepatocarcinoma patients.
Adapted from Ref [97].
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1.4.4 Radiotherapy using HPMA copolymers
The application of radiolabeled HPMA copolymers for tumor-targeted radiotherapy is
relatively new and remains to be thoroughly explored. Mitra et al. prepared HPMARGD4C conjugates and labeled them with Yttrium-90 (90Y) via the CHX-A’’-DTPA
chelator side chain [64]. 90Y is a well-known therapeutic radioisotope due to its optimal
beta emission (βmax 2.27 Mev) properties and the ability to form in vivo stable complexes
with DTPA. They evaluated the radiotherapeutic efficacy of these 90Y-labeled HPMARGD4C conjugates in a DU-145 tumor xenograft mouse model with a tumor size of
around 0.3 cm3 in volume. Biodistribution studies showed that the tumor accumulation
increased significantly (p<.01) over time from 1.05 ± 0.03 % ID/g at 1 h to 4.32 ± 0.32%
ID/g at 72 h. At the end of the therapeutic study, they observed a 7% and a 63%
average decrease in tumor volume for the single dose 100- and 250-μCi 90Y treatment
groups, respectively, while the control tumors increased by 442% on average in volume
(Figure 1.8). In addition, no acute toxicity was found in the liver and spleen samples from
the treatment groups. The study showed that HPMA copolymers are effective carriers to
deliver therapeutic doses of radioactivity to inhibit tumor growth. One recent study also
showed that the combination treatment of 90Y-labeled HPMA copolymer and PEGylated
gold nanorod-mediated hyperthermia could exhibit greater reduction in tumor growth as
compared to single treatment alone in a prostate tumor mouse model [98].
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Figure 1.8: Tumor growth of DU-145 xenografts in SCID mice after different treatment:
250 µCi 90Y-labeled HPMA-RGD4C conjugate (closed circle), 100 µCi 90Y-labeled HPMA
RGD4C conjugate (open triangle) and untreated control (closed square). Adapted from
Ref[64].
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1.5 SUMMARY AND CURRENT PROPOSAL
HPMA copolymers are very safe and biocompatible, and can effectively accumulate
in tumor sites, which makes them a promising platform for the development of SPECT or
PET tracers for pancreatic cancer imaging as well as a good carrier for targeted
radiotherapy. However, one major challenge for the development of diagnostic and/or
therapeutic HPMA copolymer based agents is their opsonization and sequestration by
the MPS. In many cases, the sequestration of these polymers leads to substantial
accumulation in the liver and spleen. From a diagnostic perspective, this MPS
accumulation in non-target organs can hinder identification of resident or nearby
metastatic lesions thereby decreasing the diagnostic efficiency. From the view of
therapeutic applications, the non-target accumulation of the polymer drug conjugates
can lead to significant toxicities which may be dose-limiting.

Our laboratory is interested in developing synthetic approaches in which HPMA
copolymers can be modified to significantly reduce the MPS accumulation or increase
the tumor accumulation, thereby enhancing the diagnostic and/or radiotherapeutic
efficacy of these agents. Hypotheses to be tested are: 1) the incorporation of metabolic
active linkers into HPMA copolymers can lead to lower liver and spleen radioactivity
retention; 2) the appropriate optimization of metabolic active linkers and the molecular
weight of HPMA copolymers can result in a viable platform for pancreatic tumor imaging;
3) the conjugation of certain targeting ligands (plectin-1 targeted peptide) to HPMA
copolymers can enhance the pancreatic tumor accumulation of radiolabeled HPMA
copolymers.
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Lu-Labeled HPMA Copolymers Utilizing Cathepsin B and S

Cleavable Linkers: Synthesis, Characterization and Preliminary
In Vivo Investigation in a Pancreatic Cancer Model

2.1 INTRODUCTION
Over the last three decades, biomedical researchers have seen the dramatic
emergence of polymeric micro- and nanoparticle drug delivery technologies for the
treatment of human disease [99-101]. These drug delivery systems include an array of
paradigms such as: liposomes, polymer micelles, dendrimers and polymer conjugates.
The development of polymeric diagnostic and therapeutic drug delivery systems offer
several advantages over traditional drug delivery including the ability to control both the
rate and location of drug release. However, one of the main disadvantages of these
micro- and nanoparticle based systems has been opsonization and uptake by
macrophages (e.g. Kupffer cells) of the mononuclear phagocyte system (MPS) [101,
102]. The hallmark of this MPS uptake is the significant accumulation of the drug
delivery system in organs containing MPS cells, specifically the liver and spleen, which
can lead to significant toxicity. The development of PEGylation strategies to create
“stealth” micro- and nanoparticle systems has contributed to a decrease in MPS
accumulation thereby increasing the longevity of the polymeric drug delivery system in
the bloodstream [101]. Unfortunately, even with the development of PEGylated
techniques, a substantial portion of these polymeric drug delivery systems are still being
sequestered by MPS tissues.
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N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers have been extensively
investigated as a drug delivery vehicle for a variety of chemotherapeutics [100, 103].
While most of the focus on HPMA polymer conjugates has centered on
chemotherapeutics, there have been published reports by a variety of investigators
regarding the development of diagnostic nuclear imaging and radiotherapeutic agents
[67, 84, 96, 104-109]. To date, the majority of these radiolabeled HPMA copolymer
conjugates have centered on radioisotopes of iodine (e.g. 131I and 123I). However, recent
work by Line, Ghandehari and co-workers, has employed various radiometals (e.g.

99m

Tc,

111

In and 90Y) common to clinical nuclear medicine [104, 105, 107, 108, 110]. The bulk

of the HPMA copolymer conjugates investigated has focused on copolymers that were
below the renal excretion threshold (i.e. ~45 kDa) in order to reduce MPS accumulation.
While HPMA copolymer conjugates with molecular weights higher than the renal
excretion thresholds have demonstrated significantly enhanced tumor delivery, the
corresponding substantial increase in MPS tissue retention has largely made this
approach undesirable for diagnostics and therapeutic agent development [103].

Cysteine cathepsins are predominantly lysosomal proteases that have been found
to have diverse functions, but are primarily attributed to protein catabolism [111]. The
function of cathepsin B has mainly been associated with the turnover of both intracellular
and extracellular (through endocytosis) proteins in the lysosomal compartment. Tissue
expression of cysteine cathepsins has been shown to be variable largely depending on
the function of the protease. In some cases such as cathepsin B, the protease is
expressed ubiquitously in almost every tissue [100, 112]. However, the highest levels of
cathepsin B activity have been found in the liver, spleen, thyroid and kidneys for both
murine and humans [113, 114]. For humans the activity of these tissues are 3 -10 fold
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higher than other non-target tissues. Conversely, the expression of some cysteine
cathepsins, for instance cathepsin S, is selectively expressed in only a small group of
cells. Cathepsin S is thought to be an integral protease in the degradation of antigenic
proteins as part of the Major Histocompatibility Complex Class II pathway in antigen
presenting cells [112, 115]. As a consequence of the critical role of cathepsin S in
human immune response, the expression of cathepsin S has been shown to reside
primarily in immune cells [116, 117]. Cathepsin B and S are both highly expressed in
tissues that are associated with MPS uptake and retention of drug delivery systems.

Protease cleavable linkers are attractive for use in drug delivery due to the typically
high serum stability and specificity of the substrate-linkers [118]. In polymer based drug
delivery, Kopeček and others have demonstrated the utility of protease cleavable linkers,
specifically cathepsin B cleavable linkers, to increase in vivo drug delivery to tumor
tissues [100, 103]. However, this technique has also been exploited to decrease
retention of radioimmunoconjugates in non-target tissues (e.g. liver) without significantly
affecting tumor retention thereby increasing the therapeutic index of the agent [119].
One of the research focuses of our laboratory has been the design of protease cleavable
linkers for the development of diagnostic and radiotherapeutic drug delivery systems.
The impetus for the development of linkers that are substrates for cathepsin B and S is
the high level of expression of these proteases in MPS tissues. The goal of this research
is to create metabolically active linkers (MALs) that will increase the efficacy of the
diagnostic or radiotherapeutic drug delivery systems by reducing the MPS accumulation.
Herein, we describe our initial efforts in the development of MALs using
radiolabeled HPMA copolymers as our model system.
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2.2 MATERIALS AND METHODS
2.2.1 Solid-Phase Peptide Synthesis
The MAL1 and MAL2 peptides were synthesized on an H-Phe-2-ClTrt and H-Pro-2ClTrt SPPS resin, respectively, using a microwave peptide synthesizer. The resin
(containing 0.25 mmole of peptide anchors) was deprotected using piperidine resulting in
the formation of the primary amine. The carboxylic acids of the Fmoc protected amino
acids (1 mmol) were activated using COMU and conjugated to the primary amines of the
growing peptide on the resin. The process of deprotection, activation and conjugation
was repeated until the desired peptide was synthesized. The selective cleavage of the
peptide from the 2-chlorotrityl resin anchor was achieved by reaction with 1% TFA in
dry DCM and subsequent filtration. The combined crude filtrates were dried by a rotary
concentrator. Purification of the peptides was performed using a semi-preparative Proteo
C12 column with a flow rate of 5.0 mL/min. HPLC solvents consisted of H2O containing
0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent B). For
both peptides, the initial gradient of 70 % A: 30 % B linearly decreased to 60 % A: 40 %
B over a 15 minute time period. At the end of the run time for all HPLC experiments, the
column was flushed with the gradient 5 % A: 95 % B and re-equilibrated to the starting
gradient. The yields after purification were 0.042 mmole, 16.9% (n = 1) for MAL1 and
0.090 mmole, 37.5% (n = 1) for MAL2. Both peptides were determined to be ≥ 95% pure
as characterized by LC/MS before in vitro or in vivo use.

2.2.2 Cathepsin Cleavage Assay of MALs
MAL1 and MAL2, 1.51 and 1.22 µmole, respectively, were each weighed and placed
into a 1 mL centrifuge tube. Each peptide was dissolved in 100 μl of buffer solution
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containing 100 mM sodium acetate, 1 mM EDTA and 5 mM DTT. Solutions of cathepsin
B and S were prepared at a concentration of 25 ng/μL. The pH of the solution for
dissolution of both the peptide and protease was adjusted to 5.0 and 6.0 for cathepsin B
and S assays, correspondingly. In the appropriate tube, 2 and 50 μl of the cathepsin B
and S, respectively, were added. The cleavage assay was allowed to proceed for 96
hours at room temperature and was evaluated every 24 hours by LC/MS. Evaluation of
the peptides was performed using an analytical Proteo C12 column with a flow rate of 1.5
mL/min. HPLC solvents consisted of H2O containing 0.1% formic acid (solvent A) and
acetonitrile containing 0.1% formic acid (solvent B). For both peptides, the initial gradient
of 70 % A: 30 % B linearly decreased to 60 % A: 40 % B over a 15 minute time period.
At the end of the run time for all HPLC experiments, the column was flushed with the
gradient 5 % A: 95 % B and re-equilibrated to the starting gradient. Cleavage estimates
were determined by integration of the peptides and metabolite peaks from the total ion
chromatogram generated by the LC/MS Waters MassLynx software.

2.2.3 Synthesis and Characterization of the HPMA Copolymer
The HPMA copolymerization was accomplished using the reversible additionfragmentation chain transfer polymerization reaction with V-501 as the initiator and CTP
as the chain transfer agent. The feed ratio of the polymerization consisted of
98.75:0.85:0.40 mole% HPMA, APMA and APMA-FITC, respectively. The
polymerization was run at a 1 M total monomer concentration in aqueous acetic buffer
(pH = 5.2, 0.27 M acetic acid and 0.73 M sodium acetate) with a molar ratio of total
monomer: chain transfer agent: initiator of 2340:3:1. Prior to proceeding with the
polymerization reaction, the glass ampule and contents were purged with argon for 20
min. Subsequently, the ampule was flame sealed and allowed to heat at 70 C in an oil
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bath for 14 hours. After cooling the HPMA copolymer was evaporated to dryness,
dissolved in methanol and purified by size exclusion chromatography using an LH-20
packing material with methanol as the eluent. The conversion rate was 71% as
determined by weight after purification. The weight average molecular weight and
polymer dispersity of copolymers were determined by FPLC equipped with UV and RI
detectors. The FPLC measurements were carried out on Superose 6 column (HR 10/30)
with PBS (pH 7.3) as the eluent. The average molecular weights of the copolymers were
estimated using HPMA homopolymer standards with narrow polydispersity indices.

2.2.4 Quantification of the Amine Content in the HPMA Copolymers
Quantitation of the primary amine content of the HPMA copolymer was assessed
using a slightly modified ninhydrin assay reported by York and co-workers [120]. A
ninhydrin solution was prepared by dissolving 5.61 mmole of ninhydrin in 25 mL ethylene
glycol. A SnCl2 solution was made by dissolving 0.177 mmole of SnCl2.2H2O in 25 mL of
0.2 M citrate buffer. A ninhydrin-SnCl2 solution, of the desired quantity, was prepared by
mixing the two solutions together in a 1:1 volumetric ratio. For the purpose of the
creation of a calibration curve, a solution of 3 mM glycine was dissolved in 10 mL DI H2O
and seven standard solutions were prepared by aliquoting amounts from 7.5 – 45 μL of
this glycine solution into separate tubes. A 3 mM HPMA copolymer solution was
prepared in DI H2O. For the unmodified HPMA copolymers, MAC0, MAC1 and MAC2 the
sample size used were 0.0171, 0.0176, 0.0173 and 0.010 µmole, respectively. For each
HPMA copolymer solution, an aliquot of 7.5 μL was added to a sample tube. To both the
standard and sample tubes, 200 μL of the ninhydrin-SnCl2 solution was added. The
sample and standard solutions were heated to 100 oC for 2 h and then allowed to cool to
room temperature. The volumes of all solutions were adjusted to 3 mL using DI H2O and
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analyzed by UV spectroscopy at 570 nm. The amine content of the HPMA copolymers
was determined based upon the calibration curve generated by the glycine standards.
Amine content in the unmodified HPMA copolymers, MAC0, MAC1 and MAC2 was
found to be 70.4, 11.5, 19.1 and 11.7 μmol/g of polymer (n = 1 for each copolymer),
correspondingly. Conjugation efficiencies were calculated by determination of the
difference in the amine content between the MAC and the unmodified HPMA copolymer.

2.2.5 Synthesis of the MACs
The HPMA copolymer (0.292 µmole) was dissolved in 500 μl of DMF. The amine
content in 0.292 µmole of HPMA copolymer was 7.04 μmol (1 equiv). In a 10 mL round
bottom flask, 20.3 (35.4 μmol, 5.0 equiv), 20.0 (16.2 μmol, 2.3 equiv) or 22.8 mg (16.2
μmol, 2.3 equiv) of MAL0, MAL1 or MAL2 was dissolved in 500 μl of DMF. The solution
was cooled to 0 C and NHS and DCC were added to the flask in the same equivalent
amount as the MAL. The solution was stirred at 0 C for 3 h. At the end of that time, the
HPMA copolymer was added and stirred for another 2 h at 0 C. Subsequently, the
reaction was allowed to warm to room temperature and continued for an additional 18
hours. The precipitate generated from the reaction was filtered off and the filtrate was
evaporated to dryness. The residue was dissolved in methanol followed by size
exclusion chromatography using an LH-20 packing material. Evaporation of the high
molecular weight fraction afforded light yellow HPMA copolymer-peptide conjugates.
Based on the determined conjugation efficiencies from the ninhydrin assays, the percent
recovery (n =1) of MAC0 was 77.6 (0.233 µmole), MAC1: 45.3 (0.140 µmole) and MAC2:
50.0% (0.157 µmole).
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Deprotection of the orthogonal protecting groups was accomplished using standard
peptide cleavage conditions. Briefly, to a 0.0875 µmole sample of the MAC0, MAC1 and
MAC2 was added 4 mL of a cleavage cocktail at 0 C consisting of a 1:1:1:37 volumetric
ratio of DODT, water, TIS and TFA. For the MAC2, the cleavage cocktail used was a
1:1:1:0.75:46.25 volumetric ratios of DODT, water, TIS, thioanisole, and TFA. Initially,
the solution was stirred for 15 min at 0 °C. Subsequently, the cleavage reaction was
allowed to warm up to room temperature and was continued for an additional 3 h. At the
end of that time, the solution was evaporated and the residue dissolved in methanol
followed by size exclusion chromatography using LH-20 packing material with methanol
as the eluent. The collected high molecular weight fractions were evaporated to dryness
to afford the deprotected copolymer-peptide conjugates. Based on the determined
conjugation efficiencies, the percent recoveries (n = 1) of MAC0, MAC1 and MAC2 were
80.2 (0.0697 µmole), 100 (0.0863 µmole) and 93.4 % (0.0808 µmole), respectively.

2.2.6 Radiolabeling of the HPMA Copolymers
The radiolabeling of the MACs was accomplished by heating the copolymer at 90 C
for 1 h in the presence of 74 MBq (2mCi) of 177LuCl3. After cooling the resulting 177Luradiolabeled MACs were purified by radio-SEC-HPLC. Isolation of the 177Lu-MACs was
accomplished using an isocratic mobile phase consisting of PBS with 0.02 mM EDTA at
pH 7.4. The linear flow rate was 0.80 mL/min. UV analysis was performed at a
wavelength of 494 nm. After collection of the peak-purified 177Lu-radiolabeled MACs,
0.113 mmole of L-ascorbic acid was added as a radiolysis inhibitor. The purified 177Luradioconjugate was concentrated using an Amicon Ultra-4 Centrifugal Filter and washed
with 5 mL of deionized water. The purified 177Lu-radiconjugates were diluted with sterile
saline to 0.37 MBq (10 μCi) per 100 μL. The radiochemical purity of all radioconjugates
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was re-evaluated before administration and found to be ≥ 95 % pure as determined by
the radio-HPLC.

2.2.7 Cathepsin Cleavage Assay of Radiolabeled Copolymers
Briefly, 0.291 nmole of each purified 177Lu-radiolabeled MACs (90~120 µCi) was
incubated in a buffer with the indicated cathepsin in Eppendorf tubes at 25 ºC. The
buffer solution consisted of 50 mM sodium acetate, 1 mM EDTA and 5 mM DTT, and pH
was adjusted 5.0 for cathepsin B and 6.0 for cathepsin S to maximize the enzyme
activity. For the MAC0, the copolymer was incubated in the presence of either cathepsin
B (5 ng/µl) or cathepsin S (10 ng/µl) in 400 µl of buffer solution. MAC1 and MAC2 were
incubated with cathepsin B (5 ng/µl) and cathepsin S (10 ng/µl), respectively, in 400 µl
buffer. After every 24 hours, a 100 µl aliquot of the copolymer solution was analyzed by
radio-SEC-HPLC to determine the relative amount of cathepsin cleavage product. The
analysis utilized an isocratic gradient with a mobile phase consisting of PBS with 0.02
mM EDTA at pH 7.4. The radio-SEC-HPLC analysis was carried out utilizing a linear
flow rate of 0.80 ml/min and a UV wavelength of 494 nm.

2.2.8 Human Serum Stability of Radiolabeled Copolymers
Briefly, 0.291 nmole of purified 177Lu-MAC0, 177Lu- MAC1 and 177Lu-MAC2 was
incubated with 1 mL of human AB serum at 37 C. After 72 h, the stability was
determined by centrifuge filtration using an Amicon Ultra Ultracel 10 kDa filter. A 100µl
aliquot was loaded in the filter and diluted with 4 mL DI water, centrifuged and washed
with an additional 4 mL DI water. The percent stability of
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was calculated based on the radioactivity of the copolymers remaining in the 10 kDa
filter and the total radioactivity added.

2.2.9 Macrophage Differentiation and Cell Culture
Human monocytes were harvested from normal donors in the UNMC Elutriation Core
Facility. Upon receipt, monocytes were immediately plated into T75 tissue culture flasks
at a concentration of 20 x106 cells in 20 mL of macrophage differentiation medium
DMEM containing 10% FBS, 1% Penicillin/Streptomycin, 2 mM l-glutamine, 1% sodiumpyruvate, 1% NEAA and 500 U rhM-CSF. Media was half-exchanged every 2 to 3 days
for 7-10 days, at which time, visual confirmation of differentiation was made and media
was changed to macrophage maintenance medium (differentiation medium without the
rhM-CSF). Cells were maintained at 37 C at 5% CO2 in air.

The HPAC cells were cultured in our laboratory, as per ATCC protocols, in a 1:1
mixture of DMEM and Ham's F12 medium containing 14.3 mM sodium bicarbonate, 2.5
mM L-glutamine, 15 mM HEPES and 0.5 mM sodium pyruvate supplemented with 0.350
µM insulin, 0.0625 µM transferrin, 0.110 µM hydrocortisone, 1.562 nM epidermal growth
factor and 5% FBS. Cells were incubated at 37 °C at 5% CO2 in air.

2.2.10 Cathepsin B and S Activity Assays
The cathepsin B and S activity in macrophage and HPAC cell lines was determined
using a commercial cathepsin B and S activity assay kit. The method is simplified as
follows: 2 million macrophage and HPAC cells each were subjected to 500 μl cell lysis
buffer. After 10-min incubation on ice, the cell lysate was centrifuged at 3000 rpm for 5
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min. For each individual assay, 50 μl of the supernatant was transferred to a 96-well
plate to which 50 µl of reaction buffer and 2 µl of either cathepsin B or S substrate was
added. For the control group, another 2 µl of cathepsin B or S inhibitor was added. The
reaction was allowed to proceed at 37 C for one hour. Samples were read using a
fluorometer with a 400-nm excitation filter and a 505-nm emission filter. Activities
correlating with the specified cathepsin protease were determined by subtraction of the
RFU measurements of the samples with and without inhibitor. Each individual assay was
replicated 10 times.

2.2.11 Internalization Study of MACs by Flow Cytometry
Macrophage and HPAC cells were seeded in 6-well plates at a density of 5 × 105
cells per well and incubated in media overnight (37 °C, 5% CO2). Cells were then
incubated with three MACs (0.1 mg/mL) at 37 °C for the indicated time periods. After
incubation, the media was removed. Cells were harvested and washed with PBS three
times followed immediately by ﬂow cytometry analysis. Each sample analysis involved
the evaluation of 1.0 × 104 cells. The collected data was averaged and reported as the
mean ﬂuorescent intensity for each sample.

2.2.12 Biodistribution Studies
Biodistribution studies were carried out using SCID mice with HPAC xenografts. The
inoculation media was prepared using a 1:1 volumetric ratio of suspended HPAC cells to
Matrigel™ to obtain a final concentration of 2 × 106 HPAC cells per 100 μl. The mice
received a 100 μl subcutaneous inoculation into each flank. Upon achieving sufficient
tumor size, (10-20 mm in diameter) the mice were considered viable for biodistribution
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studies. The mice (average weight, 25g) were injected with a 0.37 MBq (10 μCi)
intravenous bolus of the purified 177Lu-MAC. The mice were sacrificed and their tissues
excised at 24, 48 and 72 h time points post-injection. The excised tissues were weighed
and the 177Lu activity measured in each tissue using a gamma counter. Aliquots of the
injected dose were counted as a reference standard for the calculation of % ID/g values.

2.2.13 Statistical Analysis
Data is presented as mean ± SEM. Evaluation of significance between the three
groups of data was accomplished using a non-parametric Kruskal Wallis test. If the
overall p-value from the Kruskal Wallis test was < 0.05, pairwise comparisons were
made between the three groups using a non-parametric Mann Whitney test. In all cases,
the reported p-values are adjusted and an adjusted p-value ≤ 0.10 was considered
statistically significant.

2.3 RESULTS
2.3.1 Design and Synthesis of the Metabolically Active Linkers (MALs)
The MALs used in synthesis of the metabolically active copolymers (MACs) are
depicted in Figure 2.1. For MAL1 and MAL2, the peptide sequences are composed of
three parts: the radiometal chelation system, the clearance sequence, and the metabolic
sequence. Both MAL1 and MAL2 contain the same chelation system (DO3A) and
clearance sequence (G-(D)S(tBu)-(D)S(tBu)), but differ in the metabolic sequence. For
MAL1 the metabolic sequence (G-G-G-F) is a known substrate for the cathepsin B
protease whereas the metabolic sequence for MAL2 (P-M-G-L-P) is a known substrate
for cathepsin S [121, 122]. In the studies described herein, MAL0 is simply the DO3A
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chelation system and is the control for our experiments. The MAL0 contains no amino
acids and would not be expected to undergo any proteolytic degradation. All of the MALs
were prepared with intact orthogonal protecting groups in order to carry out subsequent
conjugation reactions with the HPMA copolymer. The synthesis of MAL1 and MAL2 was
accomplished using SPPS. Detachment of the protected MALs from the resin support
was accomplished with dilute acid (1% TFA) using 2-chlorotrityl anchor chemistry. The
crude MALs were isolated and peak purified (n = 1) yielding 16.9% for MAL1 and 37.5 %
for MAL2 of isolated, purified material (based on a 0.25 mmol scale synthesis). The RPHPLC retention times and the mass spectrometric characterization of the MALs are
depicted in Table 2.1.
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Figure 2.1: Schematic of the design of MALs.
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Table 2.1: MALs characterization
MAL
Peptide

Sequence

Formula

Rt (min)
RP-HPLC

Mass
Expected
+
[M+H]

Mass
Observed
+
[M+H]

MAL0

DOTA(tBu)3

C28H52N4O8

--

573.4

573.2

MAL1

DO3A(tBu)3-G-(D)S(tBu)(D)S(tBu)-G-G-G-F

C59H99N11O17

6.5

1234.7

1234.5

MAL2

DO3A(tBu)3-G-(D)S(tBu)(D)S(tBu)-P-M-G-L-P

C67H118N12O18S

9.8

1411.8

1411.5

54
2.3.2 In Vitro Metabolism of MALs
In order to confirm that the MAL1 and MAL2 will undergo proteolytic cleavage, the unmetalated, protected MALs were incubated in the presence of the appropriate cathepsin
protease. LC/MS analyses (n = 1) of the metabolism of MAL1 and MAL2 by cathepsin B
and S, correspondingly, are displayed in Figure 2.2. Under the gradient conditions
employed, the MAL1 and MAL2 peptides exhibited retention times of 5.7 and 8.9 min,
respectively. For MAL1 a significant metabolite peak was observed at a retention time of
4.3 min. At 24 and 48 h post incubation, LC/MS analyses revealed that 56 and 78 %,
respectively, of the original MAL1 peptide had been metabolized. Evaluation of the MAL1
metabolite mass (1030.5 Da) corresponds to the site of proteolytic cleavage being
between the first and second glycine residues from the C-terminus (GG┼GF). With
respect to the MAL2 peptide, a metabolite was observed with a retention time of 7.0 min.
Over the course of the study, the amount of MAL2 peptide metabolized increased from 11
to 80 %. The mass of the metabolite corresponded with the cleavage site being located
between the glycine and leucine residues (DO3A-G-(D)S-(D)S-P-M-G┼L-P). Overall,
these studies demonstrate that both MAL1 and MAL2 are proteolytically active and that
the rate of metabolism of MAL2 by cathepsin S was slower relative to the cathepsin B
cleavage of MAL1.
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Figure 2.2: Evaluation of cathepsin B and S cleavage of MAL1 and MAL2,
correspondingly. A, Total ion chromatograms of the cleavage of MAL1 by cathepsin B at
24 and 48 h post-incubation B, Total ion chromatograms of the cleavage of MAL2 by
cathepsin S at 24, 48 and 72 h post-incubation C, Depicts the enzymatic cleavage sites
of MAL1 and MAL2.
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2.2.3 Design and Synthesis of the Metabolically Active Copolymers
The scheme for the synthesis of the MACs is depicted in Figure 2.3. The HPMA
copolymer consisted of HPMA, APMA and APMA-FITC monomers which were
polymerized, using reversible addition-fragmentation chain transfer (RAFT)
polymerization, with a feed composition of 98.75:0.85:0.40, respectively. Assessment of
the synthesized HPMA copolymer by FPLC revealed a molecular weight of 343 kDa with
a polydispersity of 1.6. Evaluation by quantitative ninhydrin analysis revealed that 121%
of the APMA monomer was incorporated into the HPMA copolymer which yielded a total
amine content of 70.4 µmol/g (n = 1) of polymer.

57

Figure 2.3: Synthetic scheme for the synthesis of the 177Lu-MAC conjugates. For MAC0,
MAC1, MAC2, X = Y = null, X = GSS, Y = GGGF and X = GSS, Y = PMGLP respectively.
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Conjugation of the MALs to the HPMA copolymer was accomplished using standard
coupling chemistry. The preparation of protected peptides allowed for chemo-selective
coupling of the C-terminal carboxylic acid with the aliphatic amine of the HPMA
copolymer. Once the MALs were conjugated to the HPMA copolymer, the HPMA
copolymers were termed MAC0, MAC1 and MAC2 corresponding to the conjugated MAL.
Deprotection of the peptide components of the MACs were carried out using a standard
cleavage cocktail containing predominantly trifluoroacetic acid. The deprotection of the
MACs was verified by evaluation of MAC0 before and after deprotection using NMR
(supporting information). The signal for the t-butyl groups of the DO3A was eliminated
after the deprotection reaction corresponding to the loss of the t-butyl groups. With this
information in hand, the cleavage conditions used for MAC0 were determined to be
sufficient for the deprotection of MAC1 and MAC2. After deprotection the coupling yield
of the MACs were analyzed by quantitative ninhydrin analyses. Ninhydrin analysis gave
an 83.6, 72.9 and 83.4 % coupling efficiency (n = 1) for MAC0, MAC1 and MAC2,
respectively.

2.3.4 Synthesis, Cathepsin Cleavage and Serum Stability of

177

Lu-labeled-MACs

The 177Lu-radiolabeled MACs were prepared using relatively mild conditions.
Incubation of the MACs with 177LuCl3 for 1 h at 90 °C gave relatively moderate to good
radiochemical yields of 60 - 85 % (n = 3). Radiolabeled yields were found to be
dependent, to some extent, on the HPMA copolymer concentration. A more thorough
investigation of the parameters that influence the radiolabeling efficiency of MACs is ongoing. The ability of the synthesized 177Lu-MACs to undergo Cathepsin B and S
cleavage was investigated over a 72 h period, Figure 2.4. During the course of the
investigation, the non-cleavable control (177Lu-MAC0) was found to be stable in the
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presence of Cathepsin B and S with negligible cleavage as determined by radio-SECHPLC. However, 177Lu-MAC1 and 177Lu-MAC2 demonstrated significant cleavage as
shown by the generation of the low-molecular weight radiometabolite after 72 h of
incubation. The percentage of the generated radiometabolite was 8 and 26 % (n = 1) for
177

Lu-MAC1 and 177Lu-MAC2, respectively. The stability of the 177Lu-labeled-MACs in

human serum was investigated by incubation at 37 °C for a 72 h period. Over the course
of the study, the percentage of intact 177Lu-labeled-MACs remained greater than 98%.
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Figure 2.4: Cathepsin B and S cleavage of 177Lu-MAC0, 177Lu-MAC1 and 177Lu-MAC2 as
determined by radio-SEC-HPLC at 72 h post-incubation.

61
2.3.5 Cathepsin Activity and MAC Uptake in Macrophage and HPAC Cell Lines
In the investigation of the in vitro properties of the MACs, differentiated human
macrophage and HPAC cancer cell lines were used as in vitro models of the MPS and
pancreatic cancer. The cathepsin B and S activity in both of these cell lines were
investigated by fluorometric analysis, depicted in Figure 2.5. In a cell to cell comparison,
the differentiated macrophage demonstrated substantially higher activities of both
cathepsin proteases relative to the HPAC cell line. The protease activity in the
macrophage was 70 and 10 fold higher for cathepsin B and S, respectively, relative to
the HPAC cell line.
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Figure 2.5: Evaluation of cathepsin B and S activity between macrophage and HPAC cell
lines. Data is presented as mean ± S.D. from n=10 experiments.
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The cellular uptake of the MACs in differentiated macrophage and the HPAC cell line
was investigated. Utilizing flow cytometry analysis, the relative uptake of the MACs in
terms of mean fluorescence units is depicted in Figure 2.6. Over the 48 h incubation time,
all of the MACs investigated demonstrated steady increase in macrophage uptake. In
comparison, the HPAC cell line revealed little uptake of the MACs over the time period
studied.
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Figure 2.6: Mean fluorescence of MAC0, MAC1 and MAC2 after 0 h, 24 h and 48 h
incubation in macrophages and HPAC cells measured by flow cytometry.
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2.3.6 Biodistribution Studies of 177Lu labeled MACs in HPAC Xenograft SCID Mice
A preliminary investigation of the in vivo tumor targeting and clearance properties of
the MACs was performed in a SCID mouse model bearing HPAC tumor xenografts. The
results of the biodistribution studies of the three 177Lu-MACs at 24 and 72 h postinjection are given in Table 2.2. At 24 h post-injection, the blood retention of the 177LuMAC1 and 177Lu-MAC2 was, on average, lower than the control (177Lu-MAC0). All of
177

Lu-MACs demonstrated a 2 fold decrease in blood retention by the 72 h p.i. time point.

At 24 h post-injection, the liver accumulation of the 177Lu-MAC1 and 177Lu-MAC2 was
3.44 ± 0.82 and 5.29 ± 0.98 %ID/g, correspondingly, which was lower than the 7.27 ±
2.64 %ID/g of 177Lu-MAC0 (p = 0.34). The liver retention of the 177Lu-MAC0 increased to
a final accumulation of 11.36 ± 1.65 %ID/g at 72 h post-injection. Conversely, the liver
retention of the MACs that utilize cleavable peptides,

177

Lu-MAC1 and 177Lu-MAC2,

remain statistically the same with 3.61 ± 0.63 and 5.46 ± 0.44 %ID/g, respectively, at the
72 h time-point. At the 24 h time-point, the spleen retention of 177Lu-MAC1 and 177LuMAC2 were lower on average than the 177Lu-MAC0. However, by the 72 h time-point, the
177

Lu-MAC0 demonstrated a substantial increase in spleen retention of 21.46 ±

4.41 %ID/g. In comparison, 177Lu-MAC1 and 177Lu-MAC2 exhibited a significantly lower
retention of 5.63 ± 1.22 (p = 0.06) and 5.67 ± 0.75 %ID/g (p = 0.03), respectively, which
corresponds to a substantial 4 fold reduction in spleen accumulation at the analogous
time point. With regards to tumor retention, the control exhibited higher accumulation at
all time-points investigated. At the 24h time point, the tumor uptake of 1.18 ± 0.25 and
1.64 ± 0.18 %ID/g 177Lu-MAC1 and 177Lu-MAC2 was substantially lower than the 4.09 ±
1.41 %ID/g of the 177Lu-MAC0 (p = 0.16). By 72 h post-injection, the 177Lu-MAC0 tumor
accumulation increased by 61% to 6.58 ± 0.93. For 177Lu-MAC1 and 177Lu-MAC2, the
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tumor retention increased to 2.33 ± 0.30 and 3.49 ± 0.28 %ID/g, representing an
increase of 125 and 113%, correspondingly, at the 72 h time-point.

67
Table 2.2: Biodistribution studies of 177Lu-MAC0, 177Lu-MAC1 and 177Lu-MAC2 at 24 and
72 h post-injection in HPAC tumor-bearing SCID mice. Data is represented as %ID/g.

24 hours
b

Lu-MAC1

72 hours
a

Lu-MAC2

c

Lu-MAC0

b

Lu-MAC1

b

Lu-MAC2

c

Tissues

Lu-MAC0

Blood

28.50 ± 6.59

14.85 ± 1.23

17.76 ± 1.57

13.40 ± 1.71

8.54 ± 1.76

8.89 ± 0.65

Bladder

9.09 ± 3.49

1.63 ± 0.94

3.11 ± 0.82

7.15 ± 2.61

2.18 ± 0.25

3.61 ± 0.34

Small Int.

1.36 ± 0.42

0.85 ± 0.15

0.97 ± 0.12

1.25 ± 0.21

0.51 ± 0.09

0.67 ± 0.06

Large Int.

1.48 ± 0.38

0.84 ± 0.09

1.31 ± 0.17

1.25 ± 0.21

0.54 ± 0.09

1.06 ± 0.15

Stomach

1.02 ± 0.21

0.63 ± 0.07

0.80 ± 0.10

0.91 ± 0.14

0.37 ± 0.07

0.52 ± 0.04

Pancreas

2.16 ± 0.66

0.93 ± 0.22

1.35 ± 0.25

2.95 ± 0.55

1.10 ± 0.20

1.10 ± 0.13

Spleen

7.83 ± 3.32

5.09 ± 1.24

4.95 ± 0.49

21.46 ± 4.41

5.63 ± 1.22

5.67 ± 0.75

Kidney

5.22 ± 1.57

2.50 ± 0.59

3.34 ± 0.44

4.20 ± 0.58

1.93 ± 0.38

2.51 ± 0.17

Tumor

4.09 ± 1.41

1.18 ± 0.25

1.64 ± 0.18

6.58 ± 0.93

2.33 ± 0.30

3.49 ± 0.28

Liver

7.27 ± 2.64

3.44 ± 0.82

5.29 ± 0.98

11.36 ± 1.65

3.61 ± 0.63

5.46 ± 0.44

Lung

8.18 ± 2.60

3.81 ± 0.76

4.16 ± 0.37

5.56 ± 1.01

2.66 ± 0.46

3.56 ± 0.16

Heart

6.13 ± 1.75

2.37 ± 0.50

2.72 ± 0.30

5.00 ± 0.75

1.85 ± 0.38

2.26 ± 0.22

Brain

0.91 ± 0.23

0.30 ± 0.10

0.36 ± 0.04

0.57 ± 0.00

0.24 ± 0.05

0.27 ± 0.02

Bone

1.71 ± 0.51

0.85 ± 0.09

1.20 ± 0.16

3.06 ± 0.46

0.68 ± 0.12

1.02 ± 0.11

Muscle

1.36 ± 0.42

0.71 ± 0.13

0.75 ± 0.08

2.38 ± 0.55

1.37 ± 0.39

1.46 ± 0.15

The data is given in mean ± SEM. aN = 4, bN = 5, cN = 6.
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2.4 DISCUSSION
For cancer diagnostics and therapeutics based on biopolymers such as HPMA
copolymers, it is well known that increases in the molecular weight of the carrier typically
results in an improvement in the enhanced permeability and retention (EPR) effect [103,
123, 124]. As a result of the increase in the EPR effect of the carrier, the drug delivery
system will typically demonstrate an increased localization and retention in cancerous
tissues. Conversely, an increase in the molecular weight of a biopolymer by and large
causes a substantial increase in the MPS accumulation, particularly if the molecular
weight of the carrier is above the renal excretion threshold. The MPS accumulation of
HPMA copolymers, and other nanomedicine platforms, is a major hurdle in the
development of more efficacious biopolymer systems and the translation of these
systems to the clinic [125, 126].

Our approach to this challenge is to develop MALs that preferentially hydrolyze in
MPS cells in order to reduce the retention, and thus radiotoxicity, in non-target tissues.
In our design peptide substrates of cathepsin B and S were chosen due to the high level
of expression of these proteases in MPS tissues. As depicted in Figure 3, the MAL
design is composed of three components: radiometal chelation system, metabolic
sequence and clearance sequence. The DO3A chelation system was chosen because it
has been shown to stabilize a variety of radiometals, including 177Lu, in preclinical and
clinical investigations [127, 128]. The metabolic sequences are composed of known
peptide substrates for the cathepsin B and S enzymes [121, 122]. It is expected that
alterations of the metabolic sequence can be used to influence the rate of enzymatic
cleavage and thus affect clearance of the radiometabolites from the tissues. While the
chosen amino acid sequences have demonstrated selectivity for the corresponding
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protease relative to other lysosomal proteases, it is important to keep in mind that other
proteases may contribute to the metabolism of these sequences in vivo. In order to
better control the pharmacokinetics of the radiometabolite after cleavage, D-amino acids
were employed in the design of the clearance sequence, G-D(S)-D(S), to prevent, or at
least significantly reduce, metabolism. By preventing metabolism the pharmacokinetic
properties of the generated radiometabolite can be better controlled to influence diffusion
and thus biological clearance [129].

The MALs were prepared with intact orthogonal protecting groups using standard
SPPS techniques. Synthesis of the protected MALs was necessary for later
chemoselective conjugation to the HPMA copolymers. Both MAL1 and MAL2, protecting
groups intact, underwent incubation in the presence of the appropriate cathepsin
protease. Over the course of the metabolism study, both of the MALs demonstrated
conversion into a single metabolite. Both of these cleavage sites are in accordance with
previous literature reports [121, 130]. From these initial investigations, the enzyme
kinetics for cathepsin B for MAL1 appears to be significantly faster as compared to
cathepsin S for MAL2.

Synthesis of the HPMA copolymer backbone was accomplished using the RAFT
polymerization technique. The synthesized HPMA copolymer (Mw = 343 kDa, PDI = 1.6)
is well above the renal threshold of 45 kDa. Conjugation of the MALs to the terminal
amine of the APMA copolymer constituent was accomplished in fairly high yield as
determine by ninhydrin assay. In order to ensure chemo-selectivity, MALs were prepared
with intact orthogonal protection groups. The protecting groups prevented functional
groups other than the desired C-terminal carboxylic acid from conjugating to the primary
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amine on the HPMA copolymer. Deprotection of the MACs was accomplished, as
confirmed by NMR, in 3 hours using a standard SPPS cleavage cocktail. Radiolabeling
of the MACs with 177Lu was achieved in good yield using standard radiolabeling
conditions. Incubation of 177Lu-MAC1 and 177Lu-MAC2 in the presence of Cathepsin B
and S, respectively, demonstrated, as expected, that a low-molecular weight
radiometabolite is generated. Exposure of 177Lu-MAC0 (non-cleavable control) to either
of the investigated cathepsin did not show any signs of radiometabolite generation. This
data shows that the generation of the radiometabolite is a proteolytic process. In
additional, this data confirms that the MAL can still be cleaved despite being attached to
the HPMA copolymer support. Serum stability studies of the 177Lu-MACs revealed
essentially no degradation (> 98% intact) suggesting that the 177Lu-MACs would not
susceptible to extracellular blood proteases in vivo.

In our investigations of the in vitro properties of the MACs, we modeled the
phagocytic cells of the MPS and pancreatic cancer cells utilizing differentiated human
macrophage and the HPAC pancreatic cancer cell line, correspondingly. Evaluation of
the cathepsin B and S activity of these cell lines revealed that both cathepsin B and S
activity is substantially higher, 70 and 10 fold respectively, in the macrophages relative
to the HPAC cell line. Additionally, analysis of the internalization rate of the MACs in
these two cell lines demonstrated that macrophages undergo steady uptake of the
MACs over the course of the study, while relatively little uptake was exhibited by the
HPAC cancer cell line. These data imply that the in vivo uptake and metabolism of the
MACs should be strongly favored in MPS cells relative to the pancreatic cancer cells.
Given this, we would expect enhanced clearance from tissues containing MPS
components (i.e., liver and spleen) in vivo.
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Our initial investigation into the in vivo characteristics of the 177Lu-MACs was
undertaken in an HPAC xenograft mouse model. All of the 177Lu-MACs investigated
demonstrated extended blood circulation due to the molecular weight of the HPMA
copolymer being substantially higher than the renal excretion threshold [131].
Interestingly, the blood retention of 177Lu-MAC1 and 177Lu-MAC2 demonstrate similar
longevity in the blood pool and is approximately half of the value of the 177Lu-MAC0 at all
reported time points. The reduced blood retention of the 177Lu-MAC1 and 177Lu-MAC2
relative to the control (177Lu-MAC0) strongly suggest that the HPMA copolymers with
MALs underwent proteolytic cleavage in the blood. However, the in vitro serum stability
studies of the 177Lu-MAC1 and 177Lu-MAC2 revealed no significant proteolysis. These
data imply that the cleavage of the 177Lu-MAC1 and 177Lu-MAC2 is likely due to the
uptake and metabolism by cellular blood components. While long-term blood circulation
of the 177Lu-MACs leads to better tumor targeting, the substantial blood retention of the
177

Lu-MACs is detrimental to practical application of these agents for diagnostic and

radiotherapeutic approaches. Utilizing these initial results, our future designs of the
177

Lu-MACs will seek to provide faster blood clearance to better balance the

circulation/tumor targeting time and the clearance rates needed for clinical applications.

The significant blood retention of the 177Lu-MACs overall led to high baseline
radioactivity values observed in all analyzed tissues. When evaluating the biodistribution
data, it is important to keep in mind the contribution to the tissue radioactivity given by
blood residing in the tissue. It is undoubtedly true that the high blood activity of the

177

Lu-

MACs is contributing, to some extent, to the various tissues values, particularly those
tissues that normally contain large blood volumes (e.g., liver and kidney). However, as
we move from the 24 to the 72 h time-point we observe substantial decreases (~2 fold)
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in blood retention and, at the same time, a significant increase in both liver, spleen and
tumor retention. The increase in the liver, spleen and tumor retention, while during the
same period blood activity reduces, leads us to the conclusion that increases observed
in the biodistribution time-points is mostly attributable to the tissue uptake and not
background blood activities.

The MPS uptake of nanomedicine platforms is typified by significant accumulation of
the delivery system in the liver and spleen. The liver accumulation of the 177Lu-MAC0
demonstrated an increase from 7.27 ± 2.64 to 11.36 ± 1.65 %ID/g over the time course
of the experiment. In comparison 177Lu-MAC1 and 177Lu-MAC2 demonstrated lower
average accumulation in the liver at every time-point investigated. 177Lu-MAC1 and
177

Lu-MAC1 demonstrated a 24 h post-injection liver retention of 3.44 ± 0.82 and 5.29 ±

0.98 %ID/g, but demonstrated nearly identical values at 72 h post-injection. At 72 h postinjection, 177Lu-MAC1 and 177Lu-MAC1 gave liver retention values that were 3.1 and 2.1
times lower than the control (p=0.024,both). With regard to spleen retention, the average
spleen retention of 177Lu-MAC0 increased from 7.61 ± 1.37 to 21.46 ± 4.41 %ID/g over
the time-points investigated. For the 177Lu-MAC1 and 177Lu-MAC2, the HPMA
copolymers demonstrated substantially lower spleen accumulation compared to control.
This was particularly evident at the 72 h time-point with spleen values 3.8 and 3.7 times
lower (5.63 ± 1.22 and 5.67 ± 0.75 %ID/g) for 177Lu-MAC1 (p = 0.03) and 177Lu-MAC2 (p
= 0.06), respectively. The substantial reduction in liver and spleen retention observed in
these studies show that the MAL design is capable of enhancing clearance from the
MPS tissues.
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HPAC tumor accumulation of the 177Lu-MACs was achieved through passive
targeting due to the EPR effect. Relative to 177Lu-MAC1 and 177Lu-MAC2, 177Lu-MAC0
demonstrated superior tumor retention at all of the time points studied, with the highest
value being 6.58 ± 0.93 %ID/g at 72 h p.i. At 72 h post-injection, 177Lu-MAC1 and 177LuMAC2 gave tumor activities of 2.33 ± 0.30%ID/g (p =0.024) and 3.49 ± 0.28 %ID/g (p
=0.06), correspondingly, which were significantly lower than control. It is not clear why
the tumor retention of the values of

177

Lu-MAC1 and 177Lu-MAC2 are substantially lower

than those of 177Lu-MAC0. Possibly, the reduced blood retention of the 177Lu-MAC1 and
177

Lu-MAC2 or potential metabolism and clearance in the HPAC tumor could contribute

to lower overall tumor retention. Unfortunately, the current biodistribution study does not
unambiguously demonstrate the in vivo specificity and mechanism of the MACs. Future
studies looking into the in vitro and in vivo metabolism of the 177Lu-MACs are planned
and will hopefully shed more light with regard to the in vivo tumor-targeting and retention
properties of these agents.

2.5 CONCLUSION
In utilizing the MAL design, we seek to take advantage of the relative differences in
cathepsin B and S expression as well as the lymphatic and vasculature structure of
pancreatic cancer and non-target tissues leading to a decrease in non-target retention of
various nanomedicine systems. Herein, we have reported the synthesis and purification
of two MALs that are known substrates of cathepsin B and S. These MALs were shown
to be metabolized by cathepsin B and S into single metabolites. The MALs were
conjugated to the HPMA copolymer and radiolabeled with 177Lu. The synthesized 177LuMAC1 and 177Lu-MAC2 demonstrated a substantial decrease in long-term liver and
spleen retention relative to the control (177Lu-MAC0). However, compared to the control,
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the MALs in 177Lu-MAC1 and 177Lu-MAC2 exhibited higher clearance from HPAC tumors.
Our future work will focus on the optimization of the circulation time to achieve faster
blood clearance of the MAC design to better suit clinical application. Additionally, further
studies into the in vitro and in vivo behavior of the 177Lu-MACs are planned to elucidate
the rates of uptake and metabolism in both MPS tissues and pancreatic tumors.
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Chapter 3
Cathepsin S Cleavable 177Lu-labeled HPMA Copolymers for
Pancreatic Cancer Imaging: Investigation of the Linker
Structure-Activity Relationships

3.1 INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancerrelated deaths in the United States with a 5-year survival rate of only 6% and a median
survival of approximately 6 months [132]. The poor prognosis for pancreatic cancer
patients is mainly due to the asymptomatic nature of the early disease state with
symptoms typically presenting only in advanced stages, where effective treatment
options are severely limited [133, 134]. For the small portion of the pancreatic cancer
population (< 10%) diagnosed with localized disease, surgical resection has been shown
to be an effective treatment and is the current standard of care. Pre-operative staging is
crucial in determining whether a patient is a viable candidate for surgical resection [24].
Inaccurate identification of patients with un-resectable tumors leads to unnecessary
surgeries that can result in significant increases in patient morbidity and mortality [24].
To date, accurate staging of pancreatic cancer represents a major challenge in patient
treatment.

Several noninvasive imaging techniques are currently used for the diagnosis and
staging of pancreatic cancer. These modalities include contrast-enhanced computed
tomography (CT), abdominal ultrasound (US), magnetic resonance imaging (MRI) and
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MR cholangiopancreatography (MRCP) [24]. While these techniques have superb
anatomical resolution, these imaging modalities do not have the sensitivity and
specificity associated with nuclear imaging instrumentation, namely Single Photon
Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)
[135, 136]. Recently, the fusion of nuclear imaging with the CT modality has resulted in
hybrid imaging systems, SPECT/CT and PET/CT, which have been demonstrated to
more accurately detect and stage a variety of cancers [136]. Unfortunately, the potential
of these hybrid imaging systems for improving pancreatic cancer staging has not been
fully realized due to the lack of an effective radiotracer to target the disease [24].

The development of polymer-based diagnostics and therapeutics for human disease
has been an area of intense research and has yielded several drugs that have
progressed to the clinic [137]. N-(2-hydroxypropyl)-methacrylamide (HPMA) copolymer
is a polymeric platform that has been extensively investigated for a variety of biomedical
applications including the development of SPECT and PET tracers [64, 70, 77, 90, 91,
138-143]. HPMA copolymers are capable of targeting solid tumors either passively,
through the enhanced permeability and retention (EPR) effect, and/or actively by
inclusion of targeting vectors into the polymeric construct [40, 70, 77, 144]. However,
one major challenge for the development of diagnostic and/or therapeutic HPMA based
drugs, as well as other polymer and nanomedicine systems, is opsonization and
sequestration by the mononuclear phagocyte system (MPS) [126, 145]. In many cases,
the sequestration of these polymeric drugs leads to substantial accumulation in the liver
and spleen. From a diagnostic perspective, this MPS accumulation in non-target organs
can hinder identification of resident or nearby metastatic lesions thereby decreasing the
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diagnostic effectiveness. For therapeutic applications, the non-target accumulation of
these polymeric drugs can lead to significant toxicities which may be dose-limiting.

Our laboratory is interested in developing synthetic approaches in which HPMA
copolymers can be modified to significantly reduce the MPS accumulation thereby
enhancing the diagnostic and/or radiotherapeutic efficacy of the agent. Recently, we
have described the development of cathepsin S susceptible linkers (CSLs) [146], which
degrade in the presence of cathepsin S, a lysosomal protease that is selectively and
highly expressed in MPS tissues [117, 147, 148]. From our initial investigation, we found
that CSLs significantly reduced long-term retention of 177Lu-labeled HPMA copolymers in
tissues associated with the MPS (i.e., liver and spleen). However, the high molecular
weight HPMA copolymer (343 kDa) utilized in the study gave blood circulation times that
were not ideal for diagnostic or therapeutic use. Herein, we report our continued
investigation of the CSL design by evaluating the structure-activity impact of linking
groups of varying size on the in vitro and in vivo efficacy of HPMA copolymer based
radiopharmaceuticals. In conjunction with these studies, we utilize a lower molecular
weight HPMA (109 kDa) copolymer with a blood circulation time that is more suitable for
diagnostic and/or radiotherapeutic applications.

3.2 MATERIALS AND METHODS
3.2.1 Synthesis and Characterization of the HPMA Copolymer
The HPMA copolymerization was accomplished using the reversible additionfragmentation chain transfer (RAFT) polymerization reaction with V-501 as the initiator
and CTP as the chain transfer agent. The feed ratio of the polymerization consisted of
98.75:0.85:0.40 mole% HPMA, APMA and APMA-FITC, respectively. Polymerization
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was run at a 1 M total monomer concentration in 1 M acetate buffer (pH = 5.2) with a
molar ratio of total monomer: chain transfer agent: initiator of 1200:3:1. Prior to
proceeding with the polymerization reaction, the glass ampoule and contents were
purged with argon for 20 min. Subsequently, the ampoule was flame sealed and allowed
to heat at 70 ºC in an oil bath for 14 h. After cooling the HPMA copolymer was
evaporated to dryness, dissolved in methanol and purified by size exclusion
chromatography using an LH-20 packing material with methanol as the eluent. The
conversion rate was 42.3 % as determined by mass measurement after purification. The
weight average molecular weight and polydispersity of the copolymers were determined
by FPLC equipped with UV and RI detectors. The average molecular weights of the
copolymers were estimated using HPMA copolymer standards with narrow
polydispersity indices. Quantification of the primary amine content of the HPMA
copolymer was assessed using a ninhydrin assay [146].

3.2.2 Solid Phase Peptide Synthesis
For the synthesis of the CSLs with linking groups (CSL2 and CSL3), the resin was
manually pre-loaded. Briefly, to a fritted reaction vessel, 2-ClTrl-Cl resin (3 g, 3.60
mmol), 1 equiv of the linker group (Fmoc-5-Ava-OH or Fmoc-NH-(PEG)2-COOH) and 4
equiv of DIEA in dry DMF (30 mL) was added. The reaction mixture was stirred for 2 h,
filtered and washed sequentially with: (1) 3 X 100 mL of a solution consisting
DCM/MeOH/DIEA (17:2:1); (2) 3 X 100 mL of DCM (3) 2 X 100 mL of DMF and (4) 2 X
100 mL of DCM. The resin was dried in vacuum over KOH. For estimating residue
loading, the Fmoc group from a small sample of the resin was cleaved with 2% DBU in
DMF and the concentration of liberated dibenzofulvene was measured by UV
spectroscopy (304 nm). Using known standards of Fmoc-Gly-OH as a reference, the
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residue loading was estimated from the equation: mmole/g = (Abssample-Absref) *16.4/mg
of resin [149]. Estimation of the level of residue attachment indicated substitution of 0.60
and 0.65 mmol/g for the Fmoc-5-Ava-trityl and Fmoc-NH-(PEG)2-trityl resin, respectively.

The CSLs were synthesized using automated solid phase peptide synthesis. Briefly,
the resin (containing 0.25 mmole of peptide anchors) was deprotected using piperidine
resulting in the formation of the primary amine. The carboxylic acids of the Fmoc
protected amino acids (1 mmol) were activated using COMU and conjugated to the
primary amines of the growing peptide on the resin. The process of deprotection,
activation and conjugation was repeated until the desired peptide was synthesized. The
selective cleavage of the peptide from the 2-chlorotrityl resin anchor was achieved
by reaction with 1% TFA in dry DCM and subsequent filtration. The combined crude
filtrates were dried by a rotary concentrator. Purification of the peptides was performed
using a semi-preparative Proteo C12 column with a flow rate of 5.0 mL/min. HPLC
solvents consisted of H2O containing 0.1% formic acid (solvent A) and acetonitrile
containing 0.1% formic acid (solvent B). For all peptides, the initial gradient of 70% A: 30%
B linearly decreased to 60% A: 40% B over a 15 min time period. At the end of the run
time for all HPLC experiments, the column was flushed with the gradient 5% A: 95% B
and re-equilibrated to the starting gradient. The yields after purification were 0.1326 g
(37.5%) for CSL1; 0.166 g (44%) for CSL2 and 0.109 g (27.1%) for CSL3. The peptides
were confirmed to be ≥ 95% purity as characterized by LC/MS before in vitro/ in vivo use.

3.2.3 Synthesis of Cathepsin S Cleavable Copolymers (CSCs)
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The CSCs were prepared by condensation of the HPMA copolymer and the CSLs as
previously described. Briefly, in a 10 mL round bottom flask, 16.5 (28.9 μmol, 5.0 equiv),
16.5 (11.6 μmol, 2.0 equiv), 17.4 (11.6 μmol, 2.0 equiv) or 18.6 mg (11.6 μmol, 2.0 equiv)
of CSL0, CSL1, CSL2 or CSL3 was dissolved in 600 μL of DMF. The solution was
cooled to 0 °C and 2.4 equivalents of NHS and DCC, relative to the CSL, were added to
the flask. The solution was stirred at 0 °C for 3 h. At the end of that time, the HPMA
copolymer was added and stirred for another 2 h at 0 °C. Subsequently, the reaction
was allowed to warm to room temperature and continued overnight. The precipitate
generated from the reaction was filtered off and the filtrate was evaporated to dryness.
The residue was dissolved in methanol, isolated by size exclusion chromatography using
an LH-20 packing material and evaporated to dryness. The attached protected peptides
of the resulting CSCs were deprotected using standard peptide cleavage conditions. In
the case of CSC0, the copolymer was added to 4 mL of a cleavage cocktail consisting of
a 1:1:1:37 volumetric ratio of DODT, water, TIS and TFA. This solution was kept at 0 °C
and stirred for 2 h. For CSC1-3, the cleavage cocktail contained a 1:1:1:0.75:46.25
volumetric ratio of DODT, water, TIS, thioanisole, and TFA. After deprotection, the
mixture was evaporated to dryness and the polymers were finally purified by size
exclusion chromatography using an LH-20 packing material and methanol as the eluent.
The conjugation yield for CSC0 was determined by the ninhydrin assay. For CSC1-3, the
conjugation yield was determined using amino acid analysis conducted by the UNMC
Protein Structure Core Facility.

3.2.4 Radiolabeling of the CSCs
The radiolabeling of the CSCs was accomplished by heating 200 μg of the CSC at
90 C for 1 h in the presence of 37 MBq (~1mCi) of

177

LuCl3. After cooling, the resulting
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177

Lu-radiolabeled CSC was purified by radio-SEC-HPLC. Purification of the 177Lu-CSCs

was accomplished using a Biosep-SEC-S2000 column with an isocratic mobile phase
consisting of PBS with 0.02 M EDTA at pH 7.2. The linear flow rate was 0.80 mL/min.
UV analysis was performed at a wavelength of 494 nm. After collection of the peakpurified 177Lu-CSC, approximately 10 mg of L-ascorbic acid was added to inhibit
radiolysis. The purified 177Lu-CSC was concentrated using an Amicon Ultra-4 centrifugal
filter (10 kDa) and washed with 2 X 4 mL of deionized water. The radiochemical purity of
all radio-conjugates was re-evaluated prior to in vitro/ in vivo use and found to be ≥ 95 %
pure as determined by the radio-HPLC.

3.2.5 Cathepsin Cleavage Assay of Radiolabeled Copolymers
Human cathepsin S (20 ng/µL) in 100 µL of buffer solution (50 mM sodium acetate, 1
mM EDTA and 10 mM DTT, pH 6.0) was incubated with 100 μg of each purified

177

Lu-

CSC0-3 at 25 ºC. After 12 h, a 50 µL aliquot of each copolymer solution was analyzed
by radio-SEC-HPLC to determine the relative amount of cathepsin S cleavage product.
The analysis utilized an isocratic gradient at a linear flow rate of 0.80 mL/min with a
mobile phase consisting of PBS with 0.02 M EDTA at pH 7.2. The UV analysis of the
HPLC eluent was carried out at a wavelength of 494 nm.

3.2.6 Human Serum Stability of Radiolabeled Copolymers
Briefly, 10 μg of purified 177Lu-CSC was incubated with 1 mL of human AB serum at
37 C. After 144 h, the stability was determined by centrifuge filtration using an Amicon
Ultra-4 10 kDa filter. A 100µL aliquot was loaded in the filter and diluted to 4 mL using DI
water. The loaded sample was centrifuged and washed with 4 mL of DI water. The
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percent of intact 177Lu-CSC was calculated by dividing the remaining radioactivity in the
10 kDa filter to the total radioactivity added.

3.2.7 Cell Culture
The HPAC cells were cultured in our laboratory, as per ATCC protocols, in
DMEM/Ham's F12 medium containing 5% FBS, 1.562 nM EGF, 14.3 mM sodium
bicarbonate, 2.5 mM L-glutamine, 15 mM HEPES and 0.5 mM sodium pyruvate
supplemented with 0.350 µM insulin, 0.0625 µM transferrin and 0.110 µM hydrocortisone.
Cells were incubated at 37 °C with 5% CO2 in air.

Human monocytes were provided by the UNMC Elutriation Core Facility. Monocytes
were plated into T75 tissue culture flasks at a concentration of 20 x106 cells in 20 mL of
macrophage differentiation medium: DMEM containing 10% FBS, 1% NEAA, 500 U rhMCSF, 1% Penicillin/Streptomycin, 2 mM l-glutamine and 1% sodium-pyruvate. Media was
half-exchanged every 2 to 3 days for 7-10 days, at which time, visual confirmation of
differentiation led to media replacement with the macrophage maintenance medium
(differentiation media without the rhM-CSF). Cells were maintained in a 37 C humidified
atmosphere with 5% CO2.

3.2.8 Confocal Microscopy
Macrophage cells and HPAC cells were seeded onto 4-well chambered coverglass
units with 1 × 104 and 5 × 104 cells, respectively. FITC-labeled polymer conjugates were
diluted in blank media to 100 μg/mL concentration. The cells were then incubated with
the polymer for 24 h in a 37 C humidified atmosphere with 5% CO2. Half an hour before
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the end of this incubation, LysoTracker Red DND-99 and Hoechst 33342 were added in the
media to stain the lysosomal compartment and the nuclei. Following incubation, the media
was aspirated, and the cells were washed with PBS to remove free polymers that were
not internalized prior to confocal imaging.

3.2.9 Immunoblot Analysis
Whole cell HPAC and differentiated macrophage lysate as well as mice HPAC tumor
homogenate were prepared using RIPA buffer and a cocktail of proteases inhibitors. The
lysates and homogenate were centrifuged at 13,000 RPM at 4 ºC for 20 min. The
supernatants containing 50 μg total proteins were mixed with sample buffer and then
separated by 10% SDS-PAGE, followed by transfer to PVDF membrane. After blocking
in 5% nonfat milk, 0.1% Tween-20, and Tris-buffered saline at room temperature for 1 h,
membranes were probed with primary antibodies in blocking solution for 1 h at room
temperature, followed by extensive washing in TBS. Rabbit anti-goat and goat antimouse secondary antibodies were used for the detection of immunoreactive proteins by
chemiluminescence.

3.2.10 Biodistribution Studies
Biodistribution studies were carried out using age-matched normal CF-1 and HPAC
tumor bearing SCID mice. For biodistribution studies involving HPAC xenograft mice, the
mice were inoculated in each flank with 100 μL of a 1:1 ratio of suspended HPAC cells
and Matrigel™ to obtain a final concentration of 5 x 106 HPAC cells per 100 μL. Upon
achieving sufficient tumor size, (10-15 mm in diameter) the mice were considered viable
for biodistribution studies. The CF-1 mice and HPAC xenograft mice were injected with a
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0.37 MBq (10 μCi) intravenous bolus of the purified 177Lu-CSCs. The mice were
sacrificed and their tissues excised at 4, 24, 72 and 144 h time points post-injection (p.i.).
The blood and excised tissues were weighed, the 177Lu radioactivity measured using a
gamma counter, and the percentage injected dose (%ID) and the percentage injected
dose per gram (%ID/g) calculated for each tissue.

3.2.11 SPECT/CT Imaging Studies
Xenograft mice were intravenously injected with 400~600 μCi of CSCs in 100 μL
saline and then anesthetized with 5% isoflurane delivered in 0.5 mL/min oxygen. Image
acquisition with a 5-pinhole (1.0 mm/pinhole) collimator was acquired at 4, 24, 72 and
144 h time-points p.i. Five hundred and twelve CT projections for each image were
acquired and reconstructed using Triumph X-O 4.1 at a matrix size of 512×512×512 with
a 0.15-mm voxel dimension. Sixty four SPECT projections for each image were acquired
using a Triumph SPECT with a 20% window at 208 keV for 177Lu and reconstructed
using Triumph SPECT Reconstruction Application 1.0.8.0 at a matrix size of 64×64×64
with a 1.14 mm voxel dimension. Co-registration of anatomical CT images and
functional SPECT was performed using 3D image visualization and analysis software
VIVID based on Amira 4.1. A median filter was applied to all SPECT images.

3.2.12 Statistics
Statistical analyses were done using a two-tailed unpaired Student's t-test (2 groups)
or one way ANOVA (> 2 groups) with Bonferroni post-tests, a p < 0.05 indicating
statistically significant differences.
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3.3 RESULTS AND DISCUSSION
3.3.1 Design and Synthesis of Cathepsin S Cleavable Linkers (CSLs)
Herein, we report the evaluation of a series of CSLs incorporated into a 177Lu-labeled
HMPA copolymer construct. The objective of our approach is to utilize the CSLs to
enhance the diagnostic/therapeutic potential of HPMA copolymer based drugs by
improving the clearance properties of these agents from MPS associated tissues, in
particular the liver and spleen. The CSLs, depicted in Figure 3.1, are composed of four
components: 1) the DOTA moiety that is responsible for chelation of the diagnostic/
therapeutic radiometal; 2) the P-M-G-L-P substrate (Y) which cleaves in the presence of
cathepsin S [146, 150]; 3) a clearance sequence (X), in this case G-(D)S-D(S), that can
be modified to influence the clearance rate of the resulting radiometabolite; and finally 4)
the linker group (Z) that is used to optimize the distance of the cathepsin S substrate
from the polymer backbone. The distance of the cathepsin S substrate from the HPMA
copolymer backbone is expected to be a factor, due to steric inhibition, that influences
the cleavage rate of the cathepsin S substrate. In this study we investigate the impact of
linking groups of various lengths (0, 6 and 13 atoms) on the in vitro cleavage rate and in
vivo performance of CSLs incorporated into 177Lu-labeled HPMA copolymers.
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Figure 3.1: Schematic design of CSLs with intact orthogonal protection.
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As shown in Figure 3.1, we chose to investigate CSL1-3 containing a null, a six atom
hydrocarbon (5-Ava) and a 13 atom polyethylene glycol (PEG) linking group,
respectively. In the case of CSL3, a PEG linker was chosen in place of a 13 atom
hydrocarbon chain in order to reduce the potential for hydrophobic, intramolecular
associations that would have likely limited separation of the cathepsin S substrate and
the HPMA copolymer backbone [151, 152]. The control for our study, CSL0, is simply
the DOTA chelation system absent of any peptide components. The CSL1-3 were
synthesized with intact orthogonal protection using automated solid-phase peptide
synthesis. The synthesis of the CSLs with orthogonal protection results in the generation
of a single carboxylic acid functionality at the C-terminus which will later be used for
conjugation to the HPMA copolymer. Purification of the crude synthetic peptides by
HPLC gave yields of 37.5, 44.0 and 27.1 for CSL1-3, respectively. The HPLC and mass
spectrometric data of the CSLs are given in Table 3.1.
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Table 3.1: Characterization of CSLs.
CSL
Peptides
CSL0
CSL1
CSL2
CSL3

Sequences

Formula

Mass
Expected
+
[M+H]

Mass
Observed
+
[M+H]

DOTA(tBu)3

C28H52N4O8

573.4

573.2

C67H118N12O18S

1411.8

1411.5

C72H127N13O19S

1510.9

1510.6

C76H135N13O22S

1615.0

1614.7

DO3A(tBu)3-G-(D)S(tBu)(D)S(tBu)-P-M-G-L-P
DO3A(tBu)3-G-(D)S(tBu)(D)S(tBu)-P-M-G-L-P-5-Ava
DO3A(tBu)3-G-(D)S(tBu)(D)S(tBu)-P-M-G-L-P-PEG3
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3.3.2 Synthesis and Characterization of Cathepsin S Cleavable Copolymers (CSCs)
The scheme for synthesis of the CSCs is depicted in Figure 3.2. The HPMA
copolymer consisting of HPMA, APMA and APMA-FITC monomers were prepared by
RAFT polymerization. The estimated molecular weight of the synthesized HPMA
copolymer was 109 kDa with a polydispersity of 1.3 as determined by FPLC analysis.
Ninhydrin assay revealed a total amine concentration of 57.2 µmol/g (n=1), which
corresponds, based on the feed content, to 97% incorporation of the APMA monomer.
On average, this yields approximately six APMA moieties per polymer backbone.
Conjugation of CSLs to HPMA copolymers was accomplished using EDC/NHS
amidation chemistry. The orthogonal protection of the CSLs allowed for the chemoselective conjugation of the C-terminal carboxylic acid to the APMA moiety on the HPMA
copolymer. Conjugation of the DOTA chelation system to the HPMA copolymer (CSC0)
gave a DOTA content of 31.3 µmol/g polymer (n=1), corresponding to a 54% conjugation
yield, as evaluated by ninhydrin assay. Amino acid analysis of the conjugation of CSL1-3
to the HPMA copolymer gave a peptide content of 15.0, 13.4 and 12.7 µmol/g polymer
(n=3), which corresponds to 26.0, 23.4 and 22.2 % for CSC1-3, respectively. The
orthogonal protecting groups were removed with a cleavage cocktail (92.5% TFA) to
give the deprotected CSCs. Size exclusion chromatography was used to purify the
CSCs prior to radiolabeling.
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Figure 3.2: Schemes for the synthesis of the 177Lu-CSC conjugates. For CSC0, CSC1,
CSC2 and CSC3, X = Y = Z = null; X = GSS, Y = PMGLP; X = GSS, Y = PMGLP Z = 5Ava and X = GSS, Y = PMGLP Z = PEG3, respectively.
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3.3.3 Synthesis of 177Lu-labeled CSCs
The 177Lu-labeled CSCs were prepared by heating 177LuCl3 in the presence of CSCs
at 90°C for 1 h. The radiochemical yields for CSC0-4, as determined by radio-SECHPLC, were on average (n=3) 77%, 90%, 43% and 81%, respectively. Correspondingly,
the achievable specific activities were 142.45, 166.50, 79.55 and 149.85 MBq/mg.

3.3.4 Serum Stability and Cleavage Studies of 177Lu-Labeled CSCs
The stability of the 177Lu-CSCs in human serum was investigated over the course of
144 h at 37°C. At the end of this incubation period, 98% of the 177Lu-CSCs remained
intact thus suggesting that the 177Lu-CSCs would be stable to serum proteases in vivo
while in circulation. It is important to note that this stability study does not reflect potential
uptake and metabolism by cellular components of the blood (e.g., circulating monocytes),
which likely impacts the stability of the 177Lu-CSCs in circulation. The in vitro
susceptibility of the 177Lu-CSCs to cathepsin S cleavage was investigated by incubating
the radiolabeled copolymers at 37°C for 12 h in the presence of cathepsin S. Analysis of
aliquots of the reaction medium by radio-SEC-HPLC, Figure 3.3, revealed that 177LuCSC1-3 underwent proteolytic cleavage when challenged with cathepsin S. The noncleavable control CSC0, not shown, was found to be stable in the presence of cathepsin
S over 72 h. All of the intact 177Lu-CSCs demonstrated a retention time of approximately
10.5 min on the SEC column. Upon cleavage, the generated radiometabolite resulted in
a substantially higher retention time of 12.4 min, which corresponds to the expected
reduction in molecular weight. We have previously demonstrated that the cleavage site
for the CSLs are between the glycine and leucine residues (P-M-G┼L-P) of the substrate
sequence [146]. Over the 12 h incubation period, the 177Lu-CSC1-3 demonstrated an
average (n=2-3) of 8.4, 10.1 and 25.9 % cleavage, correspondingly.
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177Lu-CSC1

177Lu-CSC2

177Lu-CSC3

Figure 3.3: Chromatograms of CSC1-3 after a 12 h incubation with cathepsin S.
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As stated previously, the proximity of the metabolic sequence to the HPMA
copolymer backbone is expected to influence the cleavage rate of the CSCs. Our basis
for the introduction of linking groups of various lengths (Z) into the CSLs was to
investigate the structure-activity relationship, with respect to cathepsin S activity, of the
CSLs when integrated into the HPMA copolymers. From the above data, some insight
can be gleaned regarding the structure-activity relationship of the HPMA copolymer
incorporated CSLs. The inclusion of the smaller linking group, 5-Ava, into the CSL
(177Lu-CSC2) gave no statistically significant increase in cleavage relative to the null
analog (177Lu-CSC1). In the case of 177Lu-CSC3, the introduction of the longer PEG
linking group gave much higher rates of cathepsin S cleavage. These data suggest that
the length of the linking group is capable of influencing the cathepsin S cleavage activity
likely through a reduction of steric hindrance.

3.3.5 Cathepsin S Expression in HPACs and Macrophages
It is well known that the MPS is primarily responsible for the non-target accumulation
of nanomedicine platforms, particularly in the liver and spleen [153]. The MPS is
composed of phagocytic cells (e.g., macrophages and monocytes) that sequester drug
delivery systems which typically results in loss of diagnostic/therapeutic effectiveness
and potential toxicity. These phagocytic cells are also known as antigen presenting cells
(APCs) due to their function in adaptive immunity where these cells process pathogenic
material and present antigen fragments on the cellular surface. Cathepsin S is a
predominantly lysosomal proteolytic enzyme that has been shown to be highly regulated,
relative to other cathepsins (e.g., cathepsin B), and predominately expressed in APCs
[154]. The substantial expression of cathepsin S in APCs is thought to be due to its
unique role in the catabolism of pathogenic proteins [155-157]. Our design seeks to take
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advantage of the cathepsin S expression/activity in APCs to preferentially enhance
clearance from non-target tissues [134, 146].

In this study, we utilize the HPAC human pancreatic cancer cell line as our in vitro
and in vivo model of pancreatic cancer. Human monocytes have been differentiated to
macrophages to serve as our model of tissue-resident macrophages. In order to
determine cathepsin S expression, immunoblotting was performed on both cell types. As
shown in Figure 3.4, cathepsin S is highly expressed in differentiated macrophages with
negligible detectable expression in the HPAC cells. Overall, this corresponds well with
our previous observations that the cathepsin S protease activity is much higher (tenfold)
in differentiated macrophages versus the HPAC cell line [146]. Evaluation of the
cathepsin S expression in HPAC tumor homogenates revealed increased levels of
cathepsin S relative to cultured cells. This relative increase in expression may be a
consequence of the dissimilarity of the in vivo tumor microenvironment versus the in vitro
cultured milieu. However, it seems likely that the escalation in cathepsin S signal may, at
least partially, be attributable to tumor-associated macrophages (TAM), which exist in
almost all solid tumors [158].
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Figure 3.4: Western Blot analysis of cathepsin S expressions in cultured HPACs
(HPAC1), differentiated macrophages, and HPACs from corresponding in vivo tumorderived cells (HPAC2).
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The intracellular trafficking of FITC-labeled copolymers in both the differentiated
macrophages and the HPAC cell line was investigated using confocal microscopy,
Figure 3.5. In these studies, the CSC0 was utilized as our model HPMA copolymer.
Lysotracker® Red and Hoechst fluorescent markers were used to delineate the lysosome
and nucleus compartments, respectively. After 24 h incubation with CSC0, the
differentiated macrophages (Figure 3.5A) demonstrated substantially higher levels of
cellular accumulation relative to the HPAC cell line (Figure 3.5B). This is in accordance
with our previously reported flow cytometric studies working with a higher molecular
weight HPMA copolymer [146]. As can be seen in the overlay, the CSC0 accumulation in
the macrophages is co-localized with the Lysotracker® Red marker. The accumulation of
HPMA copolymers in lysosomal compartments is in agreement with previous literature
reports [159, 160]. By accumulating in the macrophage lysosomes, the CSCs are colocalized with the highest sub-cellular concentrations of cathepsin S. The selective
uptake of the CSCs in macrophages and the accumulation of the copolymer in the
lysosomal compartments are expected to substantially and selectively increase the CSC
cleavage kinetics in macrophages and other APC cell types. The proteolytic degradation
of the CSCs will result in the formation of low molecular weight radiometabolites which
are anticipated to clear more rapidly from the APC cells residing in non-target tissues
and ultimately result in higher clearance.
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HPMA Copolymer
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Figure 3.5: After 24 h incubation, FITC-labeled HPMA copolymer showed intense
accumulation in lysosomes of macrophages (A) (B).
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3.3.6 Biodistribution Studies of 177Lu-CSCs
The biodistribution properties of the 177Lu-CSCs were investigated at 4, 24, 72 and
144 h post-administration in both a normal CF-1 (Table 3.2) and HPAC xenograft mouse
models. With exception of the blood clearance rate (elaborated on below), the 177LuCSCs demonstrated similar biodistribution trends in both animal models. The data
obtained from the biodistribution studies of the 177Lu-CSCs in a HPAC xenograft mouse
model are given in Table 3.3. The calculated tumor-to-non-target ratios for selective
tissues are given in Table 3.4. At the 4 h p.i. time point, the 177Lu-CSCs revealed
excretion values that ranged from 23.82 ± 3.23 - 34.57 ± 2.41 %ID. Those HPMA
copolymers with the cathepsin S cleavable linkers (177Lu-CSC1-3) demonstrated
significantly higher levels of radioactivity excretion relative to the non-cleavable control
(177Lu-CSC0) by the 24 h time point (p < 0.05). At the 144 h time point, 83.29 ± 1.24 87.93 ± 1.49 %ID of the 177Lu-CSC1-3 had been eliminated from the body in comparison
to only 55.65 ± 2.26 %ID of 177Lu-CSC0 (p < 0.0001). The overall elimination of
radioactivity from the mouse corresponded well to the blood retention profiles of the
177

Lu-CSCs. At 4 h p.i., all four 177Lu-CSCs demonstrated blood retention profiles that

were statistically identical. By the 24 h time-point, 177Lu-CSC1 and 177Lu-CSC2
demonstrated significantly lower blood retention (p < 0.05) relative to the control. The
blood retention of 177Lu-CSC1-3 at 72 and 144 h post-administration were all
substantially lower (p < 0.001), 2.2 - 2.9 and 3.0 - 4.4 fold lower, respectively, in
comparison to 177Lu-CSC0. Comparison of the blood clearance profile of the 177Lu-CSCs
in both the CF-1 and HPAC xenograft model revealed that the CF-1 model demonstrated
a relative two-fold lower retention for all 177Lu-CSCs at all time points investigated. This
suggests that the alterations made to the SCID model (i.e., absence of functional T and
B lymphocytes) may be impacting the blood clearance of the 177Lu-CSCs. However,
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when the blood clearance profiles are taken into account, the overall trends of the 177LuCSCs, with respect to uptake, retention and clearance, in solid tissues remain consistent
among the two models.
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Table 3.2: Biodistribution of 177Lu-labeled CSCs in CF-1 mice. N=5 at each time-point.
Data are represented as mean ± SD %ID/g.
177

Lu-0

177

Lu-1

177

Lu-2

177

Lu-3

177

Lu-0

4 h p.i.

177

Lu-1

177

Lu-2

177

Lu-3

24h p.i.

blood

13.61 ± 2.35

12.03 ± 1.58

13.85 ± 3.13

13.72 ± 2.82

6.17 ± 1.20

3.82 ± 0.65

2.77 ± 0.49

4.57 ± 0.56

heart

3.40 ± 1.01

3.54 ± 0.50

5.57 ± 1.18

4.33 ± 1.14

2.10 ± 0.22

1.65 ± 0.16

1.50 ± 0.62

1.97 ± 0.12

lung

4.47 ± 1.39

3.84 ± 0.50

3.93 ± 0.77

3.97 ± 0.92

2.08 ± 0.28

1.90 ± 0.25

1.07 ± 0.19

1.89 ± 0.35

liver

2.92 ± 0.55

2.47 ± 0.15

2.73 ± 0.37

3.16 ± 0.66

2.56 ± 0.31

1.79 ± 0.29

1.74 ± 0.25

2.15 ± 0.19

pancreas

1.74 ± 0.33

1.96 ± 0.59

2.72 ± 1.29

2.39 ± 0.34

1.08 ± 0.10

1.10 ± 0.08

1.26 ± 0.43

1.26 ± 0.20

stomach

1.62± 1.06

1.33 ± 0.33

1.05 ± 0.23

1.46 ± 0.66

0.66 ± 0.11

0.97 ± 0.19

0.53 ± 0.21

0.49 ± 0.07

spleen

2.55 ± 0.43

2.11 ± 0.29

1.66 ± 0.29

2.65 ± 0.71

2.33 ± 0.26

1.26 ± 0.19

1.14 ± 0.21

1.92 ± 0.65

small int.

2.26 ± 0.53

2.01 ± 0.42

2.46 ± 0.44

2.61 ± 0.65

1.22 ± 0.25

1.21 ± 0.32

0.80 ± 0.10

1.29 ± 0.07

large int.

3.30 ± 1.34

3.11 ± 0.48

1.94 ± 0.26

2.62 ± 1.17

1.46 ± 0.45

1.43 ± 0.35

0.99 ± 0.07

1.04 ± 0.19

kidney

3.77 ± 0.87

3.88 ± 0.97

3.68 ± 0.42

3.67 ± 0.93

2.06 ± 0.33

1.93 ± 0.12

1.59 ± 0.39

2.03 ± 0.11

muscle

0.79 ± 0.23

0.76 ± 0.15

1.14 ± 0.37

0.98 ± 0.38

0.56 ± 0.06

0.62 ± 0.11

1.17 ± 0.49

0.63 ± 0.11

bone

1.22 ± 0.29

1.09 ± 0.06

1.97 ± 0.68

1.37 ± 0.44

0.68 ± 0.09

0.73 ± 0.08

0.89 ± 0.25

0.71 ± 0.07

brain

0.40 ± 0.14

0.35 ± 0.08

0.47 ± 0.17

0.59 ± 0.05

0.18 ± 0.03

0.19 ± 0.02

0.12 ± 0.04

0.21 ± 0.05

Excretion

21.56 ± 11.0

28.36 ± 3.31

37.02 ± 6.24

23.12 ± 5.59

56.15 ± 15.65

55.37 ± 2.89

59.03 ± 5.28

53.78 ± 1.90

blood

3.42 ± 0.78

1.18 ± 0.16

0.47 ± 0.09

1.13 ± 0.19

1.40 ± 0.30

0.38 ± 0.10

0.07 ± 0.04

0.26 ± 0.05

heart

1.80 ± 0.17

1.00 ± 0.08

0.80 ± 0.19

0.97 ± 0.20

1.65 ± 0.37

0.55 ± 0.04

0.42 ± 0.07

0.61 ± 0.08

lung

1.75 ± 0.36

0.78 ± 0.20

0.50 ± 0.10

0.79 ± 0.19

1.20 ± 0.18

0.25 ± 0.06

0.20 ± 0.06

0.33 ± 0.05

72 h p.i.

144 h p.i.

liver

3.49 ± 0.75

1.82 ± 0.36

0.91 ± 0.10

1.46 ± 0.08

3.45 ± 0.38

0.82 ± 0.06

0.54 ± 0.03

1.06 ± 0.08

pancreas

1.44 ± 0.47

0.82 ± 0.23

0.78 ± 0.34

0.73 ± 0.12

1.35 ± 0.53

0.53 ± 0.09

0.37 ± 0.11

0.45 ± 0.08

stomach

0.58 ± 0.16

0.46 ± 0.14

0.26 ± 0.07

0.36 ± 0.13

0.41 ± 0.17

0.11 ± 0.03

0.08 ± 0.03

0.15 ± 0.05

spleen

4.31 ± 1.47

1.85 ± 0.71

0.78 ± 0.28

1.45 ± 0.09

6.70 ± 3.46

0.82 ± 0.34

0.67 ± 0.41

1.05 ± 0.12

small int.

0.85 ± 0.19

0.54 ± 0.10

0.32 ± 0.06

0.47 ± 0.08

0.50 ± 0.07

0.23 ± 0.03

0.18 ± 0.03

0.22 ± 0.05

large int.

1.42 ± 0.27

1.22 ± 0.37

0.54 ± 0.04

0.64 ± 0.20

0.91 ± 0.14

0.35 ± 0.03

0.19 ± 0.02

0.32 ± 0.09

kidney

1.76 ± 0.31

1.04 ± 0.17

0.77 ± 0.14

1.01 ± 0.15

1.17 ± 0.24

0.49 ± 0.08

0.42 ± 0.04

0.61 ± 0.21

muscle

0.59 ± 0.08

0.42 ± 0.10

0.49 ± 0.13

0.44 ± 0.10

0.57 ± 0.15

0.19 ± 0.03

0.27 ± 0.07

0.22 ± 0.02

bone

1.03 ± 0.21

0.49 ± 0.13

0.54 ± 0.08

0.58 ± 0.18

0.72 ± 0.37

0.37 ± 0.11

0.26 ± 0.05

0.32 ± 0.12

brain

0.18 ± 0.03

0.06 ± 0.02

0.03 ± 0.01

0.07 ± 0.04

0.11 ± 0.02

0.03 ± 0.02

0.01 ± 0.01

0.02 ± 0.01

Excretion

56.94 ± 4.15

74.62 ± 1.48

81.62 ± 2.14

74.14 ± 3.35

61.71 ± 3.94

86.65 ± 0.71

89.11 ± 0.41

84.24 ± 0.60
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Table 3.3: Biodistribution of 177Lu-labeled CSCs in HPAC tumor bearing mice. N=5 at
each time-point. Data are represented as mean ± SD %ID/g.

Tissue

177

Lu-0

177

177

Lu-1

Lu-2

177

Lu-3

177

Lu-0

177

177

Lu-1

4 h p.i.

Lu-2

177

Lu-3

24 h p.i.

Blood

21.02 ± 6.09

17.62 ± 2.87

16.42 ± 2.87

20.47 ± 2.19

11.34 ± 2.24

5.80 ± 0.62

6.87 ± 1.15

9.22 ± 1.78

Heart

6.33 ± 2.04

5.05 ± 0.97

4.64 ± 1.30

5.12 ± 1.81

3.77 ± 0.35

2.44 ± 0.19

2.65 ± 1.10

3.00 ± 0.82

Lung

6.68 ± 1.09

5.32 ± 1.26

5.73 ± 1.48

6.44 ± 2.22

3.87 ± 1.18

2.83 ± 0.40

2.78 ± 0.58

4.02 ± 0.87

Liver

4.97 ± 0.74

4.20 ± 0.64

4.27 ± 0.38

5.13 ± 0.64

4.74 ± 0.65

3.33 ± 0.05

4.21 ± 0.32

4.88 ± 0.90

Pancreas

2.92 ± 0.57

2.48 ± 0.12

2.50 ± 0.66

2.98 ± 0.76

3.09 ± 1.07

2.05 ± 0.76

1.96 ± 0.47

1.65 ± 0.57

Stomach

1.04 ± 0.29

1.15 ± 0.27

1.00 ± 0.27

1.15 ± 0.28

0.93 ± 0.35

0.76 ± 0.18

0.72 ± 0.29

0.73 ± 0.27

Spleen

3.35 ± 0.56

2.88 ± 0.83

4.04 ± 1.56

3.55 ± 0.61

7.79 ± 1.47

3.24 ± 1.29

4.53 ± 2.21

4.93 ± 0.66

Small Int.

1.96 ± 0.34

2.06 ± 0.74

1.56 ± 0.29

1.66 ± 0.52

1.03 ± 0.13

0.68 ± 0.11

0.69 ± 0.13

0.96 ± 0.22

Large Int.

1.88 ± 0.20

2.33 ± 0.59

1.93 ± 0.43

1.25 ± 0.37

1.24 ± 0.16

1.50 ± 0.26

1.67 ± 0.33

Kidney

5.28 ± 1.25

3.84
± 3.42
0.748.2
5.08 ± 1.06

3.81 ± 0.76

4.63 ± 0.88

3.01 ± 1.01

2.38 ± 0.44

2.58 ± 0.20

3.03 ± 0.72

Muscle

1.21 ± 0.24

1.22 ± 0.24

1.58 ± 0.95

1.22 ± 0.31

1.89 ± 1.14

1.26 ± 0.70

1.07 ± 0.31

1.37 ± 0.42

Bone

1.52 ± 0.21

1.68 ± 0.21

1.65 ± 0.37

1.59 ± 0.21

1.42 ± 0.34

1.39 ± 0.19

1.14 ± 0.20

1.17 ± 0.21

Brain

0.68 ± 0.09

0.70 ± 0.10

0.48 ± 0.08

0.56 ± 0.10

0.46 ± 0.08

0.29 ± 0.10

0.28 ± 0.04

0.25 ± 0.04

Tumors

3.67 ± 0.72

3.29 ± 0.64

2.57 ± 0.39

3.04 ± 1.01

3.66 ± 0.62

3.70 ± 0.52

2.71 ± 0.34

3.98 ± 2.16

Excretion

23.82 ± 3.23

25.40 ± 3.08

34.57 ± 2.41

25.85 ± 4.68

40.22 ± 4.70

56.54 ± 1.75

56.44 ± 4.30

48.90 ± 1.10

Blood

5.15 ± 0.86

1.85 ± 0.35

1.75 ± 0.47

2.36 ± 0.47

2.35 ± 0.43

0.53 ± 0.19

0.68 ± 0.25

0.78 ± 0.30

Heart

3.60 ± 1.06

2.05 ± 0.43

1.22 ± 0.16

1.49 ± 0.39

2.79 ± 1.38

1.24 ± 0.36

0.88 ± 0.20

1.06 ± 0.34

Lung

3.24 ± 0.43

1.33 ± 0.20

1.21 ± 0.36

1.44 ± 0.22

1.89 ± 0.33

0.74 ± 0.22

0.50 ± 0.26

0.81 ± 0.19

Liver

5.29 ± 1.17

2.46 ± 0.30

2.83 ± 0.56

2.96 ± 0.47

5.13 ± 0.64

1.40 ± 0.33

1. 16 ± 0.19

1.48 ± 0.34

Pancreas

3.10 ± 1.70

1.02 ± 0.43

0.92 ± 0.13

0.84 ± 0.30

1.71 ± 0.56

0.75 ± 0.62

0. 41 ± 0.21

0.88 ± 0.25

Stomach

0.82 ± 0.33

0.52 ± 0.23

0.32 ± 0.07

0.29 ± 0.10

0.48 ± 0.24

0.17 ± 0.06

0.14 ± 0.07

0.24 ± 0.04

Spleen

8.22 ± 2.63

2.72 ± 0.72

3.00 ± 1.78

2.70 ± 0.69

8.27 ± 1.91

3.25 ± 0.86

3. 43 ± 1.46

3.68 ± 1.18

Small Int.

0.59 ± 0.15

0.57 ± 0.12

0.45 ± 0.05

0.62 ± 0.15

0.55 ± 0.19

0.12 ± 0.04

0.18 ± 0.07

0.29 ± 0.04

Large

1.15 ± 0.12

0.58 ± 0.09

0.63 ± 0.11

0.90 ± 0.53

0.92 ± 0.30

0.29 ± 0.04

0.31 ± 0.10

0.33 ± 0.15

Kidney
Int.
Muscle

2.40 ± 0.70

1.45 ± 0.30

1.45 ± 0.36

1.44 ± 0.18

1.95 ± 0.36

0.83 ± 0.20

0.91 ± 0.18

1.03 ± 0.07

1.57 ± 0.59

0.85 ± 0.48

0.81 ± 0.32

1.10 ± 0.29

1.21 ± 0.39

0.41 ± 0.21

0.46 ± 0.24

0.64 ± 0.16

Bone

1.88 ± 0.82

1.45 ± 0.68

0.49 ± 0.21

0.78 ± 0.14

1.30 ± 0.42

0.48 ± 0.27

0.48 ± 0.33

0.83 ± 0.24

Brain

0.30 ± 0.04

0.32 ± 0.35

0.07 ± 0.05

0.08 ± 0.02

0.20 ± 0.07

0.06 ± 0.04

0.07 ± 0.09

0.09 ± 0.09

Tumors

5.00 ± 1.40

3.28 ± 0.74

2.38 ± 0.59

2.81 ± 0.52

3.21 ± 0.68

2.61 ± 0.93

1.49 ± 0.31

1.68 ± 0.43

Excretion

51.84 ± 2.65

72.12 ± 1.28

75.70 ± 1.35

68.96 ± 3.13

55.65 ± 2.26

83.29 ± 1.24

87.93 ± 1.49

84.10 ±0.82

72 h p.i.

144 h p.i.
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Table 3.4: Tumor to non-target organ ratios of 177Lu- labeled CSCs in HPAC tumor
bearing mice. N=5 at each time-point. Data are represented as mean ± SD.
T/NT Ratios

177

Lu-0

177

177

Lu-1

Lu-2

177

Lu-3

177

Lu-0

4 h p.i.

177

177

Lu-1

Lu-2

177

Lu-3

24 h p.i.

Blood

0.19 ± 0.10

0.19 ± 0.02

0.16 ± 0.03

0.15 ± 0.06

0.33 ± 0.05

0.65 ± 0.12

0.41 ± 0.09

0.44 ± 0.17

Liver

0.74 ± 0.12

0.79 ± 0.08

0.60 ± 0.06

0.61 ± 0.22

0.79 ± 0.18

1.11 ± 0.16

0.65 ± 0.08

0.81 ± 0.31

Spleen

1.13 ± 0.35

1.23 ± 0.42

0.73 ± 0.32

0.86 ± 0.22

0.49 ± 0.12

1.26 ± 0.44

0.70 ± 0.32

0.80 ± 0.32

Kidney

0.72 ± 0.19

0.68 ± 0.19

0.69 ± 0.14

0.66 ± 0.17

1.32 ± 0.43

1.59 ± 0.28

1.06 ± 0.16

1.39 ± 0.84

Blood

0.98 ± 0.17

1.83 ± 0.39

1.46 ± 0.53

1.25 ± 0.41

1.41 ± 0.45

5.49 ± 2.32

2.47 ± 1.09

2.36 ± 0.87

Liver

0.96 ± 0.18

1.35 ± 0.26

0.84 ± 0.15

0.96 ± 0.12

0.63 ± 0.13

1.92 ± 0.68

1.31 ± 0.28

1.14 ± 0.17

Spleen

0.66 ± 0.22

1.28 ± 0.38

0.90 ± 0.28

1.08 ± 0.26

0.40 ± 0.08

0.82 ± 0.27

0.47 ± 0.11

0.48 ± 0.15

Kidney

2.14 ± 0.39

2.34 ± 0.55

1.67 ± 0.32

1.97 ± 0.36

1.69 ± 0.45

3.31 ± 1.65

1.67 ± 0.32

1.63 ± 0.35

72 h p.i.

144 h p.i.
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As with most nanomedicine platforms, the 177Lu-CSCs exhibited liver and spleen
retention as a result of MPS driven sequestration [161]. The liver and spleen uptake of
the non-cleavable control, 177Lu-CSC0, plateaued by 24 h post-injection with retention
values of 4.74 ± 0.65 and 7.79 ± 1.47 %ID/g, respectively. The retention of

177

Lu-CSC0

associated radioactivity in the liver and spleen remained essentially constant throughout
the remaining time points investigated. As a result of the incorporation of the CSLs, the
177

Lu-CSC1-3 demonstrated substantially lower levels of long-term retention in

comparison to the control. Significant differences (p < 0.05) in the spleen retention of the
177

Lu-CSC1-3 versus the 177Lu-CSC0 were observed by 24 h post-administration. By 72

h p.i., both spleen and liver retentions of the 177Lu-CSC1-3 were considerably lower (p <
0.01) than control. At our terminal time-point, the liver and spleen retentions of the 177LuCSC1-3 were 3.5 - 4.4 and 2.2 - 2.5 fold lower, correspondingly, than the 177Lu-CSC0.

The increased excretion and lower blood, liver and spleen retention profiles of

177

Lu-

CSC1-3 are undoubtedly linked to the incorporation of the cathepsin S cleavable linker
into the HPMA copolymer. The lower liver and spleen retention is likely due primarily to
the processing of 177Lu-CSC1-3 by tissue-resident macrophages (e.g., Kupffer cells of
the liver) thus resulting in low-molecular weight radiometabolites that are more readily
cleared [145, 161]. With respect to blood retention, the 177Lu-CSC1-3 are being cleared
from circulation significantly faster than the non-cleavable control. The inclusion of the
CSLs into the HPMA copolymers is possibly leading to a markedly higher opsonization
and sequestration by the MPS. Such responses have been observed with
functionalization of other drug delivery systems, but this seems unlikely given the limited
functionalization (< 1 mole%) of the HPMA copolymers used in these experiments [161].
Alternatively, and to us more likely, is the possibility that the 177Lu-CSCs are being
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internalized and processed by cellular components of the blood. The human serum
studies that were performed suggest that the 177Lu-CSCs are stable in the presence of
extracellular serum proteases. However, many drug delivery platforms are known to be
taken up by circulating blood monocytes, an APC known to express cathepsin S [162164]. If this is the case, the 177Lu-CSCs would be expected to be taken up and
processed by phagocytic cells in the blood, presumably circulating monocytes.
Metabolism of the CSLs by these APCs would lead to the generation of radiometabolites
which would likely favor clearance from the processing cell as well as the circulation
relative to the non-cleavable 177Lu-CSC0.

The 177Lu-CSCs exhibited substantial accumulation in the HPAC xenograft tumors
through the EPR effect [124, 165]. 177Lu-CSC0 demonstrated the highest tumor retention
with a peak accumulation of 5.00 ± 1.40 %ID/g at 72 h post-administration. For the 177LuCSC1-3, maximal tumor retention for each copolymer was observed by the 24 h time
point with values of 3.70 ± 0.52, 2.71 ± 0.34 and 3.98 ± 2.16 %ID/g, respectively. By the
144 h time-point, the tumor retention of 177Lu-CSC1 (2.61 ± 0.93 %ID/g) was statistically
identical to the non-cleavable control (3.21 ± 0.68 %ID/g), but was higher than 177LuCSC2 (p < 0.05) and 177Lu-CSC3 (p<0.05) (1.49 ± 0.31 and 1.68 ± 0.43 %ID/g,
correspondingly).

The tumor to non-target ratios for selected tissues at 4, 24, 72 and 144 h p.i. are
given in Table 3.3. For 177Lu-CSC1, the HPAC tumor retention and non-target clearance
properties yielded superior tumor-to-non-target ratios by 24 h p.i. relative to the other
177

Lu-CSCs, including the control. The superiority of

177

Lu-CSC1, relative to the other

copolymers, improved longitudinally with maximal divergence in tumor to non-target
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ratios being observed at the 144 h time-point. At this time-point, the tumor-to-liver,
spleen and kidney ratios of

177

Lu-CSC1 are on average 3.0 (p<0.01), 2.1 (p<0.05) and

2.0 (p=0.067) higher, respectively, than the control.

Evaluation of the biodistribution data for the CSL containing HPMA copolymers
reveals some interesting trends with regard to the structure-activity profiles of the 177LuCSC1-3 in HPAC tumor and non-target tissues. As described earlier, in vitro assays
revealed that the addition of the PEG linker (177Lu-CSC3), the longest (13 atoms) linker,
significantly enhanced the cathepsin S cleavage rate relative to 177Lu-CSC1 or 177LuCSC2. Given this, one would anticipate that 177Lu-CSC3 would have exhibited the fastest
clearance rates from MPS associated non-target tissues. However, in vivo biodistribution
studies revealed that the 177Lu-CSC1, null (0 atom) linker, exhibited overall the fastest
clearance of radioactivity from the blood, liver and spleen among the CSL containing
HPMA copolymers. In fact, at 24 h p.i., the clearance of

177

Lu-CSC1 from MPS

associated non-target tissues is statistically better (p < 0.05) than 177Lu-CSC3. Though,
by 72 h and beyond, the clearance of radioactivity in the blood, liver and spleen is
statistically identical for all three copolymers. Interestingly, this trend is somewhat
reversed with regard to HPAC tumor retention. At 144 h p.i., 177Lu-CSC1 exhibits
substantially higher tumor retention relative to both 177Lu-CSC2 and 177Lu-CSC3. At this
point, the factors driving these observations remain unclear. Likely, the clearance
kinetics of the 177Lu-CSCs relies primarily on a combination of the cleavage kinetics and
the vascular and lymphatic efficiencies of the tissue. The inequalities between the nontarget, normal tissues and the HPAC tumors with regard to the abundance of cathepsin
S expressing APCs and the vasculature and lymphatic systems are likely the driving
influences behind these observations. Currently, we are pursuing studies that will
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hopefully yield a better understanding of the in vivo cathepsin S cleavage kinetics and
clearance mechanisms of the 177Lu-CSCs.

3.3.7 Small Animal SPECT/CT Imaging Studies
For the development of nuclear imaging agents based on nanomedicine platforms,
the clinical success of antibody based agents (e.g., ProstaScint® and OncoScint®) can
serve as an example, due to the similar pharmacokinetic profiles of the two systems [166,
167]. Similar to many nanomedicine platforms, monoclonal antibodies are large
macromolecules that typically don’t achieve optimal tumor-to-non-target ratios until days
after injection. As a consequence, image acquisitions for clinical imaging agents based
on monoclonal antibodies are typically obtained between 2 and 5 days post-injection
[166, 168]. For the investigated 177Lu-CSCs, the biodistribution studies suggest that this
same time frame would be suitable, if not optimal, for diagnostic imaging.

In order to better evaluate the imaging potential of the 177Lu-CSCs, micro-SPECT/CT
studies were performed for 177Lu–CSC0, 177Lu–CSC1 and 177Lu–CSC3 in mice bearing
bilateral flank HPAC xenografts. 177Lu –CSC2 was not chosen for μSPECT/CT analysis
due to the similarity in its biodistribution profile with 177Lu –CSC3. Whole body images,
depicted in Figure 3.6, were collected at 4, 24 and 72 h post-administration. At 4 h p.i.,
visual inspection of the normalized images revealed substantial accumulation in the
abdominal cavity as well as the bladder for all three copolymers. The bladder activity at
such an early time-point suggests that the clearance of activity is likely from the
copolymer fraction that is below the renal excretion threshold [131]. Visualization of the
flank HPAC tumors was limited at 4 h p.i., but became clearly evident by the 24 h time-
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point. At 24 h p.i., decreases in the abdominal activity, which includes the liver, were
noted for the three copolymers. By the 72 h time-point, all of the investigated 177Lu–
CSCs demonstrated considerable uptake/retention in the HPAC tumors. In addition,
177

Lu–CSC1 and 177Lu–CSC3 demonstrated superior abdominal clearance relative to the

non-cleavable control (177Lu-CSC0). Overall, the SPECT/CT images agree well with the
data obtained from the biodistribution study. The substantial retention of

177

Lu–CSC1 in

the HPAC tumors coupled with the enhanced clearance of activity from the abdominal
region suggest that the CSL1 is the most promising linker to move forward with in the
development of diagnostic and radiotherapeutic HPMA copolymers.
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4 h p.i.

177Lu-CSC0

24 h p.i.

72 h p.i.

Liver

Liver

Tumors

Tumors

Bladder

Liver

Liver

177Lu-CSC1

Bladder
Tumors

Tumors
Bladder

Liver
Liver
177Lu-CSC3

Bladder

Tumors

Tumors

Bladder

Figure 3.6: Micro-SPECT/CT imaging studies of CSC0, CSC1and CSC3 in HPAC
xenograft mice.
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3.4 CONCLUSION
In summary, our laboratory is pursuing the development of CSLs that cleave in the
presences of cathepsin S, to reduce the non-target accumulation of diagnostic/
radiotherapeutic HPMA copolymers in MPS tissues. To this end, we have evaluated a
series of CSLs incorporated into a 177Lu-labeled HMPA copolymer construct with the
purpose of understanding the structure activity relationship with regard to the length of
the linking groups. In vitro cleavage assays revealed that the longest linking group (13
atoms) demonstrated the highest cathepsin S cleavage kinetics. Additionally, confocal
microscopy confirmed the selective uptake of HPMA copolymers in differentiated
macrophages and trafficking to the lysosomal cellular compartments. Contrary to in vitro
observations, in vivo biodistribution studies revealed that the linking group length in the
CSL design did not substantially impact the non-target clearance. However, in the case
of HPAC tumor retention, the CSC1 demonstrated significantly higher levels of retention
relative to the other CSCs. This gave CSC1 superior tumor-to-non-target ratios as
confirmed by longitudinal SPECT/CT imaging studies. Taken together, our results
suggest that the dissimilarities in the metabolism and clearance kinetics of the CSL
incorporated HPMA copolymers are tissue specific. Our future work will focus on gaining
an understanding of the tissue-specific underpinnings influencing CSL metabolism and
clearance. Lastly, these results demonstrate that the CSLs can substantially improve the
non-target clearance of HPMA copolymers, and likely other nanomedicine platforms,
leading to an enhancement in the tumor-to-non-target ratios and ultimately clinical
potential.
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Chapter 4
Comparison of 177Lu-Labeled Plectin-1 Targeted Peptide (PTP)
and PTP-HPMA conjugates for Pancreatic Tumor Targeting

4.1 INTRODUCTION
World-wide, radiotherapy (e.g., external beam, brachytherapy and targeted
radionuclide radiotherapy) plays a primary role in the standard of care for many cancer
types [169-171]. While the majority of today’s clinical radiotherapy centers around
external beam, systemic radiotherapy using radionuclide containing carriers that
selectively target tumors, through active or passive mechanisms, offer significant
advantages and clinical potential [169, 172, 173]. Given that the metastatic spread of
cancer, and not the primary tumor, is the main cause of most cancer related deaths;
perhaps the greatest advantage of targeted radionuclide therapy (TRT) is the potential to
systemically target and eliminate small metastatic lesions that are unobserved clinically
due to their size and/or location. Based on this potential, the development of TRT has
been an active field of research with reports of radionuclide carriers that range from low
molecular weight compounds (e.g., small molecules and peptides) to large
macromolecule platforms (e.g., antibodies and nanomedicines) [174-178].

Plectin-1 (Plec1) is a large protein (500kDa) that plays a crucial role in the
cytoskeleton in mammalian cells [179]. It is able to bind and crosslink microtubules, actin
microfilaments, and intermediate filaments in the cytoplasm. In addition, Plec1 serves as
an anchor point between the cytoskeleton and the organelles, nucleus and intracellular
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membrane. In normal cells, Plec1 is localized within the cell and as a consequence
cannot be targeted using traditional cell-surface targeting approaches. However, for
pancreatic ductal adenocarcinoma (PDAC), Plec1 becomes over-expressed on the
extracellular surface of the cell thus making it a potential molecular target [37, 180].
Based on a report by Kelly and co-workers, Plec1 is expressed on the extracellular
surface of 100% of PDAC samples (n=42), 60% of late-stage, pre-invasive pancreatic
intraepithelial neoplasia (PanIN) III samples (n = 15) and 4% of PanIN II samples (n = 26)
[180]. Furthermore, normal pancreas (n = 4), chronic pancreatitis (n = 15) and PanIN I (n
= 14) samples were negative for Plec1 extracellular surface expression. Given these
studies, it appears Plec1 over-expression and extracellular surface localization begins
during the pre-invasive PanIN III stage and further increases as the disease progresses
into the invasive stage. As a consequence, Plec1 appears to be a potentially valuable
molecular target for both diagnostic and therapeutic applications for PDAC.

Recently, a seven amino acid peptide (KTLLPTP) that exhibits submicromolar
binding affinity to Plec1 has been reported [37]. As a result of the attractive properties of
Plec1, we are interested in developing Plec1-targeted platforms, based on the above
peptide targeting vector, for PDAC TRT. Currently, we develop radiopharmaceuticals for
oncologic purposes that range in size from small receptor-targeted peptides to
nanomedicine platforms [181, 182]. It is well known that the size and molecular weight of
targeted radiopharmaceuticals plays a significant role in their in vitro and in vivo
biological performance/profile [129, 183]. As our first investigation into the development
of Plec1-targeted agents, we were interested in comparing and contrasting the biological
profiles of two starkly different Plec1-targeted carriers, specifically one based on a small
peptide and one utilizing an N-(2-hydroxypropyl)methacrylamide (HPMA) polymeric
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system. To that end, we have synthesized and characterized the two Plec1-targeted
agents outlined above. Herein, we describe the in vitro and in vivo properties of these
agents using the HPAC human pancreatic cancer cell line.

4.2 MATERIALS AND METHODS
4.2.1 Peptide Synthesis
The plectin-1 targeted peptide (PTP) analogue 1 (KTLLPTPGGG-NH2 or PTP-NH2)
was synthesized on the rink amide resin using an automated solid phase peptide
synthesizer. The resin (0.1 mmole of peptide anchors) was deprotected using 20%
piperidine in DMF resulting in the formation of the primary amine. The carboxylic acids of
the Fmoc protected amino acids (1 mmol) were activated using COMU and conjugated
to the primary amines of the growing peptide on the resin. The resulting peptide was
orthogonally deprotected and cleaved from the resin by shaking in a cleavage cocktail
consisting of TIS: H2O: DODT: TFA = 2: 2: 2: 94 for 2 h. The cleaved peptide was
subsequently precipitated and washed with ice cold methyl-tert-butyl ether (40 ml×3).
Crude peptide was purified using the semi-preparative C12 column with a flow rate of
5.0 mL/min. All HPLC experiments used solvents consisting of H2O containing 0.1%
formic acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent B). The
initial gradient of 90% A: 10% B linearly decreased to 70% A: 30% B in 15 minutes. At
the end of the run time for all HPLC experiments, the column was flushed with gradient 5%
A: 95% B and re-equilibrated to the starting gradient.

The PTP analogue 2 (DO3A-PTP) was conjugated with a DOTA at the N terminal
position, and was synthesized on rink amide resin using the peptide synthesizer. The
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resin (0.1 mmole) was deprotected using 20% piperidine in DMF resulting in the
formation of the primary amine. The carboxylic acids of the Fmoc protected amino acids
(1 mmol) were activated by COMU and conjugated to the primary amines of the growing
peptide on the resin. DOTA(tBu)3 was added to the N terminus at the final step during
the peptide synthesis. The resulting DOTA peptide conjugate was deprotected and
cleaved from the resin by stirring in a cleavage cocktail consisting of TIS: H2O: DODT:
TFA = 2: 2: 2: 94 for 2 hours. The cleaved conjugate was precipitated and washed with
ice cold methyl-tert-butyl ether (40 ml×3). Crude conjugate was purified using the semipreparative C12 column with a flow rate of 5.0 mL/min. The initial gradient of 90% A: 10%
B linearly decreased to 85% A: 15% B in 15 minutes.

PTP analogues 3 and 4 were synthesized in orthogonally protected forms on the 2chlorotrityl-Gly-resin using an automated solid phase peptide synthesizer. The resin (0.1
mmole of peptide anchors) was deprotected with 20% piperidine resulting in the
formation of the primary amine. The carboxylic acids of the Fmoc protected amino acids
(1 mmol) were activated using COMU and conjugated to the primary amines of the
growing peptide on the resin. All the protected groups and N terminal Fmoc group were
kept intact in the synthesized peptides. The selective cleavage of the protected peptides
from the 2-chlorotrityl resin anchor was achieved by reaction with 1% TFA in dry DCM
and subsequent filtration. The cleaved peptides were subsequently precipitated and
washed thrice using ice cold methyl-tert-butyl ether (40 ml×3). Purification of the
peptides was performed using the semi-preparative C12 column with a flow rate of 5.0
mL/min. For peptide 3, the initial gradient of 30% A: 70% B linearly decreased to 5% A:
95% B in 15 minutes. For peptide 4, 40% A: 60% B was linearly decreased to 10 % A:
90 % B in 15 minutes.
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The ethylenediamine-DOTA(t-Bu)3 was prepared by first reacting DOTA(t-Bu)3 (1
mmole) with DCC (1.3 mmole) and NHS (1.3 mmole) overnight in 1/1(v/v) ethyl acetate
/dioxane solution. The mixture was then washed with 5% sodium bicarbonate, followed
by water and brine. The organic layer was dried over MgSO4. The filtrate was
concentrated in vacuo, followed by addition of N-Boc ethylenediamine (1.2 mmole). The
mixture was stirred overnight. The N-Boc ethylenediamine-DOTA(t-Bu)3 product was
peak purified on HPLC using the C12 column with a flow rate of 5.0 mL/min. The initial
gradient of 70% A: 30% B linearly decreased to 60% A: 40% B over 15 minutes. The
purified N-Boc-ethylenediamine-DOTA(t-Bu)3 0.52 gram (0.74 mmole) was dissolved in 3
mL of tBuOAc, and 44 μL of 18 M H2SO4 (1.5 equiv) was added to the solution. The
mixture was stirred overnight. The solution was then neutralized with saturated sodium
bicarbonate and extracted with ethyl acetate (20 mL×3). The organic layer was dried
with MgSO4. The solution was evaporated to dryness and yielded light yellow oil as the
desired compound. The yield was 66.5% with MS found: 615.4 ([M+H]+).

The L and D forms of PTP with the C terminal conjugated with a DOTA chelator
(peptide 5 or PTP-DO3A and peptide 6 or D-PTP-DO3A) were prepared by reacting the
protected peptides 3 and 4 with ethylenediamine-DOTA(t-Bu)3. In general, 3 mg of
purified peptide 3 or 4 (2.2 μmole) was reacted with 1.4 mg of ethylenediamine-DOTA(tBu)3 in the presence of 2 equiv of EDC and DIPEA in DMF overnight. The crude product
was dried in vacuo and treated with a cleavage cocktail consisting of TIS: H2O: DODT:
TFA = 2: 2: 2: 94 for 2 h. The cleaved peptides were precipitated and washed thrice
using ice cold methyl-tert-butyl ether (40 mL×3) and then dried in vacuo. After that, 20%
piperidine in DMF was used to remove the N-terminal Fmoc group. DMF was removed in
vacuo after 20 min deprotection. The final peptides were peak purified by LC-MS on the
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C12 column with a flow rate of 5.0 mL/min. The initial gradient of 95% A: 5% B linearly
decreased to 70% A: 30% B in 15 minutes.

To prepare the PTP analogues used for “click chemistry”, an Fmoc-D-Lysine-OH
containing 5-hexynoic acid at the ԑ-amine site was synthesized first. To the 5-hexynoic
acid (5 mmole) dissolved in DCM was added NHS (6 mmole), EDC.HCl (6 mmole) and
triethylamine (6 mmole). The reaction was allowed to proceed at room temperature
overnight. The crude product was washed with H2O and extracted with DCM. The
organic layer was dried in vacuo and the crude product was separated by flash
chromatography (ethyl acetate/hexane = 1/3). The purified product (2 mmole) was
dissolved in DMF, and reacted with Fmoc-D-Lysine-OH.HCl (2 mmole) and triethylamine
(2.5 mmole). The mixture was stirred at room temperature overnight. After reaction, the
mixture was dried in vacuo and subjected to flash chromatography (MeOH/DCM = 1/9)
and the 5-hexynoyl-Fmoc-D-Lysine-OH was obtained in light yellow oil with a 41.6%
yield. 1H NMR (DMSO): δ 1.35~1.39 (m, 2H, CH2CH2C=CH), 1.36~1.39 (m, 2H,
CH2CH2CH2CH2), 1.64~1.67 (m, 4H, CH2CH2CH2CH2NH), 2.13~2.15 (t, 4H, CH2CH2CH2
C=CH), 2.75 (s, 1H, CH2CH2 C=CH), 3.03 (m, 2H, CH2CH2CH2NH), 3.90 (m, 1H,
CHCH2OCO), 4.2 (d, 3H, CH2OCO and NHCH(CH2)COOH), 7.2~7.6 (m, 8H, benzene),
7.8 (s, 2H, CONH). 13C NMR (DMSO): δ 17.6, 23.2, 24.5, 28.9, 30.6, 34.3, 38.4, 46.8,
53.9, 65.8, 71.6, 84.2, 120.2, 127.2, 127.8, 129.6, 140.9, 144.0, 156.3, 171.4, 174.1.

The L and D forms of PTP analogues 7 and 8 were synthesized on a Sieber Amide
resin using a solid phase peptide synthesizer. The resin (0.1 mmole of peptide anchors)
was deprotected using 20% piperidine resulting in the formation of the primary amine.
The carboxylic acids of the Fmoc protected amino acids (1 mmol) were activated using
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COMU and conjugated to the primary amines of the growing peptide on the resin. The N
terminal Fmoc group was also kept intact in the synthesized peptides. The selective
cleavage of the protected peptides from the Sieber Amide resin was achieved by
reaction with 1% TFA in dry DCM and subsequent filtration. The cleaved peptides were
subsequently precipitated in ice cold water (40 ml). Purification of the peptides was
performed using the C12 column with a flow rate of 5.0 mL/min. For both peptides, the
initial gradient of 40% A: 60% B linearly decreased to 10% A: 90% B over a 15 minute
time period.

The iFluor-647-labeled PTP was prepared through “click chemistry”. The PTP
analogue 9 was synthesized on a rink amide resin using a solid phase peptide
synthesizer. The resin (0.05 mmole of peptide anchors) was deprotected using 20%
piperidine resulting in the formation of the primary amine. The carboxylic acids of the
Fmoc protected amino acids (0.5 mmol) were activated using COMU and then
conjugated to the primary amines of the growing peptide on the resin. The resulting
peptide was orthogonally deprotected and cleaved from the resin by shaking in a
cleavage cocktail consisting of TIS: H2O: DODT: TFA = 2: 2: 2: 94 for 2 h. The cleaved
peptides were subsequently precipitated and washed thrice using ice cold methyl-tertbutyl ether (40 ml×3). Purification of the peptide was performed using the C12 column
with a flow rate of 5.0 mL/min. The initial gradient of 90% A: 10% B linearly decreased to
80% A: 20% B over a 15 minute time period.

For the preparation of peptide 10, 1 mg of purified peptide 9 (0.86 μmole) was first
dissolved with 1 mg of iFluro-647 (0.92 μmole) in MeOH. After that, 0.2 μmole TBTA
dissolved in 30 μL DMSO was added to a solution of 0.1 μmole CuSO4 in 100 μL
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MeOH/H2O (v/v, 1/1). Next, 0.5 μmole of L-ascorbic acid dissolved in 100 μL MeOH/H2O
(v/v, 1/1) was slowly added to CuSO4/ TBTA mixture to produce the Cu(I) ion as the
catalyst. The catalyst solution was then mixed with peptide 9 and iFluro-647 solution in
an ampoule. The ampoule was flame sealed and stirred for 48 h. The iFluro-647-labeled
plectin-1 targeted peptide 10 was finally peak purified by LC-MS on the C12 column with
a flow rate of 5.0 mL/min. The initial gradient of 90% A: 10% B linearly decreased to 60%
A: 40% B over 15 minutes.

4.2.2 Radiolabeling of the Peptides
Each 25 µg sample of peptides 2, 5 and 6 were dissolved in ammonium acetate
buffer (0.5 M, 100 μL, pH 5.5). 177LuCl3 (1 mCi) was added to the vial containing the
conjugate, and the solution was heated for 60 min at 90 °C and allowed to cool to room
temperature. To facilitate the separation of radiolabeled peptides from unlabeled
peptides on the column, 2-3 mg CuSO4 were added and incubated for 5 min at 90 °C to
increase the hydrophobicity of unlabeled conjugates. The resulting radio-conjugate was
peak purified using RP-HPLC on a C12 250 × 4.6 mm column and was concentrated
using a C18 extraction disk followed by elution with 300 μL ethanol/sterile saline solution
(v/v, 3:2) to deliver the radio-conjugate in high purity. The radiolabeled peptides were
purified by RP-HPLC with 95% H2O: 5% acetonitrile linearly decreasing to 70% H2O: 30%
acetonitrile in 15 minutes.

4.2.3 Cell Culture
The HPAC cells were cultured at 37 °C at 5% CO2 in air, as per ATCC protocols, in
DMEM/ Ham's F12 medium containing 5% FBS, 1.562 nM EGF, 14.3 mM sodium
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bicarbonate, 2.5 mM L-glutamine, 15 mM HEPES and 0.5 mM sodium pyruvate
supplemented with 0.35 µM insulin, 0.0625 µM transferrin and 0.11 µM hydrocortisone.

4.2.4 Internalization and Efflux of Radiolabeled Peptides
Internalization studies were performed using HPAC cells in 12 well plates. HPAC
cells (~1×105) were seeded in each well in DMEM/Ham's F12 media and incubated
overnight. The next day, about 100,000 cpm of 177Lu-labeled peptides was added to
each well, and cells were incubated for up to 3 h at 37°C. During the incubation, at timepoints 15, 45, 90 and 180 min, cells were washed three times with media to remove the
free radiolabeled peptide. Surface-bound radioactivity was removed by washing the cells
twice with an ice cold acid wash (50 mM glycine-HCl/0.1 M NaCl buffer, pH 2.8). The
amount of non-acid washable radioactivity in each well was measured after lysing the
cells with 10% NaOH solution.

For efflux studies, HPAC cells (~1×105) were incubated in 12 well plates overnight.
On the day of the experiment, HPAC cells were first incubated for 2 h at 37°C in the
presence of ~100,000 cpm of the 177Lu labeled peptide to reach the plateau amount of
cell associated radioactivity. Upon completion of the incubation, cells were washed three
times with medium to remove the unbound peptide. Then, fresh medium was put in each
well as the reservoir for efflux. After 0, 1, 2 and 4 h, the medium for each time point was
harvested for quantitative analysis of ligand efflux. Surface-bound radioactivity was
removed by washing the cells twice with an ice cold acid wash (50 mM glycine-HCl/0.1
M NaCl buffer, pH 2.8). The cells were then lysed using a 10 % NaOH solution, and the
remaining cell associated radioactivity was quantified. The radioactivity in the effluxed
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and cell associated fractions was determined by a gamma counter. The effluxed fraction
is expressed as a percentage of the total amount of radioactivity, which is the sum of the
effluxed and the remaining fraction in the cell.

4.2.5 In vitro Competitive Binding Study of PTP Analogues
For in vitro binding studies, the half maximal inhibitory concentration (IC50) for the
PTP-NH2 conjugate was determined on the HPAC cell line. In these studies,

177

Lu-PTP-

DO3A served as the control and PTP-NH2 as the cold ligand for comparing the relative
effectiveness of the conjugates. Briefly, HPAC cells (~5×104) were seeded in each well
of a 24-well plate and allowed to adhere overnight. The cells were then incubated at
37 °C for 1 h in the presence of radiolabeled 177Lu-PTP-DO3A (~100,000 cpm) and
various concentrations (10-9~10-4 M) of the PTP-NH2. At the end of the incubation, the
media was removed and cells were washed with cold PBS three times. The cellassociated radioactivity was measured by a gamma counter and the IC50 value was
determined by nonlinear regression using the one-binding site model of GraphPad Prism
5 (U.S.). The IC50 values for peptide 2 and 6 were determined using the same protocol.

4.2.6 Confocal Microscopy
HPAC cells were seeded onto 4-well chambered coverglass units with 5 × 104 cells.
The iFluor-647 labeled peptide 10 was dissolved in blank media to 5 μM concentration.
The cells were then incubated with the peptide for 4 h in a 37 ºC humidified atmosphere
with 5% CO2. Half an hour before ending the incubation, LysoTracker Red DND-99 and
Hoechst 33342 were added in the media to stain the lysosomal compartment and the
nuclei respectively. Following incubation, the media was aspirated, and the cells were
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washed with PBS to remove free peptides that were not associated with cells prior to
microscopic imaging.

4.2.7 Biodistribution of the Radiolabeled PTP Analogue
Biodistribution studies were carried out using age-matched HPAC tumor bearing
SCID mice. The animals were inoculated in each flank with 100 μL of a 1:1 ratio of
suspended HPAC cells and Matrigel™ to obtain a final concentration of 5 x 106 HPAC
cells per 100 μL. Upon achieving sufficient tumor size (10-15 mm in diameter), the mice
were used for biodistribution studies. The HPAC xenograft mice were injected with a 10
μCi (0.37 MBq) intravenous bolus of the purified 177Lu-PTP-DO3A. The mice were
sacrificed and the tissues excised at 1 and 4 h time-points p.i. The blood and excised
tissues were weighed, the 177Lu radioactivity was measured using a gamma counter, and
the percentage injected dose per gram (%ID/g) was calculated for each tissue.

4.2.8 Metabolic Stability in Human Serum
The stability of peptide 5, PTP-DO3A and 177Lu-PTP-DO3A in human serum was
determined. Briefly, 10 µg of PTP-DO3A or 200 µCi (7.4 MBq) of 177Lu-PTP-DO3A was
added to 100 µL of human serum and incubated at 37 °C for 15 minutes. After the
incubation, 100 µL of an ethanol/ acetonitrile (v/v, 1:1) was added to the serum and the
whole mixture was vortexed to help precipitate the serum proteins. The resulting mixture
was centrifuged at 12000 x g for 10 min. The supernatant was collected and purged with
N2 gas for 20 minutes to remove the ethanol and acetonitrile. The resulting sample was
dissolved in 100 µL water and injected into LC/MS or radio-HPLC for analysis. The
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gradient used was 95% H2O: 5% acetonitrile linearly decreasing to 70% H2O: 30%
acetonitrile in 15 minutes.

4.2.9 Synthesis and Characterization of “Click” Reactive HPMA Copolymer
The “click” reactive monomer: N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)
methacrylamide (AzMA) was synthesized. First, 1 gram of methacrylic acid (11.63
mmole) was reacted with 1.38 gram of NHS (12 mmole) and 2.3 gram of EDC.HCl (12
mmole) in DCM overnight, the resulting mixture was washed with water, and extracted
with ethyl acetate. The organic layer was dried in vacuo. The dried product was
monitored over 90% pure on LC-MS so directly used without purification. The dried
product (1 gram) was dissolved in DMF followed by addition of 1.2 gram of 11-Azido-3, 6,
9-trioxaundecan-1-amine (5.5 mmole) and triethylamine (11 mmole). The mixture was
stirred overnight, then washed with water, and extracted with DCM twice. The organic
layer was dried and subjected to silica gel flash chromatography (ethyl acetate/DCM =
9/1) and yielded 0.6 gram of pure monomer-AzMA (40% yield). 1H NMR (CDCl3): δ 1.90
(s, 3H, CH2=CCH3), 3.32 (t, 2H, CONHCH2CH2), 3.45 (t, 2H, CH2CH2-N3), 3.50~3.70 (t,
12H, CH2OCH2), 5.67 and 5.28 (s, 2H, CH2=CCH3). 13C NMR (CDCl3): δ 18.7, 39.5,
50.8, 70.2, 70.2, 70.2, 70.6, 70.6, 70.7, 119.9, 139.9, 168.8.

The HPMA copolymerization was accomplished using the reversible additionfragmentation chain transfer polymerization reaction with AIBN as the initiator and CTP
as the chain transfer agent. The feed ratio of the polymerization consisted of 78: 19. 6:
2.2: 0.20 mole% HPMA, AzMA, APMA and APMA-FITC, respectively. The
polymerization was run at a 1 M total monomer concentration in a dioxane: H2O (v/v, 2/1)
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mixture with a molar ratio of total monomer: chain transfer agent: initiator of 100: 1: 1.
Prior to proceeding with the polymerization reaction, the glass ampoule and contents
were purged with nitrogen for 20 minutes. Subsequently, the ampoule was flame sealed
and allowed to heat at 50 ºC in an oil bath for 48 h. After cooling, the HPMA copolymer
was evaporated to dryness, dissolved in methanol and purified by size exclusion
chromatography (SEC) using an LH-20 packing material with methanol as the eluent.
The conversion rate was 81% as determined by weight after purification. The weight
average molecular weight and polymer dispersity of copolymers were determined by the
TDA 305 equipped with UV, RI and static light scattering detectors. The static light
scattering was calibrated with a PolyCALTM PEO-24K standard. The SEC was carried
out on an Asahipak GF-510 HQ column with 40% acetonitrile in PBS as the eluent. The
average molecular weights of the copolymers were estimated by OmniSEC 5.1 software.

4.2.10 Synthesis and Characterization of PTP-HPMA Conjugates
The L and D form of PTP analogues - peptide 7 and 8 and were conjugated to HPMA
copolymer by copper catalyzed “click chemistry”. Briefly, 100 μmole TBTA dissolved in
30 μL DMSO was first added to 54 μmole CuSO4 in 100 μL (v/v, 1/1) MeOH/H2O. Then
250 μmole L-ascorbic acid in 100 μL of (v/v, 1/1) MeOH/H2O was slowly added to
CuSO4/TBTA mixture to produce the Cu(I) ion as the catalyst. Next, 2 μmole “click”
reactive HPMA copolymer dissolved in 100 μL MeOH was mixed with 54 μmole of
peptide 7 or 8 (1.2 mole equivalent of azide group in the copolymer) in an ampoule. The
reduced Cu+ solution was added slowly to the HPMA and peptide mixture. The ampoule
was flame sealed and stirred at 40 ºC over 48 h. After reaction, the mixture was
subjected a LH-20 size exclusion chromatography for purification. The polymer peptide
conjugates were collected and dialyzed against EtOH/H2O (v/v, 3/1) for 48 h. The
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dialyzed products were dried and reacted with DCC activated DOTA(tBu)3 (2 equiv) in
DMF. The final HPMA conjugates were precipitated in cold ether to remove free DOTA.
The conjugation efficiency was determined by ninhydrin assay as reported. The
conjugates were then deprotected with 20% piperidine in DMF and precipitated in cold
ether again. The conjugates were finally treated with a peptide cleavage cocktail. The
final polymer peptide conjugates were precipitated again in cold ether and lyophilized for
storage.

4.2.11 Internalization Study of PTP-HPMA Conjugates by Flow Cytometry
HPAC cells were seeded in 12-well plates at a density of 1 × 105 cells per well and
incubated in media overnight (37 °C, 5% CO2). Cells were then incubated with two
different peptide polymer conjugates (0.2 mg/mL) at 37 °C for the indicated time periods.
After incubation, the media was removed. Cells were washed with PBS three times, then
harvested and fixed followed by ﬂow cytometry analysis. Each sample analysis involved
an evaluation of ~1.0 × 104 cells. The collected data was averaged and reported as the
mean ﬂuorescent intensity for each sample.

4.2.12 Radiolabeling and in vitro Evaluation of 177Lu Labeled PTP-HPMA Conjugates
The radiolabeling of the conjugates was accomplished by heating the peptide
polymer conjugate (200 μg) dissolved in water at 90 ºC for 1 h in the presence of 14.8
MBq (400 μCi) of 177LuCl3. After cooling, the 177Lu-labeled HPMA conjugates were
purified by size exclusion chromatography using an LH-20 packing material in methanol.
All the purified 177Lu-labeled HPMA conjugates were concentrated using an Amicon
Ultra-4 Centrifugal Filter and washed twice with 5 mL of de-ionized water. For
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internalization study, HPAC cells were seeded in 12-well plates at a density of 1 × 105
cells per well overnight (37 °C, 5% CO2). Cells were then incubated with different 177Lulabeled HPMA conjugates (~ 100,000 cpm in each well) at 37 °C for 6 and 24 h. After
incubation, the media was removed. Cells were washed with PBS three times, and then
lysed with 10% NaOH solution. The internalized amount of radioactivity was measured
by the gamma counter. For competitive binding study, HPAC cells (~5×104) were seeded
in each of 24-well plate overnight and incubated at 37 °C for 1 hour in the presence of
177

Lu-PTP-DOTA (~100,000 cpm, 100 µl), with or without 200 µg HPMA-PTP conjugate.

At the end of the incubation, the incubation media was removed and cells were washed
with media. The cell-associated radioactivity was measured by a gamma counter.

4.3 RESULTS
4.3.1 Design and Synthesis of PTP Analogues
A series of plectin-1 targeted peptide (PTP) analogues were synthesized by solid
phase peptide synthesis and characterized by LC/MS. The peptide sequences and mass
spectrometric analysis were summarized in Table 4.1. The plectin-1 targeted peptide
sequence was initially identified by phase display and consisted of a seven amino acid
sequence - KTLLPTP. It has been shown that the C terminal of this peptide could be
modified with other compounds without causing the loss of binding affinity to Plec1. In
order to investigate whether the N terminal of this peptide is essential for plectin-1
binding, we prepared a PTP analogue with modification at the N terminal. Peptide 2 or
DO3A-PTP was synthesized with the N terminal conjugated with a DOTA molecule by
adding DOTA in the last step during solid phase peptide synthesis. A GGG linker was
inserted between the targeting sequence and the DOTA (Figure 4.1). In order to prepare
a C terminal DOTA modified peptide, orthogonally protected peptide 3, consisting of ten

125
amino acids: KTLLPTPGGG, was synthesized on the 2-chlorotrityl-Gly resin. Peptide 4
had the same peptide sequence and molecular structure with peptide 3 and was
prepared following the same strategy with 3 except that all the amino acids used in 4
were the corresponding D forms other than glycine. By evaluating the binding affinity of
D-PTP towards plectin-1, we can determine whether the cell-association/binding of the
PTP is target-specific or due to any contribution from non-specific binding.

The ethylenediamine(EDA)-DOTA(t-Bu)3 was synthesized and used to modify the C
terminal of peptide 3 and 4 with a DOTA molecule. N-Boc-ethylenediamine was firstly
reacted with DCC activated DOTA(tBu)3, followed by treatment with dilute H2SO4 in
tBuOAc solution in order to selectively remove the N-Boc protecting groups. The EDADOTA(t-Bu)3 was then conjugated to the C terminal carboxylic acid of peptide 3 and 4
via EDC and NHS coupling. The crude products were not purified but directly subjected
to TFA and piperidine treatment to remove the protecting groups. The final desired
peptide 5 (PTP-DO3A) and 6 (D-PTP-DO3A) were purified by LC/MS based on the
presumed molecular weight in a relatively poor yield. The poor yield might be due to our
one-pot conjugation and deprotection method. We might achieve a better yield if we had
purified desired products after each reaction.
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Table 4.1: MS characterization of plectin-1 targeted peptide analogues. All the D form
amino acids were abbreviated in lower case letters. (a, the exact molecular formula of
iFluor-647 was unknown. b, corresponding to [M+2H+]/2)
Peptide
No.

Sequences

Formula

Mass
Observed
+
[M+ H]

RP-HPLC
retention
time / min

Yield
(%)

1

KTLLPTPGGG-NH2

C42H74N12O12

939.33

8.03

34.1

2

DO3A-GGGKTLLPTPG-NH2

C60H103N17O20

1382.39

13.77

43.4

3

Fmoc-KTLLPTPGGG-OH

C70H107N11O17

1374.61

6.88

31.5

4

Fmoc-ktllptpGGG-OH

C70H107N11O17

1374.61

9.67

30.5

5

KTLLPTPGGG-EDA-DO3A

C60H105N17O19

1368.72

9.37

13.3

6

ktllptpGGG-EDA-DO3A

C60H105N17O19

1368.61

9.31

15.1

7

Fmoc-KTLLPTPGGG-p(4-F)-

C91H134FN15O19

1761.78

10.77

30.7

k(5-hexynoate)
8

Fmoc-ktllptpGGG-p(4-F)-k(5hexynoate)

C91H134FN15O19

1761.82

10.21

32.1

9

KTLLPTPGGG-k(5-hexynoate)

C54H92N14O14

1161.44

10.93

29.5

b

11.88

30.1

10

KTLLPTPGGG-k(5-hexynoate)iFluor-647

a

N/A

1120.43
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Figure 4.1: Structure of DO3A-PTP conjugate and synthesis for PTP-DO3A conjugate.
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We next prepared an amino acid derivative that can be used in peptide synthesis to
introduce the alkyne functional group into PTP analogues. Those PTP analogues
bearing alkyne groups can be conjugated to azide functionalized compounds through
“click chemistry”. The ɛ-amine of Fmoc-D-lysine was conjugated with a 5-hexnoic acid
within two steps (Figure 4.2). The resulting product: 5-hexynoate-Fmoc-D-lysine was
then used for the synthesis of peptides 7-10. Peptides 7 and 8 were synthesized in
orthogonally protected form on the Sieber Amide resin. An amino acid derivative 4-19F Dphenylalanine was inserted between the GGG linker and the 5-hexynoate-D-lysine and
functionalized as a “tag”. Thereby, the amount of peptide conjugated to the copolymer
could be easily determined by 19F NMR. Except for glycine, 4-19F D-phenylalanine and 5hexynoate-D-lysine, all the other amino acids in peptide 7 was in L forms while all the
other amino acids in peptide 8 was in D forms. Peptide 8 was used in the following
section to prepare a polymer peptide conjugate as a control. Peptide 9 was a PTP
analogue with a GGG linker after the targeting sequence, followed by the 5-hexynoateD-lysine at the C terminal position. Peptide 9 was used to conjugate with a near infrared
fluorophore by “click chemistry”.
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Figure 4.2: Synthesis of 5-hexynoate-Fmoc-D-lysine and iFluor-647-labeled PTP.

130
The fluorophore labeled PTP analogue 10 was synthesized by copper (I) catalyzed
“click chemistry” and was used to investigate the cellular localization of PTP on
pancreatic tumor cells. The Cu(I) ion was in-situ generated after reducing CuSO4 with
ascorbic acid. TBTA could protect Cu(I) from oxidation and disproportionation, while
enhance its catalytic activity. The fluorophore we used is iFluor-647, which has an azide
functional group in it with similar excitation/emission spectra as Cy 5.5 but the exact
molecular structure was unknown. However, the molecular weight was known to be
1079.1. The desired peptide peak was identified in LC/MS based on the calculated
molecular weight and peptide 10 was purified by RP-HPLC. The “click” reaction yield
was about 30%, which should be increased by optimizing the reaction conditions. Even
though we didn’t characterize the excitation/emission property of the collected peptide,
the conjugate showed a deep blue color in solution, which confirmed the successful
conjugation of the fluorophore to the peptide.

4.3.2 Competitive Binding, Internalization, Efflux Studies of 177Lu PTP Analogues
The binding affinity, internalization and efflux of plectin-1 targeted peptide analogues
were investigated on HPAC cell lines. All the peptides were successfully labeled with
177

Lu at > 90% efficiency. The non-radiolabeled peptides were labeled with Cu(II) by

adding excess amount of CuSO4.5H2O (2 mg) to the labeling mixture, which results in
better separation from the 177Lu labeled peptide in HPLC. The synthesized cold ligand,
KTLLPTPGGG-NH2(PTP-NH2) could compete with 177Lu-PTP-DO3A towards plectin-1
binding on HPAC, with a IC50 at 1.6 ± 0.2 µM (Figure 4.3 A), which is very close to the
reported tetrametric PTP analogue [14]. The 177Lu-labeled PTP-DO3A exhibited very
efficient targeting ability in vitro, with a initial 24.49 ± 3.94% of cell associated
radioactivity in 15 min, and increased to 46.77 ± 1.36% after 3 h incubation. The acid
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washable portion was very low, but increased from 1.64 ± 0.53% at 15 min to 3.72 ±
0.37% at 3 h (Figure 4.3 B). Neither the DO3A-PTP nor the D-PTP-DO3A showed any
significant binding toward plectin-1, with IC50 > 200 µM. Neither exhibited any uptake to
pancreatic cancer cells, which implys that N terminal of KTLLPTP is more essential for
plectin-1 binding and cell-association/binding of the PTP is target-specific but not due to
any contribution from non-specific binding. In our experiments, we also found that 177LuPTP-DO3A did not exhibit any binding toward plectin-1 when we performed the
competitive binding assay at 4 ºC, the reason is still unknown. The IC50 value was
obtained at 37 ºC instead of 4 ºC. The efflux study was initiated after 1 h incubation of
177

Lu-PTP-DO3A with HPACs. The 1 h incubation time was chosen because based on

the internalization study, the uptake level reached the plateau as soon as in 45 min. The
effluxed amount of cell associated activity increased from 8.47 ± 0.50% at 1 h to 29.63 ±
0.91% at 4 h (Figure 4.3 C).
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A

B

C

Figure 4.3: Competitive binding, internalization/efflux studies of 177Lu-labeled PTP
analogues in HPAC cells. A, the N terminal modified analogue DO3A-PTP showed more
than 100 times lower binding ability towards plectin-1 as compared to the C-terminal
modified analogue PTP-DO3A. B and C, the 177Lu-PTP-DO3A exhibited the highest
uptake and sustained efflux in the study period.
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4.3.3 Confocal Microscopy Study of iFluor-647 labeled PTP analogue
The cellular localization of plectin-1 targeted peptide on HPAC human pancreatic
cancer cell was determined using the iFluor-647-labeled peptide with confocal
microscopy. Single and triple cell staining studies were performed. In the triple staining
study, the lysosome compartments were labeled with the Lysotracker (red) and the
nuclei were stained with Hoeschst 33342 (blue). After 4 h incubation, the majority of the
peptide was found on the HPAC cell membrane (Figure 4 A, red and 4 B, pink) instead
of inside the lysosome compartment (Figure 4 B, red). Even though the internalization
study showed that most cell-associated radioactivity was acid non-washable, the
peptides were not internalized after 3~4 h.
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A

B

Figure 4.4: Cell trafficking of iFluor-647-labeled PTP in HPAC cells under confocal
microscopy. A, overlay of bright field image and near infrared image of the localization of
iFluor-647-labeled PTP in HPAC; B, iFluor-647-labeled PTP staining (pink), lysosome
staining (red) and nuclei staining (blue) of HPAC cells and the merge picture.
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4.3.4 Biodistribution Study of 177Lu-labeled PTP Analogue
The in vivo targeting efficacy for pancreatic tumor was evaluated in an HPAC
xenograft mice model by intravenous injection of

177

Lu-PTP-DO3A. The radioactivity was

eliminated quickly, mainly throughout the renal system. At 1 h p.i., even though the
absolute value was low, tumor sites still had the second highest radioactivity level
(ID%/g of tumor vs spleen, p = 0.70) among all tissues (Table 4.2 and Figure 4.5). The
tumor to muscle ratio was 3.45 ± 1.66. At 4 h p.i., the radioactivity was absent in all
tissues except the kidney (2.50 ± 0.30 % ID/g).
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Table 4.2: Biodistribution (ID%/g) of 177Lu-PTP-DO3A in HPAC xenograft mice at 1 and 4
h p.i. N=3 at each time-point.
Tissue

1 hour

4 hour

blood

0.46 ± 0.05

0.09 ± 0.10

heart

0.26 ± 0.08

0.04 ± 0.06

lung

0.38 ± 0.04

0.05 ± 0.06

liver

0.37 ± 0.18

0.19 ± 0.05

pancreas

0.16 ± 0.06

0.05 ± 0.06

stomach

0.08 ± 0.01

0.01 ± 0.02

spleen

0.89 ± 0.67

0.06 ± 0.07

small int.

0.47 ± 0.36

0.04 ± 0.01

large int.

0.31 ± 0.14

0.20 ± 0.01

kidney

4.33 ± 1.59

2.50 ± 0.30

tumor

0.72 ± 0.28

0.08 ± 0.03

muscle

0.32 ± 0.33

0.01 ± 0.01

bone

0.28 ± 0.40

0.06 ± 0.08

brain

0.04 ± 0.02

0.01 ± 0.01
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Figure 4.5: Biodistribution (ID%/g) of 177Lu-PTP-DO3A in HPAC xenograft mice at 1 and
4 h p.i. N=3 at each time-point. Tumor sites had the second highest accumulation at 1 h
but were quickly decreased at 4 h.
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4.3.5 Metabolic Stability of Plectin-1 Targeted Peptide
The low tumor uptake in vivo was considered due to the instability of the 177Lu-PTPDO3A in the blood. In vitro serum stability study was performed to investigate the
stability and metabolite of the radiolabeled and non-radiolabeled plectin-1 targeted
peptides. The 177Lu-PTP-DO3A was degraded very fast in serum, generating one major
metabolite and two other metabolites after 15 min incubation with human serum (Figure
4.6 A&B). The LC-MS analysis was used to investigate the metabolites of non labeled
PTP-DO3A in human serum. We found that the major metabolite was the product from
the N-terminal D-lysine residual cleavage (peak 4, calculated 620.84 / found 620.81).
Two other metabolites were identified where cleavage sites were between the 3L--4L
residual (peak 1, calculated 513.77 / found 513.75) and 2T--3L residual (peak 2,
calculated 570.31 / found 570.29) (Figure 4.6 C&D).
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C

D

Figure 4.6: Metabolism of plectin-1 targeted peptide in human serum. A, Radio-HPLC
signal of 177Lu-PTP-DO3A before incubation; B, radio-HPLC signal of the degradants of
177
Lu-PTP-DO3A after 15 min incubation; C, total ion chromatography of PTP-DO3A
after 15 min incubation; D, the corresponding mass-spectra of peak 1-4.

140
4.3.6 Synthesis and Characterization of PTP-HPMA Conjugates
Click reaction has shown improved conjugation efficiency as compared to many
other bio-conjugation methods. In order to prepare the “click” reactive HPMA copolymer,
we first developed a monomer bearing the azide functional group. The monomer AzMA
was synthesized by reacting methacrylic acid with the 11-Azido-3, 6, 9-trioxaundecan-1amine (Figure 4.7). The PEG3 linker between the azide group and the HPMA backbone
was considered to help increase the conjugation efficiency by decreasing the steric
hindrance. HPMA copolymers containing APMA and AzMA were prepared by RAFT
polymerization using CTP as the chain transfer agent and AIBN as initiator. Dioxane and
water mixture (v/v, 2/1) was used to solubilize all the monomer content. The copolymer
had a molecular weight 25,610 Da and the PDI 1.2 based on the static light scattering
measurement. The mole content of HPMA, APMA and AzMA unit in the copolymer was
determined by 1H NMR (Figure 4.8). The copolymer had 14.5 mole% and AzMA 1.2
mole% APMA, which corresponded to 132 molecules of HPMA unit, 23 molecules of
AzMA unit and 2 molecule of APMA on average in each copolymer backbone. The PTP
analogues 7 and 8 were successfully conjugated to the HPMA copolymer by “click
chemistry”, as confirmed by the 19F NMR. Initially we tried to use D-propargylglycine,
which was commercially available, to introduce the alkyne group into the peptide but the
resulting peptide did not conjugate well with the polymer, possibly due to steric
restriction. We switched to the 5-hexynoate-D-lysine as it had longer distance between
the alkyne group and the amino acid back bone, which should help increase the
conjugation efficiency. We also optimized the “click chemistry” reaction conditions to
increase the conjugation efficiency. The amount of CuSO4 we used was one molar
equivalent to the alkyne group. This is a much larger quantity as compared to amounts
other researchers reported (normally between 0.01 to 0.1 mole equivalent). The amount
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of peptide conjugated to the HPMA copolymer was determined by quantitative

19

F NMR.

Known amounts of the 4-fluoro-3-nitrobenzotrifluoride were added as the internal
standard. The peptide content was calculated out based on the 19F NMR integral area
ratio between the -CF3 peak (0 ppm) from the internal standard and the –PhF peak
(56.7 ppm) from the D-phenylalanine residual (4-F). We obtained a high conjugation
yield with 10.4 mole% peptide 7 and 8.9 mole% peptide 8 conjugated to the HPMA
copolymer, corresponding to 71.1% and 60.8% conjugation efficiency. The average
number of peptides in the copolymer was about 16 for peptide 7 and 14 for peptide 8.
The conjugated peptides in the copolymer were subsequently deprotected by piperidine
and then TFA cocktail, after conjugation with DOTA(tBu)3. Ninhydrin assays showed that
23% and 25% of APMA in the copolymers were linked with DOTA(tBu)3, respectively.
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Figure 4.7: Synthesis of HPMA-AzMA-APMA copolymer and plectin-1 targeted peptide
conjugated HPMA copolymers (PTP-HPMA) and the control (D-PTP-HPMA).
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Figure 4.8: 1H NMR spectra of “click” reactive HPMA-AzMA-APMA copolymer in D2O
solvent. The corresponding position of each hydrogen atom is denoted in the spectra.
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4.3.7 Internalization Study of PTP-HPMA conjugates
The efficacy of the plectin-1 targeted peptide conjugated HPMA copolymer (PTPHPMA) and the corresponding control conjugate (D-PTP-HPMA) for pancreatic tumor
targeting was evaluated by flow cytometry (Figure 4.9). At 200 μg/ml concentration, the
D-PTP-HPMA conjugate didn’t show any uptake from 6 to 24 h. At 6 h, there wasn’t any
uptake difference between the PTP-HPMA conjugate and the D-PTP-HPMA conjugate.
The PTP-HPMA conjugate had a significantly higher uptake than the D-PTP-HPMA
conjugate at 24 h. However, such increase didn’t seem to be mediated by plectin-1, as
an excess amount of free PTP-NH2 couldn’t block the uptake after a 24 h co-incubation.
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F

Figure 4.9: Analysis of FITC-labeled peptide-HPMA conjugate cell uptake at 6 and 24 h.
A and B, uptake of D-PTP-HPMA conjugate at 6 and 24 h; C and D, uptake of PTPHPMA conjugate at 6 and 24 h; E and F, uptake of PTP-HPMA conjugate after coincubation with 200 μg/ml PTP-NH2 at 6 and 24 h.
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The internalization of PTP-HPMA conjugate in pancreatic tumor cells was also
investigated using radiolabeled conjugates. Both conjugates could be labeled with 177Lu
easily with efficiency > 80%. But the 177Lu-labeled, PTP-HPMA copolymer had very
minimal amounts of cell uptake, even though slightly higher than the 177Lu-labeled, DPTP-HPMA copolymer at 6 h, but their cellular uptake was not significantly different at
24 h (Figure 10). An excess amount of free PTP-NH2 again did not affect the overall
internalization of 177Lu-PTP-HPMA at 6 or 24 h. Overall, the 177Lu-labeled, PTP-HPMA
exhibited much lower cell uptake as compared to the free peptide 177Lu-PTP-DO3A.
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Figure 4.10: Internalization of 177Lu-PTP-HPMA conjugates in HPAC cells at 6 and 24 h.
The uptake of 177Lu-PTP-HPMA conjugate was slightly higher at 6 h but not significantly
different from 177Lu-PTP-HPMA conjugate at 24 h.
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The interaction between PTP-HPMA conjugate and the plectin-1 was also examined
by competitive binding study. However, even with 200 µg/ml of PTP-HPMA conjugate
present in the media, the uptake of 177Lu-PTP-DO3A wasn’t decreased. This, in another
aspect, showed the conjugate didn’t exhibit any plectin-1 binding capability.

4.4 DISCUSSION
There is an urgent need to develop better diagnostic agents for pancreatic cancer
detection and staging [184, 185]. Recent reports by Kelly and colleagues identify plectin1 as a potential biomarker for PDAC [14]. Plectin-1 is a cytoskeleton protein that is
ubiquitously expressed in cells, but is normally constrained to the intracellular
compartment. However, in the case of PDAC, plectin-1 becomes aberrantly expressed
on the extracellular surface. Plectin-1 appears to be a potentially valuable molecular
target for diagnostic applications for PDAC. Herein, we prepared two different plectin-1
targeted carriers, the small peptide and the peptide HPMA conjugates and radiolabeled
these carriers with 177Lu. We evaluated the in vitro and in vivo properties of these
carriers using the HPAC human pancreatic cancer cell line.

Based on existing knowledge, the C-terminus of the PTP can be modified without
substantial loss in binding affinity to plectin-1. However, based on our results from
incorporating a N-terminal DOTA (peptide 2), the N-terminus was found to be more
sensitive to modification, greater than a 100 fold decrease in binding affinity relative to
C-terminally modified PTP-DO3A (peptide 5), thus suggesting that the N-terminal amino
acids are crucial for activity. In addition to modification of the termini of the peptide, we
investigated the D-form analogue of the PTP (D-PTP-DO3A, Peptide 6) to determine
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what role the physiochemical properties of the targeting vector plays in cell-association
activity. The D-form of the PTP (177Lu-D-PTP-DO3A) demonstrated negligible cellassociation toward the HPAC cells and lacked the ability to competitively inhibit the
binding of the L-form of the PTP to plectin-1. These studies suggests that the cellassociation/binding of the PTP is target-specific and not due to any contribution from
non-specific binding.

Using a fluorescently labeled PTP analogue (Peptide 10), the cell trafficking of the
PTP was investigated in the HPAC cell line. At the 4 h time-point, it was found that the
PTP localizes on the cell membrane with little evidence of internalization, which is
consistent with reported findings. This data was important for the subsequent
interpretation of the internalization and efflux data of the PTP. The C-terminal modified
PTP (177Lu-PTP-DO3A) exhibited a high percentage of cell associated radioactivity in as
little as 15 min and plateaued after 45 min. Attempts to distinguish internalized
radioactivity from surface-bound, using was acid buffer washes, initially led us to believe
that the radio-conjugate was being internalized. However, based on the confocal studies,
it seems that the standard acid buffer wash is unable to remove radiolabeled PTP from
the cell surface. We are currently working on developing more rigorous surface removal
buffers to adequately distinguish surface-bound from internalized radioactivity. One
alternative explanation for this observation is the possibility that the fluorescently labeled
peptide (peptide 10) has markedly different internalization properties relative to

177

Lu-

PTP-DO3A. However, this seems unlikely since distance of the chelator/fluorophore
from the pharmacophore is quite large, relative to other receptor-targeted peptides, and
would not be expected to generate such a contrasting phenomenon in terms of
internalization profiles.
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Encouraged by the in vitro results, we investigated 177Lu-PTP-DO3A in an HPAC
xenograft mouse model. At the 1 h time-point, the radio-conjugate cleared rapidly from
the blood and other non-target tissues and was excreted from the mice largely by the
renal system. Due to this excretion profile, the kidneys were found to have the highest
radioactivity retention with 4.33 ± 1.59 %ID/g and 2.50 ± 0.30 %ID/g at the 1 and 4 h
post-injection time-points, respectively. While the HPAC tumors sites had the second
highest uptake among all tissues, the tumor uptake was only 0.72 ± 0.28 ID/g at 1 h and
had essentially cleared all remaining activity by the 4 h time-point. These results are
disappointing, particularly in light of reports by Kelly and co-workers in which they
describe the successful application of a tetrameric PTP which demonstrated good in vivo
targeting [14]. Based on their reports, it seems likely that the tetrameric PTP radioconjugate allows for better in vivo targeting and/or metabolic stability (due to sterics)
relative to the monomeric 177Lu-PTP-DO3A. Based on the strong in vitro performance of
the 177Lu-PTP-DO3A, it seems likely that the poor in vivo performance is due, at least
partially, to the metabolic instability of the PTP. It is well known that peptides with a free
N-terminus can be susceptible to certain proteases called aminopeptidases [186], which
are also known to exist in the blood and on the surface of the tumor vasculature [187].
The rapid in vivo metabolism of 177Lu-PTP-DO3A would explain both the poor initial
uptake at 1 h and rapid clearance by the 4 h time-point.

To further examine the metabolic stability of 177Lu-PTP-DO3A, an in vitro serum
stability study was conducted using both radiolabeled and un-metallated peptides. Using
radio-HPLC and LC-MS, it was found that PTP was easily degraded in serum leading to
one major and two minor metabolites. The major metabolite corresponded to the loss of
the first lysine residue, while the other two minor metabolites corresponded to cleavages
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at the subsequent amino acids 2T-3L and 3L-4L. The sequential nature of these
degradations is consistent with what would be expected from an aminopeptidase [188].
However, to further confirm this, a protease inhibition study should be performed in the
future. Given this and the in vivo biodistribution data, it is clear that alterations to the
PTP are needed to increase the in vivo metabolic stability of future PTP radio-conjugates.

The peptide-polymer conjugate is a promising targeting platform for targeted
diagnostic and therapeutic agent development due to the potential of the multi-valency
effect [189]. We prepared “click” reactive HPMA copolymers bearing azide groups on the
side chains and conjugated it with an alkyne group functionalized PTP (peptide 7). The
“click” chemistry resulted in incorporation efficiencies of greater than 60%. It has been
shown that the incorporation of receptor-targeted peptides of just 10 mole% into HPMA
copolymers has led to substantial increases in multivalent binding [190], however, the
resulting PTP-HPMA conjugate demonstrated substantially lower than expected binding
towards pancreatic tumors, as established by flow cytometry and the competitive binding
studies. This is particularly evident, when one compares the cell-associated activity of
the 177Lu-PTP-HPMA conjugate to the 177Lu-PTP-DO3A peptide from the internalization
and efflux studies. The reason why the plectin-1 binding for the PTP- HPMA conjugate is
so poor remains unknown. One possible explanation is that the steric hindrance between
the peptide and the polymer backbone is impeding plectin-1 binding. In such a case, a
possible solution might be the insertion of a longer PEG chain between the PTP and the
HPMA copolymer to alleviate steric interference.

152
4.5 CONCLUSION
In this study, we found that the PTP analogue with DOTA conjugated to the C
terminal (PTP-DO3A) had significantly higher binding affinity and cellular uptake as
compared to the N terminal DOTA conjugated PTP (DO3A-PTP). The PTP-DO3A was
un-stable in vivo, leading to decreased targeting efficacy to pancreatic tumor in a
xenograft mouse model. PTP can be efficiently conjugated to HPMA copolymer by “click
chemistry”, but the resulting PTP-HPMA conjugate lost the binding affinity towards
plectin-1, possibly due to steric hindrance. The 177Lu-labeled PTP-HPMA exhibited much
lower targeting ability to pancreatic tumors as compared to 177Lu-labeled PTP in vitro.
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Chapter 5
Summary
Pancreatic tumor remains difficult to diagnose at the early stages and all clinically
available biomarkers and diagnostic tools fail to detect early stage PDAC or suffer from
low specificity and sensitivity [14]. SPECT/CT imaging can provide information about the
anatomical structures as well as the functional, metabolic or molecular status of specific
tissues or organs and holds great potential for PDAC diagnosis because of its high
sensitivity and spatial resolution [191]. However, the application of SPECT/CT in PDAC
diagnostic imaging is hampered by the lack of an effective clinical radiotracer. There is
an urgent need for the development of more effective SPECT/CT probes for the
diagnosis of pancreatic tumors.

The advancement of nanomedicine has offered new opportunities for the
development of novel probes for the effective targeting of cancer [192]. Nanomedicine
has many advantages such as the increased circulation time and targeted drug delivery
[193]. Nanomaterials can passively target tumor sites due to the EPR effect [40]. Those
nanomaterials can be multifunctional and modified to carry diagnostic probes and/or
therapeutic drugs with the targeting ligands at the same time [194]. Many nanomedicine
platforms have been evaluated for pancreatic cancer diagnosis [195]. One of the
platforms we are interested in is HPMA copolymers. HPMA copolymers are non-toxic
and non-immunogenic and many of HPMA-drug conjugates have been evaluated in
clinical trials without causing any major side effects [62]. HPMA copolymers can
effectively accumulate in the tumor sites through the EPR effect. HPMA copolymers can
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be multifunctional and modified to introduce diagnostic probes such as radioisotopes or
fluorescent dyes, or carry therapeutic drugs and targeting ligands. Radiolabeled HPMA
copolymers have been successfully applied to for tumor imaging with the imaging
modality SPECT/CT. However, a major problem associated the radiolabeled HPMA
copolymers, as well as other nanomedicine platforms, is their opsonization and
sequestration by the mononuclear phagocyte system [196]. As a result of MPS uptake,
these polymeric drugs tend to accumulate in the liver and spleen. This MPS
accumulation in non-target organs can hinder identification of resident or nearby
metastatic malignant lesions thereby decreasing the diagnostic efficacy of polymer
based diagnostic agents. With regard to therapeutic applications, the non-target
accumulation of these polymeric drugs can lead to significant toxicities which may be
dose-limiting [181].

We are interested in developing new approaches in which radiolabeled HPMA
copolymers can be synthetically modified to significantly reduce the MPS accumulation
and/or to increase the tumor accumulation, thereby enhancing the diagnostic and/or
radiotherapeutic efficacy of the agents. In chapter 2, we incorporated metabolic active
linkers (MAL) into radiolabeled HPMA copolymers in order to reduce the MPS
radioactivity accumulation. Those linkers are peptide substrates for cathepsin B and S,
which have higher levels of expression in MPS tissues as compared to tumor tissues.
We confirmed the in vitro cleavage of these linkers and conjugated them to a 343 kDa
HPMA copolymer prepared by RAFT polymerization. We further investigated the cellular
uptake of those conjugates; all the conjugates were easily taken up by differentiated
macrophages while little uptake was observed in human pancreatic tumor cells. All the
polymer conjugates were labeled efficiently with 177Lu. The in vitro serum stability studies
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of all the radiolabeled conjugates revealed no significant proteolysis. However, we found
that after treatment with cathepsins, small molecule radio-metabolites were generated
from radiolabeled HPMA bearing MAL. The small molecular weight and hydrophilic
radio-metabolite were considered to be favorably cleared away from the MPS tissues
after in vivo accumulation. In a pancreatic tumor xenograft mice model, the synthesized
cathepsin B and S cleavable HPMA copolymers: 177Lu-MAC1 and 177Lu-MAC2
demonstrated a substantial decrease in long-term liver and spleen retention relative to
the non-cleavable HPMA copolymer control (177Lu-MAC0). The significant reduction in
liver and spleen retention observed in these studies prove that the MAL design is
capable of enhancing radioactivity clearance from the MPS tissues.

The promising results from the previous study prompted us to further develop a
better HPMA copolymer based diagnostic agent used for SPECT/CT imaging. In
chapter 3, an HPMA copolymer with molecular weight 109 kDa and PDI 1.3 was
prepared by RAFT and conjugated to three different cathepsin S cleavable linkers in
order to evaluate the structure-activity relationship with regard to the length of the linking
groups on the in vitro and in vivo efficacy of radiolabeled cathepsin S cleavable HPMA.
The 109 kDa allowed efficient tumor targeting due to the molecular weight being above
the renal clearance threshold (~45 kDa), but also demonstrated relatively fast clearance
from the blood to achieve satisfying tumor to blood ratio. In vitro cleavage assays
showed that the longest linking group (13 atoms) possessed the highest cathepsin S
cleavage kinetics. In addition, confocal microscopy confirmed the selective uptake of
HPMA conjugates in differentiated macrophages and trafficking to the lysosomal cellular
compartments. Contrary to in vitro observations, in vivo biodistribution studies in
pancreatic tumor bearing mice revealed that the linking group length in the cathepsin S

156
cleavable linker design did not substantially impact the non-target clearance of
radiolabeled cathepsin S cleavable HPMA. However, in the case of HPAC tumor
retention, the one with the shortest length linker - CSC1 demonstrated significantly
higher levels of retention relative to the other cathepsin S cleavable HPMA copolymers.
This gave CSC1 superior tumor-to-non-target ratios as confirmed by longitudinal
SPECT/CT imaging studies. Our results demonstrated that the introduction of cathepsin
S cleavable linkers can substantially improve the non-target radioactivity clearance of
HPMA copolymer based radiopharmaceuticals, and likely many other nanomedicine
platforms, leading to an enhancement in the tumor-to-non-target ratios and ultimately
clinical translation.

Many peptide ligands have been conjugated to polymers and have successfully
increased the in vitro and/or in vivo targeting ability of polymers [197]. Pancreatic tumors
can highly express many biomarker proteins[44] and these biomarkers can become
potential targets to increase the tumor targeting efficacy of HPMA copolymers. The
plectin-1 protein is a recently discovered biomarker that is aberrantly expressed on the
extracellular surface of PDAC [14]. The peptide sequence KTLLPTP, discovered by
phage display,[37] was found to have submicromolar affinity for plectin-1. In chapter 4,
to further improve the pancreatic tumor targeting ability of HPMA copolymer and solve
the problem associated with the low tumor uptake of plectin-1 targeted peptide (PTP) in
vivo, we prepared a 177Lu-labeled PTP-HPMA conjugate and evaluated its targeting
efficacy. We found even though up to 10 mole% PTP could be successfully conjugated
with HPMA copolymers through “click chemistry”, the PTP-HPMA conjugate did not
display any multivalent effects but rather lost the binding affinity towards plectin-1. The
177

Lu-labeled HPMA-PTP exhibited very little uptake in pancreatic cancer cells while the

157
177

Lu-labeled PTP showed very efficient uptake in vitro. Incorporation of the PTP into the

HPMA copolymer diminished the activity of the peptide. One possible explanation is that
steric hindrance, between the targeting peptide and the polymer backbone, inhibits
plectin-1 binding. A possible solution can be inserting longer PEG chains between the
targeting peptide and the HPMA copolymer.

Future Studies
Even though the above studies proved the great potential of 177Lu radiolabeled
cathepsin S cleavable HPMA for pancreatic tumor imaging, the agent can be improved
to achieve better efficacy.

1) The efficacy of

177

Lu-labeled cathepsin S cleavable HPMA for pancreatic tumor

imaging should be determined in a transgenic mice model. In chapter 2 and 3, we
evaluated the cathepsin S cleavable HPMA in a subcutaneous xenograft mouse model
and had encouraging results. The xenograft mouse model provides a relevant and
convenient model for the initial evaluation of many investigational drugs. However, it is
well-known that there are many great differences between the xenograft mouse model
and the transgenic mouse model. The transgenic mouse model can offer many
advantages in our future study: (1) the mice are immuno-competent such that the tumor
microenvironment can be mirrored as much as possible in a murine model; (2) specific
genetic abnormalities present in human tumors can be reproduced, in an inducible
manner, at specific ages in the tissue-type of origin; (3) the stages of tumor progression
can be studied over time; (4) several therapeutic approaches can be explored at various
stages of tumor development [198]. The model we will use is the LSL-KrasG12D; p53R172H;
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Pdx-1-Cre (KPC) mouse model. The KPC model is well validated as a clinically relevant
model of the morphology, metastatic spread, and chemotherapeutic response of
pancreatic cancer. For example, treatment of the KPC model with gemcitabine gave only
a 10-15% response rate, correlating well with the clinical disease profile. The evaluation
of our agents in a transgenic mouse model will help to better measure the potential
towards clinical translation.

2) Other biomarkers and targeting ligands can be exploited for pancreatic tumor
targeting. In this thesis, we have successfully explored the feasibility of incorporating
targeted peptide ligands (PTP) into HPMA copolymers even though the final conjugate
did not exhibit significant binding affinity. The failure may be due to the steric hindrance
problem. We’d like to investigate whether adding longer spacers between the peptide
ligand and polymer backbone can increase the interaction. Pancreatic tumors also
express many other receptors such as EGFR and uPAR, which can become potential
targets [199, 200]. Peptide ligands with high affinity to those receptors have been
reported previously and can be conjugated to HPMA copolymers using similar strategies.
However, those peptide polymer conjugates should be designed carefully and
investigated in detail using various in vitro and in vivo studies to determine their
structure-activity relationships.

3) Radiotherapeutic efficacy study can be carried out to prove another advantage of
177

Lu labeled cathepsin S cleavable HPMA. 177Lu is also an effective beta emitter, which

enables the application of 177Lu-labeled cathepsin S cleavable HPMA for tumor targeted
radiotherapy. The cathepsin S cleavable HPMA can lead to lower liver and spleen
radioactivity accumulation, which should help increase the therapeutic index. This
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means we can deliver a higher dose of radioactivity to the tumor site without causing any
greater damage to other non-target tissues. The maximum tolerated doses for the 177Lu
radiolabeled cathepsin S cleavable HPMA copolymers is expected to be higher than the
non-cleavable control copolymer and can be easily determined in a mouse model.
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